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The incidence of central nervous system (CNS) diseases, such as glioblastoma, 
Alzheimer’s disease and Parkinson’s disease, will increase substantially in the next 
few decades. However, treatment for diseases of the brain is limited due to the 
restrictive physical and functional blood-brain barrier (BBB) dividing the brain and 
the vascular system. Bolaamphiphilic (BA) vesicles, produced from vernonia oil, 
encapsulate a wide range of therapeutic molecules, and offer an alternative drug 
delivery system to penetrate the brain to treat diseases of the CNS. We present 
novel anionic BA vesicles that cross biological barriers including the blood-brain 
barrier. 
BA vesicles were characterised by dynamic light scattering, transmission electron 
microscopy, zeta potential analysis and size exclusion column chromatography. In 
vitro studies were performed on numerous CNS-representative and other cell lines 
- BV2 microglia, SH-SY5Y neurones, LN229 glioblastoma, HEK-293T epithelia, 
hCMEC/D3 endothelia and HASTR/ci35 astrocytes. In vivo studies were performed 
using C57BL/6 male mice. A novel methodology was developed to permit synthesis 
of the novel BAs first described here, directly from vernonia oil, the starting material.  
This study has shown that a novel preparation of anionic BA form vesicles that 
encapsulate a range of different cargoes including tracer dyes and antibody 
fragments albeit with a low encapsulation efficiency. They do not influence cell 
viability or cause an acute immune response. They have been shown to penetrate 
the BBB in vivo. Analysis of the original BA material has shown to consist of two 
compounds, both of which have been synthesised and characterised.  
The original material synthesised from vernonia oil and used to produce BA vesicles 
was thought to be cationic. However, after profiling the vesicles synthesised were 
found to have a negative zeta potential demonstrating that they are novel. They 
were further tested and found to cross biological barriers in vitro. Newly synthesised 
vesicles require further characterisation and optimisation to improve stability and 
encapsulation efficiency. The original anionic BA material has been shown to cross 
the BBB within 30 minutes of intravenous injection. These results demonstrate that 
whilst further studies are required this is a candidate drug delivery system to treat 
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poor prognosis. Roles for peptidylarginine deiminases (PADs) in GBM have 
recently been highlighted. Here, two GBM cell lines were treated with PAD2, PAD3 
and PAD4 isozyme-specific inhibitors. Effects were assessed on extracellular 
vesicle (EV) signatures, including EV-microRNA cargo (miR21, miR126 and 
miR210), and on changes in cellular protein expression relevant for mitochondrial 
housekeeping (prohibitin (PHB)) and cancer progression (stromal interaction 
molecule 1 (STIM-1) and moesin), as well as assessing cell invasion. Overall, GBM 
cell-line specific differences for the three PAD isozyme-specific inhibitors were 
observed on modulation of EV-signatures, PHB, STIM-1 and moesin protein levels, 
as well as on cell invasion. The PAD3 inhibitor was most effective in modulating 
EVs to anti-oncogenic signatures (reduced miR21 and miR210, and elevated 
miR126), to reduce cell invasion and to modulate protein expression of pro-GBM 
proteins in LN229 cells, while the PAD2 and PAD4 inhibitors were more effective 
in LN18 cells. Furthermore, Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways for deiminated proteins relating to cancer, metabolism and inflammation 
differed between the two GBM cell lines. Our findings highlight roles for the different 
PAD isozymes in the heterogeneity of GBM tumours and the potential for tailored 
PAD-isozyme specific treatment. 
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Abstract: Glioblastoma multiforme (GBM) is the most common and aggressive 
form of primary malignant brain tumor inadults, with poor prognosis. Extracellular 
vesicles (EVs) are key mediators for cellular communication throughtransfer of 
proteins and genetic material. Cancers, such as GBM, use EV release for drug-
efflux, pro-oncogenicsignaling, invasion and immunosuppression; thus, the 
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modulation of EV release and cargo is of considerableclinical relevance. As EV-
inhibitors have been shown to increase sensitivity of cancer cells to chemotherapy, 
andwe recently showed that cannabidiol (CBD) is such an EV-modulator, we 
investigated whether CBD affects EVprofile in GBM cells in the presence and 
absence of temozolomide (TMZ). Compared to controls, CBD-treated cellsreleased 
EVs containing lower levels of pro-oncogenic miR21 and increased levels of anti-
oncogenic miR126; these effects were greater than with TMZ alone. In addition, 
prohibitin (PHB), a multifunctional protein with mitochondrial protective properties 
and chemoresistant functions, was reduced in GBM cells following 1 h 
CBDtreatment. This data suggests that CBD may, via modulation of EVs and PHB, 
act as an adjunct to enhancetreatment efficacy in GBM, supporting evidence for 
efficacy of cannabinoids in GBM. 
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Abstract: Glioblastoma multiforme (GBM) is the most aggressive form of adult 
primary malignant brain tumour with poor prognosis. Extracellular vesicles (EVs) 
are a key-mediator through which GBM cells promote a pro-oncogenic 
microenvironment. Peptidylarginine deiminases (PADs), which catalyze the post-
translational protein deimination of target proteins, are implicated in cancer, 
including via EV modulation. Pan-PAD inhibitor Cl-amidine affected EV release 
from GBM cells, and EV related microRNA cargo, with reduced pro-oncogenic 
microRNA21 and increased anti-oncogenic microRNA126, also in combinatory 
treatment with the chemotherapeutic agent temozolomide (TMZ). The GBM cell 
lines understudy, LN18 and LN229, differed in PAD2, PAD3 and PAD4 isozyme 
expression. Various cytoskeletal, nuclear and mitochondrial proteins were identified 
to be deiminated in GBM, including prohibitin (PHB), a key protein in mitochondrial 
integrity and also involved in chemo-resistance. Post-translational deimination of 
PHB, and PHB protein levels, were reduced after 1 h treatment with pan-PAD 
inhibitor Cl-amidine in GBM cells. Histone H3 deimination was also reduced 
following Cl-amidine treatment. Multifaceted roles for PADs on EV-mediated 
pathways, as well as deimination of mitochondrial, nuclear and invadopodia related 
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proteins, highlight PADs as novel targets for modulating GBM tumour 
communication. 
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1.1 Introduction  
The incidence of diseases of the brain, such as Parkinson’s disease (PD), 
Alzheimer’s disease (AD) and glioblastoma, is forecast to increase as the global 
population as well as the aged population increases (Prince et al, 2016a; Feigin et 
al, 2017). AD is the most common form of dementia aetiologically characterised by 
the formation of protein aggregates called beta-amyloid plagues, as well as 
accumulation of mutated tau protein forming tau tangles within neurons 
(Alzheimer’s Association, 2018). PD develops due to the loss of dopaminergic 
neurons located in the substantia nigra in the brain (Maiti, Manna and Dunbar, 
2017; Surmeier, 2018). Gliomas are a brain cancer derived from glial cells, such as 
astrocytes, oligodendrocytes or ependymal cells (Louis et al, 2007; Hanif et al, 
2017). They are the most common and aggressive of brain cancers in adults 
(Ohgaki and Kleihues, 2005; Verhaak et al, 2010) with poor mean survival of 14-15 
months, and the more dismal recurrence survival of 5-7 months (De Witt Hamer et 
al, 2010; Sørensen et al, 2015; Hanif et al, 2017). It may be fair to assume that as 
the global population increases, so too will the global incidence. A recent study 
investigating epidemiology of conditions of the central nervous system (CNS), has 
found that in the 25 years from 1990-2015, both AD and PD saw the number of 
reported cases double (Feigin et al, 2017; Dorsey et al, 2018), with a prediction of 
130 million suffering and diagnosed with AD by 2050 (Prince et al, 2016b). Duration 
is measured from diagnosis to death, there is no recovery from diseases such as 
AD and PD (Prince et al, 2016a). Unfortunately, there is no cure for these diseases, 
and treatment is palliative. 
The impact of such statistics demonstrates the scope of this issue. However, there 
is a direct, as well as an indirect, burden. The indirect cost may be due to the loss 
of income by the patient or family member (Castro et al, 2010). Whereas the direct 
burden is associated with the cost of medical treatment and, depending on the 
status of the patient, social services (Castro et al, 2010). With the estimated 
worldwide cost of AD reaching (US) $1 trillion by 2018 (Prince et al, 2016b; Wimo 
et al, 2017) it can be appreciated that if the current statistics regarding increase of 
diagnosed patients, the cost, both financial and societal will also increase. These 
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brain diseases share the same challenge, despite their differing aetiologies, of an 
effective delivery of treatment. 
The average time scale for drug discovery from concept to market is approximately 
12 years at a cost that exceeds $1 billion (DiMasi et al, 2010; Van Norman, 2016; 
Mohs and Greig, 2017). Thus, demonstrating the challenges faced developing 
novel treatments. There have been no successful novel therapeutics for AD in the 
past 16 years despite the vast sums of money invested in numerous failed clinical 
trials (Sabbagh et al, 2019). High attrition rates of clinical trials is a further issue 
influencing and limiting discovery of novel treatments that can enter the brain 
(Morgan et al, 2012; Reichel, 2015; Vandenberghe et al, 2016; Chaturvedi et al, 
2019). As a result, many pharmaceutical companies have reduced, downsized or 
closed their research centres, such as AstraZeneca, Johnson and Johnson, 
GlaxoSmithKline and Pfizer (Gautam and Pan, 2016; Hunter et al, 2018). With the 
lack of success, there is less investment at present in drug targeting (Pardridge, 
2009; Chaturvedi et al, 2019).  
This is not a recent development; Pardridge (2001) highlighted these shortcomings 
nearly two decades ago. However, there is a lack of investment in the targeting of 
novel compounds designed to treat diseases of the brain from within the 
pharmaceutical industry (Pardridge, 2009; Abbott, 2011). One of the deficiencies 
noted was that the majority of investment was focused towards drug discovery for 
CNS rather than drug delivery (Pardridge, 2009). The same rules used for 
pharmaceuticals for systemic treatment do not apply to the blood brain barrier 
(BBB). The challenges lie in the fact that the BBB prevents the effective delivery of 
compounds (Abbott, 2013). However, there appears to be a lack of understanding 
of the reasons for these failures including the target exposure, target engagement 
and the level of efficacy of the compound commensurate to the exposure and 
engagement (Morgan et al, 2012; Reichel, 2015). 
1.2 Challenges for the delivery of therapeutics to treat diseases of the brain 
There are a number of challenges for the delivery of therapeutics to treat diseases 
of the brain, requiring an understanding of the complexities surrounding the barriers 
that protect it (Chaturvedi et al, 2019). To treat a disease, a drug must be able to 
both elicit a suitable pharmacological effect (Reichel, 2015), and be able to reach 
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its site of action at a concentration sufficient/adequate in order to elicit this effect 
(Reichel, 2015). For therapeutics for the CNS, this second requirement is a major 
limitation, drugs must be able to cross the BBB and penetrate the brain 
parenchyma, against the natural role of the BBB as a barrier to xenobiotics, 
including most drugs (Alavijeh and Palmer, 2010; Chaturvedi et al, 2019). The 
design of therapeutics for the CNS must be based on the characteristics of the BBB 
(Pardridge, 1995). As a result, the neuropharmacokinetics and pharmacodynamics 
must account for this design of novel drug targeting (Reichel, 2015). 
The BBB is a physical, functional, enzymatic and pharmacological barrier designed 
to protect and selectively restrict the entry of compounds into the brain (Bodor and 
Buchwald, 2002). The BBB is the interface of the vascular system and the central 
nervous system (CNS). It is a physical, functional and pharmacological barrier 
protecting and restricting entry of foreign substances and toxins (Abbott et al, 2010). 
The brain requires a strict homeostatic environment in order to perform its functions. 
As a result, the majority of therapeutics designed to treat diseases of the brain are 
unable to reach their intended target (Pardridge, 2009; Alavijeh and Palmer, 2010). 
The statics are quite sobering as approximately 98% of small drugs are prevented 
from crossing the BBB. Molecules, including therapeutics greater than 400 Da are 
also restricted. As a result of the selectively restrictive permeability of the BBB, 
hydrophilic or charged therapeutic agents are essentially prevented from crossing 
the BBB (Olanow et al, 1991; Garcia-Garcia et al, 2005) with many that do so being 
rapidly removed by the numerous efflux transporters found in the brain endothelial 
cells (BECs), for example p-glycoprotein (P-gp) or breast cancer resistance protein 
(BRCP) (Hartz and Bauer, 2011).  
The only therapeutics that are able to penetrate to the brain parenchyma are small 
lipophilic drugs (Pardridge, 2002). The challenge in developing a therapeutic to 
cross the BBB is that there are a number of hurdles that the drug must overcome. 
The first of these hurdles is overcoming the BECs which differ from peripheral 
endothelial cells in that they lack fenestrations and have tight junction complexes, 
effectively restricting paracellular entry (Abbott, 2013; Miller, 2015; Arvanitis et al, 
2019). Secondly, the BECs are limited in the expression of transmembrane 
transporters designed to selectively restrict entry to the brain to maintain 
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homeostasis (Pardridge, 2012; Abbott, 2013). Thirdly, the high expression of efflux 
transporters, the ATP Binding Cassette transporters protecting the brain from 
xenobiotics and foreign substances (McArthur et al, 2016). In order that we can 
understand the difficulties presented by the BBB we need to consider the case of 
need in respect of the delivery of a therapeutic agent to the brain.   
1.3 The Structure and Function of the Blood Brain Barrier  
The main functions of the BBB are to regulate homeostasis and protect the CNS 
by restricting the entry of toxins and foreign substances (Luissint et al, 2012; 
Obermeier, Daneman, and Ransohoff, 2013). Whilst doing this, it must selectively 
allow passage of nutrients and molecules and remove potentially toxic metabolic 
waste (Abbott, 2013; Daneman and Prat, 2015; McArthur et al, 2016). This is 
achieved by a combination of the physical and functional characteristics: the tight 
intercellular junctions, limited and selective transport systems and a highly effective 
and efficient family of ATP-binding cassette (ABC) efflux transporters such as P-
glycoprotein (P-gp) and multi-drug resistance-associated proteins (MRP-1 and 
MRP-2) (Bart et al, 2000; Abbott, 2013; McArthur et al, 2016). This is further 
supported by the presence of a population of active phagocytes, in particular 
perivascular macrophages in vascular walls (Faraco et al, 2017).  
The heavy demand for oxygen and glucose by the neurons is transported through 
the cerebral blood flow via the 600 kilometres of vascular network and across the 
BBB (Wong et al, 2013; Pulgar, 2019). The surface area of the BECs is estimated 
to be 15-25 m2 (Wong et al, 2013; Pulgar, 2019). As a result of this vast network, it 
is thought that each neuron is within 20 µm of a capillary to ensure rapid solute 
equilibrium (Oldendorf et al, 1977; Wong et al, 2013; Sweeney et al, 2018). 
The unique structure and hallmarks of the BBB are attributable to the neurovascular 
unit (NVU) comprised of pericytes, astrocytes, neurons, microglia, and specialised 
brain endothelial cells (BECs) as shown in figure 1.1A (Baeten and Akassoglou, 
2011).  
1.3.1 Brain endothelial cells  
Brain endothelial cells (BECs) line the vast capillary network providing protection 
from pathogens and foreign substances, such as xenobiotics, and nourishment of 
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the CNS, whilst controlling and maintaining the homeostatic conditions of the 
extracellular neural environment (Blanchette and Daneman, 2015). The luminal 
membrane faces the circulation whilst the basolateral membrane faces the brain 
interstitial fluid (ISF) (Banks, 2019). A monolayer of BECs line the capillaries. 
However, in the narrowest regions of the capillaries the BECs form tight junctions 
with adjacent BECs (Banks, 2019). They are narrower than muscle endothelial cells 
at 200-500 nm in width (Coomber and Stewart, 1985; Abbott et al, 2010; Reichel, 
2015).  
BECs differ structurally and functionally from peripheral endothelial cells (ECs) in 
several ways (Abbott et al, 2006; Pinto et al, 2017). They lack fenestrations (Banks, 
2019), display reduced pinocytosis (Gastfriend et al, 2018) and low expression of 
leukocyte adhesion molecules (LAMs) to limit the entry of immune cells (Langen, 
Ayloo and Gu, 2019). They have complex inter-endothelial junctions with 
contributions from both adherens and tight junction molecules (AJs and TJs, 
respectively) (Figure 1.1B) (Baeten and Akassoglou, 2011; Pinto et al, 2017) 
restricting paracellular transport to the brain. BECs have a high expression of the 
ABC transporters, such as P-gp transporter on both the luminal and abluminal 
membranes effectively removing potentially toxic and harmful substances and 
trafficking compounds into the brain parenchyma (Miller, 2015). In order to 
overcome the large energy requirements necessary for the demands of the ATP-
binding cassette transporters and the sodium and potassium ATPase gates 
(Zlokovic, 2011), they express a larger number of mitochondria than peripheral ECs 
(Coomber and Stewart 1985). Routes of entry, such as intercellular pores and 
paracellular or transcellular channels and transporters, including caveolae, present 
on peripheral organs, are greatly limited at the BBB (Pardridge, 2012; Abbott, 2013; 
Obermeier et al, 2013). BECs are highly charged as a result of the TJs selectively 
restricting the entry of ions and small charged molecules resulting in the luminal 
surface being more polar than that of the abluminal (Blanchette and Daneman, 
2015; Abbott et al, 2006; Sharif et al, 2018). The luminal membrane of BECs are 
lined with glycocalyx, a layer of negatively charged carbohydrates, providing a 
barrier between blood and endothelial cells (Abbott, 2013; Haeren et al, 2016; 
Kutuzov et al, 2018). They have recently been described as an endocrine tissue in 
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that they secrete and transport chemical signals across and out of the brain (Banks, 








Figure 1.1 Structure of the neurovascular unit. A. Schematic representation of the 
neurovascular unit which comprises brain endothelial cells with the inter-endothelial 
tight junctions, endothelial and astrocytic basement membranes, pericytes, 
astrocyte end feet and microglia. B. Detail of inter-endothelial junctions and the 
molecular relationships between junctional complexes and the actin cytoskeleton. 
The tight junction complex consists of occludins, claudins and junctional adhesion 
molecules (JAMs). The C-terminus of the tight junction proteins bind to scaffolding 
proteins zona occludens-1, -2, and -3 which in turn link with the actin cytoskeleton. 
The adherens junctions comprise vascular endothelial (VE) cadherins which bind 
via catenins to the actin cytoskeleton. Adapted from McArthur et al, 2016, with 











1.3.1.1 Tight junctions and adherens junctions  
Junctional complexes, such as tight junctions (TJs) and adherens junctions (AJs), 
located between adjacent endothelial cells, create a physical and functional barrier 
restricting the paracellular passage of molecules (Abbott et al, 2010). TJs are a 
complex of transmembrane proteins providing a physically limiting barrier between 
neighbouring endothelial cells (Luissant et al, 2012; Savaiva et al, 2016). Due to 
their polarity they form a highly selective diffusion barrier restricting delivery of 
pharmaceuticals (Ballabh et al, 2004; Bicker et al, 2014; Blanchette and Daneman, 
2015; Tietz and Englehardt, 2015).  
Inter-endothelial junctions between BECs are complex, multi-part structures, 
including TJs, AJs, junctional adhesion molecules (JAMS) and endothelial cell-
selective adhesion molecules (ESAMs) (Tietz and Englehardt, 2015; Freskgård and 
Urich, 2017; Stamatovic et al, 2016). Occludin, claudin-5 and JAMs, membrane 
linker proteins, all form homodimer bridges linking adjacent endothelial cells 
(Cummins, 2012; McArthur et al, 2016; Stamatovic et al, 2016). Intracellular 
accessory proteins, such as zonula occludens-1, -2, and 3, act as scaffolding 
proteins connecting the cytoplasmic tails of transmembrane proteins occludin and 
claudin-5 to F-actin, providing the rigidity to the TJs (Almutairi et al, 2016; Cummins, 
2012; Stamatovic et al, 2016). ESAMs interact, as the other proteins, with zonula 
occludens in the plasma membrane of the adjacent cells, to mediate the linkage 
formed with the actin cytoskeleton, creating an additional physical barrier, further 
restricting permeability (Stamatovic et al, 2016). AJs form junctional complexes 
between neighbouring ECs and are composed of the transmembrane protein 
vascular endothelial (VE)-cadherin binding to intracellular catenins, (Harris and 
Nelson, 2010; Luissint et al, 2012; Tietz and Englehardt, 2015). The 
transmembrane protein-protein links provide greater protection and limited entry of 
foreign substances across the BBB. Each of these elements is important in forming 
the BBB. As a result of such interactions, a difference in polarity between the apical 
and basolateral sides of BECs is created. The measurement of this structural and 




TEER is a measurement of the tightness of the BBB, controlling transportation of 
molecules into and out of the cell (Abbott et al, 2006; Blanchette and Daneman, 
2012; Srinivasan et al; 2015). It has been measured at 1500 Ω cm2 (Crone and 
Christensen, 1981), but has been estimated to be as high as 5000 Ω cm2 in humans 
(Lauschke, Frederiksen, and Hall, 2017; Srinivasan and Kolli; 2019). The tighter 
the TJs the higher the TEER, thus influencing the level of transcellular and 
paracellular entry of molecules and compounds (Redzic, 2011). The TEER of other 
barriers of the body is considerably less than that of the BECs, such as the brain 
cerebrospinal fluid barrier 150 Ω cm2 (Saito and Wright, 1984; Redzic, 2011) or 
other tissues of 3-33 Ω cm2 (Crone and Christensen, 1981; Redzic, 2011). This 
highlights the distinct, restrictive, protective and unique characteristics of the BBB.   
1.3.2 Basement membranes 
The basement membrane (BM) is located between the endothelial cells and 
astrocytic end feet and is composed of extracellular matrix proteins secreted from 
the pericytes, BECs and astrocytes (Baeten and Akassoglou, 2011). The BM is 
comprised of two closely apposed membranes - the endothelial and the astrocytic 
BM, also referred to as the glia limitans (Baeten and Akassolou, 2011; Blanchette 
and Daneman, 2015; Daneman and Prat, 2015; Pinto et al, 2017). The membranes 
are lined with extracellular receptors, involved in cell-cell and cell-matrix 
communication (Baeten and Akassoglou, 2011). The BMs are also involved in the 
prevention of leukocyte permeation due to the presence of laminins secreted from 
the BECs and astrocytes (Baeten and Akassoglou, 2011; Pinto et al, 2017; Wang 
et al, 2006). These basal laminae play an important role in the structure of the BBB 
acting as a support for the endothelial cells, as well as communicating with and 
providing nutrients for the parenchyma (Baeten and Akassoglou, 2011; McArthur 
et al, 2016). Embedded within the basement membranes are pericytes.  
1.3.3 Pericytes 
Pericytes, through their interactions with the endothelial cells, are involved in the 
development, differentiation, maturation and regulation of the BBB (Obermeier et 
al, 2013; Jackson et al, 2017). The number of pericytes is directly proportional to 
that of endothelial cells and is referred to as the endothelium/pericyte ratio (Jackson 
et al, 2017). Pericytes, along with perivascular macrophages, are the first line of 
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immunologic defence involved in phagocytosis (Thomas, 1999; Guillemin and 
Brew, 2004; Faraco et al, 2017). They are involved in the regulation of cerebral 
blood flow and capillary diameter (Bell et al, 2010; Winkler et al, 2014; Jackson et 
al, 2017). Pericytes and astrocytic end feet, the distal end of astrocyte processes, 
regulate permeability of the BBB through their interaction with the basement 
membranes and induction of TJ formation (Bell et al, 2010; Obemeier et al, 2013; 
Winkler et al, 2014). 
1.3.4 Astrocytes 
Astrocytes, the most abundant type of glial cell, provide structural support to the 
cerebral blood vessels, maintaining homeostasis of fluid, electrolytes, amino acids 
and neurotransmitters, the control of cerebral blood flow and removal of metabolic 
waste from the parenchyma (Takano et al, 2006; Wolburg-Buchholz et al, 2009; 
Baeten and Akassoglou, 2011; Bicker et al, 2014; McArthur et al, 2016;). 
Astrocytes, through their endfeet, ensheath microvessels in the CNS (Wolburg-
Buchholz et al, 2009; Daneman, 2012; Bicker et al, 2014). In vitro astrocytes have 
been shown to influence and induce the expression of BEC characteristics such as 
P-glycoprotein and TJs in non-CNS endothelial cells (Abbott et al, 2006; Alvarez et 
al, 2013), demonstrating their influence over the integrity of the BBB.  They are 
involved in numerous functions including neuronal development and synapse 
formation (Liddelow and Barres et al, 2017). They have been suggested to be 
responsible for brain ageing (Clarke et al, 2018), neurodegenerative disease 
(Liddelow and Barres et al, 2017), and are potentially neuroprotective after 
traumatic brain injury (Shinozaki et al, 2017). These factors have been observed in 
numerous studies investigating models of reactive astrocytes demonstrating the 
heterogeneity within the population cells (Molofsky et al, 2012; Zamanian et al, 
2012; Liddelow and Barres et al, 2017). This highlights the complexity of the 
populations of astrocytes and their roles in health and disease. 
1.3.5 Microglia 
Microglia are known as the macrophages of the brain, providing immunity through 
regulation of both innate and adaptive immune responses (Gomez-Nicola and 
Perry, 2015). Through constant surveillance of the brain parenchyma, they respond 
acting as phagocytes ingesting and degrading debris, such as dead cells, and 
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harmful agents including pathogens (Davalos et al, 2005; Nimmerjahn, Kirchhoff 
and Helmchen, 2005; Yin et al, 2017). They are involved in the integrity of the brain, 
from normal development and function to repair (Tremblay et al, 2011; Bicker et al, 
2014; Gomez-Nicola and Perry, 2015; McArthur et al, 2016). Microglia are involved 
in the normal development of the brain through interactions with neurons to promote 
differentiation and survival by production and release of specific neurotrophic 
factors including insulin growth factor (Michell-Robinson et al, 2015; Yin et al, 
2017). They are involved in tissue repair and maintaining homeostasis (Derecki et 
al, 2013). However, microglia convert to a pro-inflammatory phenotype during 
disease and brain injury (Derecki et al, 2013; Eggen et al, 2013). This has a 
negative impact as is observed with diseases such as Alzheimer’s disease and 
glioma that they are implicated in progression and proliferation (Hambardzumyan, 
Gutmann and Kettenmann, 2016; Wolf, Boddeke, and Kettermann, 2017). Such a 
response demonstrates the adaptive characteristics of the microglial cells in 
maintaining plasticity of the brain (Nimmerjahn, Kirchhoff and Helmchen, 2005; 
Tremblay et al, 2011; McArthur et al, 2016). 
1.4 Routes of Entry 
Both the BBB and the brain require the entry of molecules, such as glucose, in 
order to provide the high levels of energy needed to maintain healthy functioning 
(Benarroch, 2014). The metabolic waste produced must also be removed. As the 
brain is so heavily protected and entry into the brain and across the BBB is 
restricted and, in some instances, prevented, molecules enter and exit via 
endogenous transport pathways and a number of mechanisms, such as 
transcytosis or diffusion (Freskgård and Urich, 2017). There is a lower expression 
of endogenous transport systems on the BBB (Stewart, 2000; Pardridge, 2005), 
further restricting and limiting the entry of molecules and compounds required for 
the brain. However, the systems located on both the apical and basolateral sides 
of the BECs are specific to the requirements of the brain (Patching, 2017). The 
pathways and mechanisms involved include: 
• Paracellular entry (Bicker et al, 2014; Saraiva et al, 2016; Pinto et al, 2017) 
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• Macropinocytosis, absorptive mediated transport and receptor mediated transport, 
which includes both clathrin-mediated and caveolae-mediated transport; are the 
main vesicular pathways of the BBB (Goulatis and Shusta, 2017).  
• Carrier-mediated transporters (Pardridge, 2005; Ohtsuki and Terasaki, 2007; 
Abbott, 2013; Lajoie and Shusta, 2015)  
• ATP binding cassette (ABC) efflux pumps (Abbott, 2013; Qosa et al, 2015; 
Strazielle and Ghersi-Egea, 2015; van Tellingen et al, 2015; Freskgård and Urich, 
2017) (Figure 1.2) 
 
  
Figure 1.2. The different modes of transport into and across the BBB. The 
routes of entry of the BBB include paracellular diffusion, efflux pumps, carrier-
mediated transport, adsoptive-mediated transport, macropinocytosis and receptor-
mediated transport, including both caveolae- and clathrin-mediated transport. The 
material packaged within each delivery system may be transcytosed to the 
basolateral side via the endosome, delivered for further distribution within the cell, 
recycled thus exiting the cell, or be digested in the lysosome.  
 
1.4.1 Paracellular diffusion 
Paracellular diffusion is the route by which molecules diffuse at the site of the TJs, 
in the instance of ions and gaseous molecules, or across the plasma membrane of 
the BECs for lipophilic substances (Bicker et al, 2014; Saraiva et al, 2016; Pinto et 
al, 2017). However, due to the formation of the TJs between adjacent cells that 
regulate diffusion, paracellular transport is severely restricted (Wong et al, 2013). 
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This is due to the limited intercellular pore size, approximately 1 nm (Sarin, 2010; 
Furtado et al, 2020). As a result, small molecules and ions are effectively prevented 
from crossing (Abbott et al, 2010; Wong et al, 2013). Diffusion across the 
membranes is specific to lipophilic compounds that are able to cross dependent 
upon criteria such as size and the number of hydrogen bonds (Pardridge, 2005; 
Furtado et al, 2020). 
1.4.2 Transcytosis and endocytosis 
Transcytosis involves the transportation of vesicles through the cell, from one side 
of the plasma membrane to the contralateral, for example, from the luminal to the 
abluminal of the brain endothelial cells (Okamoto, 1998; Stewart, 2000) (Figure 
1.3A). Whereas endocytosis is the process in which extracellular compounds, such 
as proteins and lipids, are internalised to the cell by the fusion of the plasma 
membrane to form vesicles (Doherty and McMahon, 2009) (Figure 1.3B). There are 
a number of pathways involved in endocytosis once the vesicle is internalised 
(Okamoto, 1998; Henry et al, 2012; Goulatis and Shusta, 2017) (Figure 1.2). The 
vesicle fuses with endosomes to form the early endosome (Huotari and Helenius, 
2011; Scott, Vacca and Gruenberg, 2014). The function of the early endosome is 
to act as the initial sorting station to determine the destination of the cargo to 
regulate the pathways of the vesicle (Huotari and Helenius, 2011; Scott, Vacca and 
Gruenberg, 2014). During this process the internalised cargo will be either recycled, 
redirected towards the trans-golgi network, degraded or transcytosed (Okamoto, 
1998; Huotari and Helenius, 2011; Scott, Vacca and Gruenburg, 2014). The initial 
binding of the ligand to the receptor determines the fate of the endosome and its 














Figure 1.3. The different pathways of vesicle transportation after entry into 
the cell. A) Transcytosis. The transport of vesicles through the cell from the side 
they are formed to the other where they are released. B) Endocytosis. The 
process by which compounds from the extracellular matrix are internalised by the 
cell membrane. The cell membrane fuses together to form a vesicle which 
transports the molecules encapsulated within the vesicle inside the cell.  
1.4.3 Macropinocytosis 
Although macropinocytosis is one of the pathways in which molecules transcytose, 
there are few macropinocytic vesicles present on the BBB (Brightman and Reese, 
1969). Macropinocytosis is the non-selective uptake of extracellular fluid (Lim and 
Gleeson, 2011; Goulatis and Shusta, 2017). It is a signal dependent process 
involving the rearrangement of the cytoskeleton and ruffling of the plasma 
membrane to form vesicles (Lim and Gleeson, 2011; Goulatis and Shusta, 2017). 
These vesicles differ from other vesicles in that they do not have a coating and 
appear much larger (0.2 µm- 5 µm) than clathrin (100 nm) and caveolae- mediated 
transport (Lim and Gleeson, 2011).  
1.4.4 Adsorptive-mediated transport systems 
Adsorptive-mediated transport is involved in the transport of cationic molecules 
(Goulatis and Shusta, 2017). Due to the electrostatic interactions between anionic 
moieties, such as sialic acid, present on the luminal cell membrane, positively 
charged molecules, such as glycoproteins, are non-specifically invaginated and 
transcytosed through the cell to be exocytosed from the abluminal membrane by 




1.4.5 Receptor-mediated transport 
Receptor mediated transport (RMT) is the vesicular transport of materials from the 
apical membrane of BECs to the basolateral side (Jones and Shusta, 2007). It 
involves the interaction of a ligand to a specific receptor located on the surface of 
the BEC (Jones and Shusta, 2007; Goulatis and Shusta, 2017). This complex 
results in the invagination of the membrane to form an intracellular transport vesicle 
(Brown and Greene, 1991). This initiates transport of the vesicle through the BEC 
cytosol to the basolateral membrane to be transcytosed and released (Jones and 
Shusta, 2007; Huotari and Helenius, 2011; Scott, Vacca and Gruenburg, 2014). 
RMT includes both clathrin-mediated and caveolae-mediated transport vesicular 
pathways of the BBB (Goulatis and Shusta, 2017).  
Receptor-mediated transporters are involved in the selective transportation of 
larger molecules, such as transferrin, insulin, and low-density lipoprotein, across 
the BBB to the brain (Pardridge, 2002). This process involves the formation of 
vesicles through the binding of a ligand, such as insulin or transferrin, to its specific 
receptor, for example insulin receptor (IR) or transferrin receptor (TfR), 
respectively, located on the luminal plasma membrane (Guo et al, 2012; Bicker et 
al, 2014; Lajoie and Shusta, 2015). These receptors, as well as the low-density 
lipoprotein receptor (LDL-R), are highly expressed on the BBB (Goulatis and 
Shusta, 2017). The vesicles are either transcytosed through the 200 nm of 
cytoplasm to the abluminal membrane to the brain parenchyma or mediated 
towards the endosomal pathway for degradation (Pardridge, 2002; Lajoie and 
Shusta, 2015; Goulatis and Shusta, 2017). As previously mentioned, both clathrin-
mediated and caveolae-mediated transport are examples of RMT.  
1.4.5.1 Clathrin-mediated transport 
Clathrin-mediated transport involves the interaction of the adaptor protein 
complexes, adaptor protein 2 (AP2), and clathrin in the formation of endocytic 
vesicles (Goulatis and Shusta, 2017; Lim and Gleeson, 2011). Assembly of the 
lattice-like clathrin coat is initiated through the binding and recruitment of the 
specific ligand and the transmembrane receptors to adaptor protein complexes and 
clathrin (Lim and Gleeson, 2011; Schmid, 1997). Thus, the assembly of proteins, 
as well as the intrinsic curvature of the clathrin coating, encourage the bending and 
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invagination of the membrane to form the vesicle (Ungewickell and Hinrichsen, 
2007). Budding and packaging of the clathrin coated endosomal vesicle is 
completed on fission from the plasma membrane (Schmid, 1997). The transferrin 
receptor is an example of the clathrin mediated transport system (Goulatis and 
Shusta, 2017; Jefferies et al, 1984). On disassembly of the network of clathrin and 
adaptor proteins, the endosomal vesicle fuses with the early endosome where the 
cargo and receptors are sorted and are either transcytosed, degraded or recycled, 
the latter is exclusive to the receptors (Mayor and Pagano, 2007; Huotari and 
Helenius, 2011; Goulatis and Shusta, 2017).  
1.4.5.2 Caveolae-mediated transport 
Caveolae are specialised lipid rafts which converge in regions of the plasma 
membrane, involved in endocytosis, exocytosis, regulation of cholesterol and signal 
transduction (Hommelgaard et al, 2005; Thomas and Smart, 2008; Bastini and 
Parton, 2010; Parton and del Pozo, 2013). The regions in which caveolae structures 
are located are rich in saturated phospholipids, sphingolipids, cholesterol and lipid-
linked proteins (Xu et al, 2015; Andreone et al, 2017). They are composed of 
proteins called caveolin (Kovtun et al, 2015). Caveolae appear in different 
conformations (Thomas and Smart, 2008), such as flask like shaped invaginations 
(Parton, Joggerst and Simons, 1994; Gumbleton et al, 2000; Bastini and Parton, 
2010) or tubular structures (Benlimame et al, 1998). Cholesterol dependent 
caveolae appear flat (Rothberg et al, 1992).  The low-density lipoprotein (LDL) 
receptor is located in these lipid rich regions on the plasma membranes of BECs, 
demonstrating that caveolae-mediated transport involves the transcytosis of LDL to 
the brain parenchyma (Méresse et al, 1991; Candela et al, 2008). The formation of 
the caveolae vesicles involves the interaction of the caveolin coating proteins and 
cavin protein complex, and budding involves GTPase dynamin (Bastini and Parton, 
2010; Preston, Abbott and Begley, 2014; Andreone et al, 2017).  
1.4.6 Carrier-mediated transport 
Carrier-mediated transporters (CMT) are located on the endothelial membranes 
and shuttle small hydrophilic molecules and essential nutrients to the brain such as 
glucose (GLUT 1) and amino acids (Large neutral amino acid- LAT-1) (Pardridge, 
2005; Ohtsuki and Terasaki, 2007; Abbott, 2013; Lajoie and Shusta, 2015). These 
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transporters are important in the regulation, support and functioning of the CNS 
(Ohtsuki and Terasaki, 2007; Abbott, 2013). Due to the presence of numerous 
mitochondria of the BECs and the high energy requirements of the brain fed almost 
exclusively by glucose (Oldendorf, Cornford and Brown, 1977; Benarroch, 2014), 
the GLUT1 transporter is one of the most abundant transporters of the BBB 
(Patching, 2017). 
1.4.7 ATP binding cassette (ABC) transporters  
ATP binding cassette (ABC) efflux pumps are responsible for the active transport 
of exogenous and endogenous molecules across membranes (Abbott et al, 2010; 
Abbott, 2013; Qosa et al, 2015; Strazielle and Ghersi-Egea, 2015; van Tellingen et 
al, 2015). Whilst these transporters are located on tissues and organs involved in 
adsorption, distribution, metabolism and excretion, they are highly expressed on 
the BBB (Robey et al, 2018). ABC efflux transporters play an important role in the 
protection of the brain through the removal of potentially harmful xenobiotics, as 
well as metabolic waste (Ashraf, Kao and Bendayan, 2014). However, they do this 
indiscriminately such that therapeutics designed for treatment of diseases such as 
glioblastoma, epilepsy and HIV, are also excluded and excreted (Miller, 2015). The 
level of expression relates directly to the accumulation and concentration of drug in 
the brain (Chan et al, 2013; Miller and Cannon, 2014). 
Of the seven ABC transporter family, A-G, the three most studied families include 
ABCB (specifically ABCB1), ABCC and ABCG (specifically ABCG2) due to their 
multidrug resistance (Xiong et al, 2015; Leandro et al, 2019). One of the most 
important of this family though, is the protein P-glycoprotein (P-gp or MDR1), 
encoded for by the gene ABCB1. This protein, located on the luminal surface of the 
BECs (Berarroch, 2012; Robey et al, 2018), acts to remove many pharmaceutical 
and non- pharmaceutical compounds, including many chemotherapeutics (Redzic, 
2011; Xiong et al, 2015; Thomsen et al, 2017).   
The ABCC family consists of the multidrug resistance-associated proteins 1-6 
(MRP1-6) located on both the luminal and abluminal membranes of BECs (Hartz 
and Bauer, 2011; Berarroch, 2012; Miller, 2015; Dréan et al, 2018). Substrates of 
MRP transporters are primarily, though not restricted to, chemotherapeutics as for 
P-gp transporter (Xiong et al, 2015).  ABCG2 encodes for the breast cancer 
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resistance protein (BCRP) transporter located on the luminal surface of BECs 
(Berarroch, 2012). Substrates include tyrosine kinase inhibitors, such as gefitinib, 
antineoplastic agents, including mitoxantrone, and antibiotics (Robey et al, 2007).  
Many ABC transporters are also expressed on astrocytes, pericytes, microglial cells 
and neurons (Löscher and Potschka, 2005; Ashraf et al, 2012; Sanchez- 
Covarrubias et al, 2014; Qosa et al, 2015). Whilst this mechanism is highly effective 
at protecting the brain from foreign substances and maintaining the homeostatic 
environment, for treating diseases of the brain, such as glioblastoma, this can prove 
extremely challenging. ABC transporters have also been reported to be 
overexpressed on glioblastoma cells conferring chemoresistance (Khamisipour et 
al, 2016; Dréan et al, 2018).  
1.5 Challenges faced developing a drug delivery system to the brain  
There are a number of factors influencing the delivery of drugs to the brain such as 
the restrictive, functional and pharmacological characteristics of the BBB, as 
previously mentioned (Section 1.1). However, the drug itself also presents itself 
with numerous challenges including the pharmacokinetics of the drug (adsorption, 
distribution, metabolism and excretion - ADME), size, charge, lipophilicity, solubility, 
binding to plasma proteins and permeability (Alavijeh et al, 2005; Bergström, 2005; 
Mannhold, 2005; Manallack, 2007). 
1.5.1 Pharmacokinetics 
The two most important characteristics of the ability of a drug to cross cell 
membranes include lipophilicity and solubility (Bergström, 2005; Mannhold, 2005). 
The acid-base dissociation constant, pKa, influences the ability of a drug to cross 
biological barriers (Manallack, 2007). This is based on the Henderson-Hasselbalch 
equation: 




where pH is the acidity of a buffer solution, pKa is the pH at which half of the drug 
is deprotonated/ionised, [A-] is the concentration of the conjugate base (accepting 
protons) and [HA] is the concentration of the acid (donating protons) (Manallack, 
2007). The equation describes the interaction of the drug in its ionised and non-
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ionised state which in turn relates to the lipophilicity and solubility of a drug and the 
pH of the environment in which it is interacting (Po and Senozan, 2001; Manallack, 
2007). A soluble or ionised drug is unable to cross a biological barrier. The rare 
exception is where a carrier mediated transporter exists, for example levodopa (L-
DOPA) transported by the large amino acid transporter 1 receptor (LAT1) (Tsuji, 
2005). However, the more lipophilic or non-ionised a drug the more permeable it is, 
leading to non-specific absorption throughout the body and influencing the 
concentration of the drug. Nonetheless, there are factors that influence and may 
prevent rapid uptake. 
The molecular weight and the number of hydrogen bonds a therapeutic can make 
influence its ability to penetrate the BBB (Habgood et al, 2000; Pardridge, 2003). 
Small drugs, which do not exceed 400-500 daltons (Da) appear to cross the BBB 
(Habgood et al, 2000). However, the more hydrogen bonds a molecule can form 
reduces the delivery of the drug across the BBB (Habgood et al, 2000). One such 
example is histamine, which is only 111 Da. It contains three nitrogen atoms that 
can form hydrogen bonds with water, and these prevent penetration across the 
BBB (Pardridge, 2003). When developing and designing a drug delivery system, 
such factors need to be considered.  
Penetration of compounds/drugs to the CNS is dependent upon a number of factors 
such as the rate (speed of delivery) and the extent (the concentration of the drug 
that crosses) (Reichel, 2015). Each of these factors have their own rate limiting 
steps. It is considered that the rate limiting factor influencing the rate at which a 
compound crosses the BBB is dependent upon the cerebral blood flow (CBF) and 
the permeability at the site of entry (Reichel, 2015). Other factors include the 
mechanism by which the compound requires to enter the brain, the transporters 
present at the BBB and the binding of the compound to plasma proteins (Reichel, 
2015).  
1.5.2 Drug extrusion from the BBB 
As previously mentioned, the ABC transporters are involved in adsorption, 
distribution, metabolism and excretion (ADME) through the influx of molecules and 
the removal of waste and xenobiotics (Section 1.4.7) (de Lange, 2004; Neuwelt et 
al, 2011). Paradoxically, the ABC transporters not only protect the brain from 
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xenobiotics, they also extrude certain drugs required to treat diseases of the brain 
through multidrug resistance (de Lange, 2004; Mahringer and Fricker, 2016; Robey 
et al, 2018). Acquired multidrug resistance is the ability of cells to develop 
resistance, after having been directly exposed, to drugs and their analogues (de 
Lange, 2004). The challenges faced are compounded by vast categories of 
substrates for the ABC transporters, most specifically P-gp transporters (Sanchez-
Covarrubias et al, 2014), including chemotherapeutics, antibiotics, antiepileptics, 
antidepressants and HIV-1 protease inhibitors (Mahringer and Fricker, 2016).  
The expression signatures of these transporters are also dependent upon CNS 
pathogenesis, for example overexpression of transporters P-gp, Bcrp, Mrp1 and 
Mrp 2 is observed with epilepsy, in AD and PD P-gp expression is downregulated 
(Mahinger et al, 2011) whilst overexpression of P-gp has been implicated in 
multidrug resistance of cancers such as glioblastomas (Haar et al, 2012; Miller, 
2015; Qosa et al, 2015).  Down regulation of P-gp and Brcp transporters, exporters 
of beta-amyloid plagues, is thought to facilitate the accumulation these neurotoxic 
proteins observed in AD (Mahinger et al, 2011). Whilst overexpression of ABC 
transporters on tumour cells is believed to reduce the accumulation and hence 
efficacy of therapeutics through extrusion (Wijaya, Fukuda and Schuetz, 2017). 
Both in vivo and in vitro studies have demonstrated an overexpression in ABC 
transporters correlating to higher resistance of chemotherapeutics including, but 
not limited to, etoposide (Nakai et al, 2009), a topoisomerase inhibitor, and 
alkylating agents carmustin and temozolomide (Goldwirt et al, 2014). 
1.6 Circumventing the BBB 
Due to the protective mechanisms of the BBB, drug delivery is intrinsically 
challenging. There are only a small number of drugs that are able to cross the BBB 
that treat diseases such as epilepsy, affective disorders and chronic pain (Ajay et 
al, 1999). Therefore, techniques have been developed in order to circumvent the 
BBB altogether.   
In order to overcome the physiochemical characteristics and challenges of the BBB 
a drug delivery system must fulfil certain criteria, as mentioned previously (section 
1.1 and 1.3), to deliver therapeutics to the target site. The key requirements for a 
successful drug delivery system have been suggested by Popov et al (2012) are 
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stability in blood, the ability to penetrate biological barriers and to demonstrate site 
specificity for target organs. Further requirements include the reduction of side 
effects, biocompatibility, retention of biological functionality and biodistribution (De 
Jong and Borm, 2008; Nagpal et al, 2013).  
A number of techniques have been used in order to circumvent the BBB or improve 
the delivery of drug across the BBB. One such example of the latter, is to increase 
the lipophilicity of the drug (Pardridge, 2003; Lu et al, 2014). Whilst this can lead to 
increased membrane permeation, this permeation will be non-specific potentially 
leading to unwanted toxic effects (Pardridge, 2003; Manallack, 2007; Nagpal et al, 
2013). This further results in non-target specificity and uptake which in turn 
influences both the pKa and pharmacokinetics, ultimately altering the concentration 
of drug available for delivery to the brain (Pardridge, 2003; Manallack, 2007). 
Increasing the lipophilicity of the therapeutic may also increase the molecular 
weight which can in turn restrict the drug from traversing the BBB (Pardridge, 2003). 
Therefore, rather than altering the drug, further techniques have focused on 
circumventing the BBB for drug delivery. 
1.6.1 Trans-cranial drug delivery 
Trans-cranial drug delivery involves the use of invasive techniques designed to 
bypass the BBB (Gabathuler, 2010; Vogelbaum and Aghi, 2015). They include: 
intracerebroventricular (ICV) delivery, intracerebral implantation and convection 
enhanced diffusion (CED) (Pardridge, 2005; Vykhodtseva et al, 2008; Cohen-
Pfeffer et al, 2017). ICV consists of a reservoir of drugs implanted under the scalp 
connected to a catheter delivering therapeutics to the cerebrospinal fluid of the 
ventricles (Temsamani et al, 2000; Pathan et al, 2009). Intracerebral implantation 
involves the delivery of therapeutics using controlled-release polymer implants 
(Brem et al, 1991; Fung et al, 1996). As these methods rely on diffusion across the 
brain, the concentration of the therapeutic from the site of administration to the brain 
parenchyma is seriously limited (Pardridge, 2005; Vykhodtseva et al, 2008). A 
further limiting factor may be a result of the initial steep drug concentration locally, 
potentially leading to toxicity to the surface of the brain (Pardridge, 2016).  
Convection enhanced diffusion is an alternative transcranial technique. Fluid 
containing a therapeutic is delivered, using a continuous pressure gradient, via a 
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catheter to the brain parenchyma (Bobo et al, 1994; Kunwar et al, 2010; Vogelbaum 
and Aghi, 2015). In studies in mice, the forced infusate demonstrated a preferential 
flow along white matter tracks, which appears to be linked to astrogliosis (Ai et al, 
2003; Voges et al, 2003; Pardridge, 2005). This demonstrates the limitations and 
potential concerns with such methods for humans. 
1.6.2 Trans-nasal delivery 
There are a number of therapies using the nasal route as a technique to circumvent 
the BBB using devices such as nebulisers and atomisers (Suman et al, 1999; Moller 
et al, 2011; Djupesland, 2013a), nanocarriers, examples include nanoparticles and 
nanogels (Khan et al, 2017) and further strategies including vasoconstriction and 
mucoadhesion (Perez et al, 2012). The rationale of trans-nasal delivery involves 
the delivery of the drug from the submucosal space to the arachnoid membrane, to 
enter the olfactory cerebral spinal fluid (CSF) and thus the BBB (Pardridge, 2005). 
However, it appears there are several factors preventing these events occurring 
(Pardridge, 2005). Due to the rapid clearance of CSF, drugs delivered to this locale, 
regardless of route of entry, will swiftly be removed and enter the peripheral 
bloodstream, and this is observed with ICV (section 1.6.1) (Pardridge, 2005). 
However, it has been suggested that delivery may occur via the trigeminal nerves, 
potentially bypassing the CSF (Liu et al, 2011; Djupesland et al, 2013b; Sisa et al, 
2019). Nonetheless, the arachnoid membranes, one of the three layers of the 
meninges involved in protecting the brain, consist of TJ’s similarly restrictive and 
preventative as the BECs (Kristensson and Olsson, 1971). Further limitations 
include restricted volume of administration of drugs, low permeability of hydrophilic 
drugs and short retention time influencing drug absorption (Wu et al, 2008; 
Lochhead and Thorne, 2012; Erdő et al, 2018). Anatomically, the olfactory region 
for rodents (50% of the nasal mucosa) and human (3-5% of the nasal mucosa) 
differs such that detection is difficult to track in CSF of humans (Graff and Pollack, 
2004; Westin et al, 2005; Pardridge, 2012). 
1.6.3 Cerebrospinal fluid vs blood-brain barrier delivery 
Drug delivery to the brain is a complex process due to the barrier produced by the 
BBB. CSF has been used an alternative to overcome this barrier (Rediz, 2011; 
Pardridge, 2012 and 2016). Drugs can be injected directly into the CSF; however, 
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penetration of the brain parenchyma is limited by diffusion (Pardridge, 2016). 
Therefore, it is a perceived misconception to measure drug concentration from the 
lumbar puncture (CSF) as an indicator of drug concentration of the brain interstitial 
fluid (ISF) (Pardridge, 2012 and 2016; Rizk et al, 2017). The BBB and blood 
cerebrospinal fluid barrier (BCSFB) are functionally and physiologically diverse 
(Pardridge, 2012; Rizk et al, 2017). The BBB is the interface of the vascular system 
and the CNS, and the BCSFB is the interface of the vascular system and CSF 
(Pardridge, 2012). The BCSFB comprises epithelial cells lining the choroid plexus 
(Pardridge, 2012). Anatomically, the BCSFB has a higher expression of pinocytotic 
vesicles, which includes clathrin-mediated, caveolae-mediated and 
macropinocytotic vesicles (Coomber and Stewart, 1986; Strazielle and Ghersi-
Egea, 2013). However, this difference also appears to influence the functionality of 
the barrier indicating a site of high endocytic activity (Strazielle and Ghersi-Egea, 
2013). 
The CSF compartment is separated from the blood by the choroid plexus 
(Pardridge, 2017). The primary role of the BCSFB is to secrete cerebrospinal fluid 
from the cerebral epithelial cells of the choroid plexus (Redzic, 2011). Delivery and 
exchange of molecules between the cerebrospinal fluid and interstitial fluid, the fluid 
that surrounds the brain parenchyma, are dependent upon similar factors governing 
the BBB such as size and lipophilicity, presence of receptors and concentration 
gradients (Abbott et al, 2018).  Therapeutics injected to the CSF in fact 
preferentially distribute to the blood rather than the brain (Pardridge, 2016). The 
surface area of the BBB and the number of capillary supplying and distributing 
blood within the brain parenchyma is considerably greater, 130-fold and 10-fold 
respectively, than that of the choroid plexus, thus influencing the potential uptake 
and concentration of drugs the brain is exposed to (Pardridge, 2016). This work 
demonstrates that this method is an unsuitable alternative.   
1.6.4 BBB Disruption 
BBB disruption has been used to circumvent the BBB. It is the physical disruption 
of the BBB to allow for paracellular entry. Methods include chemical disruption and 
ultrasound (Khan et al, 2017). One of the earliest chemical disruption techniques, 
osmotic shock, employed the injection of a hypertonic solution, mannitol, to 
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instigate cell shrinkage leading to opening of the tight junctions (Neuwelt et al, 1979; 
Brasnjevic et al 2009). However, disruption to the BBB does not discriminate which 
molecules can access the brain, and allows entry to potentially toxic plasma 
proteins, such as albumin (Guo et al, 2012).   
The use of focused ultrasound to transiently disrupt the BBB to improve drug 
delivery is another technique employed in order to circumvent the BBB (Hynynen 
et al, 2003; Kobus et al, 2016; Aryal et al, 2017). Janowicz et al (2019) used focused 
ultrasound to deliver AD antibody therapeutics in mice. There was no difference in 
uptake from the site of sonication or the whole brain. As a result of the appearance 
of skull distortions, this technique has been modified to improve the specificity with 
the introduction of intravenously injected microbubbles to allow for the use of a 
lower frequency, due to the oscillation of the microbubbles (Hynynen et al, 2006; 
Liu et al, 2016). Goutal et al (2018) demonstrated that disruption of the brain did 
not influence the delivery of erlotinib (an ATP inhibitor). Therefore, suggesting that 
further research is required to ensure the efficacy of delivery of specific therapeutics 
using this technique, and that there are no long-term health risks through the 
disruption of the BBB (Mäger et al, 2016).  
1.6.5 ‘Trojan Horses’ for endogenous transport systems 
Although the expression of specific receptors is lower for the BBB than other 
tissues, there are a number of receptors found that are overexpressed, such as the 
transferrin receptor, insulin receptor and low-density lipoprotein receptor (Guo et 
al, 2012; Gao, 2016).  As a result, endogenous transporters have been targeted as 
a potential drug delivery system, more specifically the transferrin receptor (TfR) has 
been the most widely targeted (Gao, 2016; Pardridge, 2006 and 2017). Trojan 
horse technology has been modified to investigate delivery of therapeutics across 
the BBB by ‘piggy backing’ the endogenous receptor. The Trojan horse is a receptor 
specific monoclonal antibody (mAb) designed to bind to the endogenous receptor, 
then penetrate the BBB with a fused therapeutic peptide (Pardridge, 2006 and 
2017). Despite the specificity of ligands to the receptor, it has been reported that 
the antibody binds to a region separate to the endogenous ligand rather than 
competing (Skarlatos, Yoshikawa and Pardridge, 1995). A further limitation is that 
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such receptors are located systemically indicating the possibility of non-brain 
specific uptake. 
1.6.6 Prodrugs  
A prodrug is a therapeutic that in its native state is biologically inactive. However, 
on arrival at the target site is activated. An example of a prodrug is levodopa (L-
DOPA), the precursor to dopamine, and the therapeutic used for the treatment of 
Parkinson’s disease (PD). Due to its structure, L-DOPA has a high affinity for a 
carrier mediated transporter (CMT) the large amino acid transporter 1 receptor 
(LAT1). Once L-DOPA is delivered to the brain, it is decarboxylated by the enzyme 
dopamine decarboxylase converting it from L-DOPA to dopamine (Pardridge, 
2006). Another example is Temozolomide (TMZ) an alkylating chemotherapeutic in 
the treatment of glioblastomas (Zhang et al, 2012). Once taken up, it is rapidly 
metabolised to the active form involved in methylation of purine bases of DNA (5-
aminoimidazole-4-carboxamide or AIC) (Zhang et al, 2012). Whilst these 
treatments can cross the BBB, there are specific drawbacks. L-DOPA is non-
specifically metabolised throughout the body leading to a number of side effects. 
Whereas the specific obstacle surrounding TMZ is chemoresistance, observed in 
some glioblastomas overexpressing protein methylguanine methyltransferase 
(MGMT).  
1.6.7 Liposomes 
Liposomes are colloidal drug carriers. They are bilayered vesicles carrying their 
payload within the lumen of the vesicle (Lian and Ho, 2001). The composition of 
the liposome membrane contains biocompatible materials, such as cholesterol, 
designed to improve its stability and capacity to cross biological barriers including 
the BBB (Brasnjevic et al, 2009; Kabanov and Batrakova, 2017). The formulation 
and composition of the bilayer will determine the size of the liposome from 
nanometres to micrometres (Sharma and Sharma, 1997; Lian and Ho, 2001; 
Kabanov and Batrakova, 2017). There are numerous benefits to encapsulating a 
therapeutic within a colloidal drug carrier as they can reduce the potential for 
adverse side effects and protect against enzymatic interactions with the drug, 
potentially improving bioavailability (Brasnjevic et al, 2009; Kabanov and 
Batrakova, 2017). However, liposomes are rapidly removed from cells by efflux 
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pumps (Tamai and Tsuji, 2000; Kabanov and Batrakova, 2017) and have a 
relatively low encapsulation capacity (Grinberg et al, 2010). Liposomes have also 
demonstrated aggregation in plasma hampering their delivery (Ishida et al, 2002; 
Zhang et al, 2016). Cationic liposomes have a rapid clearance in tissues such as 
lung, spleen and liver (Thurston et al, 1998).   
1.6.8        Exosomes  
Exosomes are extracellular vesicles that originate from endosomes (Alvarez-Erviti 
et al, 2011). They are produced from intraluminal vesicles formed in multivesicular 
bodies of late sorting endosomes that are transported to the plasma membrane for 
exocytosis (Kallumi and LeBleu, 2020). They are endogenous vesicles of 
approximately 40-160 nm in size encapsulating a range of constituents from RNA 
to proteins (Alvarez-Erviti et al, 2011; Kallumi and LeBleu, 2020). They can be 
engineered to deliver a range of therapeutics including siRNAs (Alvarez-Erviti et al, 
2011), and can also be synthesised to mimic the characteristics of endogenous 
exosomes (Jang et al, 2013; Oh et al, 2015). For example, exosomes have been 
engineered to express the rabies virus glycoprotein (RVG), to target neurons and 
glial cells, in order to deliver siRNAs specific to BACE1, a protease that cleaves the 
amyloid precursor protein (APP) involved in the aggregation of β-amyloid protein, 
resulting in knockdown of this gene (Alvarez-Erviti et al, 2011). However, there are 
a number of limitations to the therapeutic use of exosomes, including difficulties in 
endosomal isolation and purification as well as their heterogenous sizes (Furi et al, 
2017; Li et al, 2019). Moreover, the use of endogenous exosomes is limited by 
differential shape, cargo and production efficiency by differing cell types 
(Mentkowski et al, 2018; Li et al, 2018).   
1.6.9 Bolaaamphiphiles  
Bolaamphiphilic (BA) compounds are molecules with either one or two long alkyl 
carbon chains, or, in some instances, macrocyclins such as porphyrins or steroids 
connected by hydrophilic head groups (Escamilla and Newkome, 1994; Fuhrhop 
and Fritsch, 1986; Fuhrhop and Wang, 2004). However, for this thesis the focus is 
on BAs comprised of a carbon chain with polar head groups. The word ‘bola’ 
originates from South America relating to a missile weapon consisting of two ball 
shaped heads connected by a cord (Fuhrhop and Fritsch, 1986). In 1951, the term 
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‘bolaform electrolyte’ was used to describe a hydrophobic chain connected to ionic 
headgroups at either end (Fuoss and Edelson, 1951; Fuhrhop and Fritsch, 1986).  
1.6.9.1 Structure of bolaamphiphiles  
Synthetic BAs are based on monolayered lipid membranes produced by archaea 
(Fuhrhop and Fritsch, 1986). BAs produced from archaea are difficult to isolate, as 
a result their architecture has been reproduced (Grinberg et al, 2010). However, 
rather than the characteristic ether bonds designed to enable archaea to inhabit 
highly acid environments, synthetic BAs are formed by ester bonds (Fuhrhop and 
Fritsch, 1986; Fariya et al, 2014). Synthetic BAs are composed of one or two 
hydrophobic chains connected by two hydrophilic head groups (Han et al, 2004). 
There are a number of potential combinations of head groups or moieties for BAs 
as they do not need to be identical nor polar (Fuhrhop and Fritsch, 1986; Han et al, 
2004). The head groups can compose of different moieties to form asymmetric or 
symmetric compounds (Fuhrhop and Fritsch, 1986; Han et al, 2004; Nuraje et al, 
2013). They can form numerous different structures based on the length of the 
hydrophobic portion and presence of a moiety, such as nanotubules (Fuhrhop et 
al, 1993; Shimizu et al, 2005), nanorods (Fuhrhop et al, 1993; Shimizu et al, 2005), 
ribbons (Shimizu and Masuda, 1997), spherical vesicles (Grinberg et al, 2010), 
cylindrical vesicles (Fuhrhop and Wang, 2004; Shimizu et al, 2005; Singh et al, 
2018), helices (Shimizu and Masuda, 1997) and fibrous structures (Franceschi et 
al, 2000, Grinberg et al, 2010). Fariya et al (2014) reported that condensation and 
substitution reactions are utilised in the production of BAs composed of α,ω-diols, 
-diamines, -dihalides and dicarboxylates. 
Theoretically, BAs encapsulate a higher volume by default as the lumen volume 
should be greater than that of a bilayered vesicle of the same size (Puri et al, 2009). 
They are deemed more stable due to the transmembrane configuration of the 
membrane protecting from delamination (Puri et al, 2009; Singh et al, 2018). By 
virtue of the monolayer lipid membrane, BAs are less likely to fuse with lipid 
membranes, referred to as lipid exchange, as well as themselves than bilayered 
vesicles (Puri et al, 2009).  As a result, they exhibit the potential to cross the 
biological barrier intact (Puri et al, 2009).   
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Vernonia oil, obtained from Vernonia galamensis has been utilised as a suitable oil 
to synthesise BA molecules with a range of different head groups (Grinberg et al, 
2008; Grinberg et al, 2010). BAs can form a mono-layered membrane in the form 
of a raft when in aqueous/polar solutions.  When disrupted by ultrasound the raft 
forms vesicles encapsulating molecules present in the aqueous solution. They are 
similar to liposomes, mentioned previously (section 1.6.7), as they form vesicles 
encapsulating cargo in the lumen (Popov et al, 2010). They are biocompatible and 
certain BA derivatives with choline head groups have been suggested to cross the 
BBB (Dakwar et al, 2012; Popov et al, 2012 and 2013). However, unlike liposomes, 
BA form monolayered vesicles, increasing their potential encapsulation capacity 
(Puri et al, 2009; Popov et al, 2010). This is also advantageous as there is less 
lipid-lipid exchange between biological membranes and the vesicles in comparison 
to liposomes with their bilayer membrane, with the potential to retain both their 
structure and cargo (Puri et al, 2009; Popov et al, 2010). They are reportedly more 
stable than liposomes (Grinberg et al, 2010). As BA vesicles encapsulate their 
cargo, they can increase the bioavailability, and reduce adverse side effects if they 
can be made to target particular sites (Zhang et al, 2015).  
1.6.9.2 Applications of bolaamphiphiles  
BAs have been used for a number of applications such as gene delivery (Gupta et 
al, 2015), electronics and drug delivery (Nuraje et al, 2013). BAs, synthesised from 
jojoba oil, have been investigated for the delivery of siRNAs due to the electrostatic 
interactions between the cationic headgroups and anionic properties of the siRNA 
(Gupta et al, 2015).  
BAs have the potential to be used as a brain drug delivery system. Popov et al, 
(2012) suggested that using an acetylcholine ester group would be hydrolysed by 
the presence of CNS derived acetylcholine esterase (AChE) preventing their 
egress. Dakwar et al (2012) showed in mice that vesicles made from such BAs 
when loaded with fluorescein isothiocyanate (FITC)-labelled BSA, delivered 
intravenously, penetrate all major organs. In the presence of the peripherally- acting 
AChE inhibitor, pyridostigimine, vesicle stability increased and significant levels of 
labelled BSA were found in the brain. As pyridostigimine is licensed for the 
treatment of myasthenia gravis (Maggi and Mantegazza, 2011) it is proposed that 
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it will be safe for adjunct therapy. These vesicles were subsequently reported to 
have been used to successfully treat brain HIV infections with encapsulated drugs 
normally excluded by the BBB, however, a full report of this study has not yet been 
published (Heldman et al., 2014). A further property of positively charged BAs is 
their ability to bind siRNA on their surface. Studies have been reported showing 
their successful delivery of siRNA, bound on the vesicle exterior, to neuroblastomas 
(Kim et al, 2013 and 2020). 
The precise mechanism whereby this group of BA vesicles can cross the BBB has 
not been demonstrated. It has been hypothesised on the basis of limited data to 
occur through transcytosis (Fenhart et al, 1999, Dakwar et al, 2012). It is not clear 
if the acetylcholine head group is required for uptake or if some character of the 
backbone fatty acid chain derived from vernonia oil imparts this capability. It is clear 
that their stability in whole serum is limited (approximately two hours) and that 
pyridostigimine more than doubles this (to five hours). The question arises as to 
whether BA vesicles could be an effective delivery system for glioblastomas. 
Chemotherapeutics, such as etoposide, have difficulty crossing the BBB (Bart et al, 
2000). A study demonstrating the use of folic acid and lactoferrin tagged 
poly(lactide-co-glycolide) (PLGA) nanoparticles encapsulating etoposide for 
treatment of glioblastomas appeared to target tumours though compromised the 
viability of the BBB (Kuo and Chen, 2015). Using brain penetrating BA vesicles 
encapsulating cytotoxic drugs such as etoposide could be an effective method to 
deliver to glioblastomas.   
1.7 Hypothesis and aims 
BAs produced from vernonia oil can be used as a suitable drug delivery system to 
treat diseases of the brain.  
The overall aim of the project is to develop a robust methodology in order to 
produce stable BA vesicles to ultimately cross the BBB and delivery therapeutics 
to the brain to be used as an effective drug delivery system to treat diseases of the 
brain.  
In order to test the hypothesis and reach the overall aim there are several criteria 
and objectives to ensure the drug delivery system is suitable. Therefore, the main 
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objectives will be to test the physicochemical properties of the vesicles. The system 
will need to be profiled for size, charge/stability, and encapsulation efficiency, as 
well as to test the ability of the vesicles to encapsulate various tracer dyes, 
molecules and drugs (Chapter 2). Secondly, it is important to investigate the 
potential toxic effects of BA vesicles and to determine whether they are taken up 
by both brain cell types and cells representative of putative clearance pathways, 
studies that will be further supported by analysis of vesicle uptake in vivo (Chapter 
3).  The final objective of this thesis is to produce a protocol to improve the overall 












2.1  Challenges surrounding penetrating the blood-brain barrier 
The lack of pharmaceuticals that can successfully penetrate the brain is one of the 
challenges faced in treating CNS disorders. The BBB protects the brain and 
maintains the homeostatic environment of the CNS, which is essential for healthy 
neuronal function (Daneman, 2015). It is a highly effective pharmacological, 
metabolic and physical barrier, and is the primary impediment for delivery of 
treatment for diseases of the brain. Therapeutic agents are restricted from crossing 
the BBB based on their lipid solubility, molecular size, the number of hydrogen 
bonds that can be formed and charge (Olanow et al., 1991; Garcia-Garcia et al, 
2005; Banks and Greig, 2019). Large molecules are unable to penetrate the BBB 
due to the limited expression of receptors located on the brain endothelial cells 
(BECs). The tight junctions of the BECs also prevent paracellular entry of >98% of 
small molecules across the BBB to the brain  (Pardridge, 2005; Pardridge, 2012, 
He et al, 2018). Chemotherapeutics, such as etoposide, are effectively ejected from 
BECs by the ABC transporters (Bart et al, 2000, Wang et al, 2019). Thus, 
developing a delivery system that is capable of delivering drugs to the brain whilst 
ensuring the integrity of the brain and the functions of the barrier are not 
compromised is a significant challenge.  
The measurement of drug efficacy is the ability of the drug to reach the target site 
in its unbound state to elicit its response (Warren, 2018). Encapsulation of drugs in 
vesicles and nanoparticles may thus allow for greater delivery of a therapeutic to 
the target site, restricting non-specific interactions and allowing for more of the 
therapeutic to be delivered. This would reduce the potential for unwanted side 
effects, whilst increasing bioavailability. An example is the non-pegylated liposomal 
doxorubicin (NPLD), Myocet™, used to treat ovarian and breast cancer (Leonard 
et al., 2009). Doxorubicin is an anthracycline, a cytotoxic drug which is also 
cardiotoxic (Von Hoff et al, 1979). Encapsulation of doxorubicin within the lumen of 
the liposome has been shown to reduce cardiotoxicity and improve delivery to 
highly vascularised sites, such as tumours (Leonard et al., 2009). Bolaamphiphiles 
(BAs) may be used for similar applications, specifically to cross the BBB and deliver 
drugs to the brain.  
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2.1.1  Bolaamphiphiles as a vehicle for drug delivery 
BA vesicles can encapsulate molecules, including therapeutic agents, present in 
the original solution in which they form rafts prior to ultrasound disruption (Popov et 
al, 2010). GLH-20 (figure 2.1), a cationic BA molecule with an acetylcholine head 
group, forms vesicles that apparently cross the BBB via transcytosis (Dakwar et al, 
2012; Popov et al, 2012). GLH-20 vesicles are hydrolysed by acetylcholinesterase 
(AChE) (Popov et al, 2012) which is found in appreciable amounts in the brain, as 
well as throughout the periphery and (as pseudocholinesterase) in the blood, where 
it is responsible for terminating nerve transmission by cleaving the neurotransmitter 
acetylcholine into acetic acid and choline (Gjerløff et al, 2014; Watabe et al, 2014). 
In these studies on GLH-20, pyridostigmine was used to inhibit circulating 
cholinesterase lysing the vesicles (Popov et al, 2012; Dakwar et al, 2012).  
BAs present several advantages over the liposome vesicles that have been used 
previously. Most notably, they are capable of forming monolayered vesicles (Popov 
et al, 2010), and are thus less likely to interact with the cell membrane and are 
therefore more likely to remain intact (Grinberg et al, 2008; Popov et al, 2010). 
Moreover, bolaamphiphile vesicles have the potential to encapsulate a higher 
payload than liposomes, with evidence suggesting that they may be able to 
encapsulate small proteins (Dakwar et al, 2012). Thus, they are likely to prove a 
significantly more efficient therapeutic delivery system.  
 
Figure 2.1. The molecular structure of bolaamphilphilic compound GLH-20. 
GLH-20 is synthesised from vernolic acid. The acetylcholine head groups of the 
bolaamphiphile enable the vesicles to be lysed by acetylcholinesterase. 
2.1.1.1  Antibody fragments 
New generation anti-cancer therapeutics have been designed linked to small chain 
variable fragments (scFv) that target them to specific antigen expressing cells 
(Flynn et al, 2016; Zammarchi et al., 2016). ADCT-502 is one such antibody drug 
conjugate (ADC) that targets HER-2 expressing tumours (Zammarchi et al, 2016). 
However, to effectively treat glioblastomas with such therapeutics, they must 
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access the brain. Whilst whole antibodies are large molecules and thus may be 
difficult to encapsulate, antibody fragments comprised of the variable heavy and 
variable light regions of the antibody, and containing the important antigen binding 
site, are smaller and may offer an alternative approach. The fragment scFv 4D5-
8RFP (figure 2.2) is smaller than an antibody (52 kDa as opposed to 150 kDa, 
respectively), but retains the antigen binding characteristics (Markiv et al., 2011). 
scFv 4D5-8RFP is specific to human breast and ovarian cancer, binding to the 
HER2 protein, and is engineered to contain the red fluorescent protein to identify 
cells expressing HER2 (Eigenbrot et al, 1992; Markiv et al, 2011). To model the 
ability of BAs, to carry therapeutic proteins, including antibody fragments, across 
the BBB, scFv 4D5-8RFP has been selected. 
                
Figure 2.2. A 3D model of REDantibody molecule. The scFv 4D5-8RFP is 
comprised of variable heavy and light chains (green and yellow domains, 
respectively) attached through linkers to the red fluorescent protein domain (mRFP) 
[Reproduced with permission from Markiv et al, 2011]. 
2.2  Aims: 
The overall objective is to investigate the capabilities of the BA vesicles as a drug 
delivery system in vitro. 
1. To investigate the encapsulation of small molecules such as the dyes 




2. To investigate the size and stability of these vesicles 
3. To investigate the physical characteristics of the vesicles and their different 
cargoes 
2.3  Methods 
2.3.1  Materials- source of reagents 
Table 2.1. The list of materials and their suppliers used throughout 
chapter 2.  
MATERIALS SUPPLIER ADDRESS 
Candida Antarctica lipase B 
(CALB) (Novozym 435) 
(catalog # 06-3123) 
Strem Chemicals Newtown, Cambridge, 
UK 
uranyl acetate (catalog # 
AGR1260A) 
Agar Scientific Stanstead, Essex, UK 
DMEM (catalog # BE12-614F), 
PBS (catalog # BE17-516F), 
Trypsin/EDTA (catalog # CC-
5012), penicillin/streptomycin 
(catalog # 09-757F),   
Lonza Slough, UK 
EtOH (catalog # 20821.330DP)  VWR Chemicals Leicestershire, UK 
Cholesterol (catalog # C8667), 
cholesteryl hemisuccinate 
(catalog # C6512), glycerol 
(catalog # G5516), Brilliant 
Blue R (catalog # S5130) 
Sigma Aldrich Irvine, UK 
Fetal bovine serum heat 
inactivated (catalog # FB-
1001H) 
Biosera East Sussex, UK 
TEMED (catalog # 17919), 
acetic acid (catalog # 
10384970), 1,10 decanediol 
(catalog # 10403515), 
petroleum ether (catalog # 
42085.K7), ethyl acetate 
(catalog # 22912.K2), Pierce™ 
unstained protein MW marker 
(catalog # 26610), CellMask 
Plasma Membrane stain 
(catalog # C10046), DAPI 
(4',6-diamidino-2-phenylindole) 
(catalog # D1306), propidium 







MATERIALS SUPPLIER ADDRESS 
chloroform (catalog # C2432), 
methanol (catalog # 10675112 
Formaldehyde (catalog # 
104003), sodium dodecyl 
sulphate (catalog # 817034), 
bromophenol blue (catalog # 
108122), toluene (catalog # 
108331), diethyl ether (catalog 
# 309966), chloroacetic acid 
(catalog # 800412), ampicillin 
(catalog # 171254), 
tetracycline (catalog # 58346), 
chloramphenicol (catalog # 
220551), IPTG (catalog # 
420322), imidazole (catalog # 
104761), Triton X-100 (catalog 
# X100), mowiol (catalog # 
475904) , Ni-NTA agarose 
resin (catalog # GE17-5268-
01), sepharose CL-4B beads 




Alexa Fluor 546 (catalog # 
A10237) 
Invitrogen Renfrewshire Scotland 
Acti-stain-488 phalliodin 
(catalog # PHDG1) 
Cytoskeleton, Inc Denver, USA 
• Tris (catalog # 60040), glycine 
(catalog # G36050), yeast 
extract (catalog # Y20025), 
NaCl (catalog # S23020), 
kanamycin (catalog # K22000), 
acrylamide (catalog # A11275), 
ammonium persulphate 
(catalog # A20500), tryptone 
(catalog # T60060), lysozyme 
(catalog # L38100), 
dithiothreitol (DTT) (catalog # 
D11000) 
Melford CheImsworth, Ipswich, 
UK 






2.3.2 Synthesis of bolaamphiphile GLH-20 
A crude vernonia oil preparation was obtained from Arno Hugo (University of the 
Free State, Bloemfontein, South Africa). The general scheme for the synthesis is 
shown in figure 2.3. Synthesis of BAs was performed in collaboration with Dr Sumi 
Lee and Professor Lawrence Williams (Rutgers, USA) Grinberg et al (2008). The 
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addition of 1,10-decanediol and an immobilised Candida antarctica lipase B (CALB) 
(Novozym 435), as the catalyst, with toluene for 8 hours generated product 3. 
Toluene was dissolved in the mixture of product 3 with the addition of chloroacetic 
acid at 100 oC for 21 hours monitored by thin layered chromatography (TLC). 
Diethyl ether was added to the cooled mixture and washed, twice with 5% (w/v) 
sodium bicarbonate solution and four times with water. The final step was the 




Figure 2.3 Schematic representation of the production of GLH-20 bolaamphiphile. There are four steps involved in the 
production of GLH-20 BAs. The first step is the hydrolysis of esters, followed by the coupling reaction in the presence of the 
catalyst Candida antarctica lipase B (Novozym 435). Step 3 involves the addition of chloroacetic acid. The final step is the addition 
of acetylcholine. The methods have been improved for stability and yield. 
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2.3.3 Protein expression and purification 
Rosetta gami BL21-DE3 (kindly given by Dr Anatoliy Markiv), containing a plasmid 
expressing the red fluorescent protein 4D5-8RFP, were inoculated into lysogeny 
broth (LB - 10 g/l tryptone, 10 g/l yeast extract and 5 g/l sodium chloride) (Sezonov, 
Joseleau-Petit and D’Ari, 2007) containing 100 μg/ml ampicillin, 12.5 μg/ml 
tetracycline, 15 μg/ml kanamycin and 34 µg/ml chloramphenicol, then grown 
overnight at 37oC with shaking. The overnight culture was diluted 1/100 into pre-
warmed LB broth with antibiotics as above and incubated at 37oC under agitation 
at 250 rpm until an optical density (595nm) of 0.5-0.8 was reached. Flasks were 
placed on ice for 30 minutes, after which 0.3 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added and the culture was incubated for a 
further 20 hours at 20oC under agitation at 250 rpm. Bacterial cells were then 
pelleted at 4800 x g for 20 minutes using a Heraeus Megafuge 40 centrifuge, then 
resuspended in Tris-Glycerol-NaCl (TGN) buffer (50 mM Tris, pH 7.5, 250 mM 
NaCl, 10% v/v glycerol) with 10 mM imidazole, approximately 25 ml per litre of 
original culture. These cells were stored at -80oC. 
To purify overexpressed protein frozen cells were defrosted in an ice/water bath. 
Lysozyme was added to 1 mg/ml final and incubated on ice for 30 minutes, followed 
by addition of Triton X-100 to 0.1% v/v final concentration with a further incubation 
on ice for 30 minutes. Lysed cells were then sonicated using a MS73 probe 
(Bandelin Sonopuls, Germany) for a minimum of 3 x 30 second bursts at 40% 
maximum amplitude in an ice-water bath. Cell debris and sheared DNA was 
removed by centrifugation at 25,000 x rpm using a Sorvall T-865 ultracentrifuge.  
Soluble protein was then incubated with Ni-NTA agarose resin (GE Healthcare, 
Sweden). Ni-NTA agarose beads were prepared by centrifuging for 1 minute at 
1500 x rpm using a Universal 320R centrifuge before resuspending in TGN 10 mM 
imidazole buffer.  Beads were washed twice more with this buffer before adding to 
the protein supernatant. The mixture was then agitated gently at 4oC before beads 
were collected by centrifugation for 1 minute at 1000 x rpm using a Universal 320R 
centrifuge. Beads were resuspended in TGN with 10 mM imidazole, poured into a 
25 ml chromatography column (Bio-Rad, Hertfordshire, UK) then washed with a 
minimum of 50 column volumes of TGN with 10 mM imidazole. Protein was eluted 
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with 5 column volumes of Tris 50 mM pH 7.5, glycerol 10% v/v, NaCl 100 mM and 
imidazole 250 mM.  
2.3.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Equivalent volumes of protein samples and Laemmli buffer (4% w/v SDS, 20% v/v 
glycerol, 200 mM dithiothreitol (DTT), 0.01% w/v bromophenol blue and 0.1 M Tris 
HCl), were mixed and denatured by heating at 95°C for 10 minutes, to linearise the 
protein, and centrifuged at 13000 x g for 5 minutes using a Universal 320R Hettrich 
centrifuge prior to loading onto a 12% polyacrylamide gel (resolving gel - 0.375 M 
Tris, pH 8.8, 40% w/v polyacrylamide, polymerised by the addition of TEMED and 
10% w/v ammonium persulphate in a 1:5 ratio: stacking gel -125 mM Tris, pH 6.8, 
4-5% w/v polyacrylamide, again polymerised by the addition of a 1:5 ratio of 
TEMED and 10% w/v ammonium persulphate). Samples and molecular weight 
ladder (MW 116 - 14.4 kDa) (Thermo Fisher Scientific, UK) were then separated by 
electrophoresis at 180 V for 45 minutes in running buffer (250 mM Tris, pH 7.5, 1.92 
M glycine, 1% w/v SDS). 
Gels were stained with Coomassie Brilliant Blue (methanol 40% v/v, acetic acid 
10% v/v, dH2O and 0.25% w/v Brilliant Blue R) for 30 minutes on a shaker at 60 
rpm and destained (in the same buffer omitting 0.25% Brilliant Blue R) for 
visualisation of protein separation. 
2.3.5 Synthesis of vesicles  
The compounds encapsulated were AF546 in PBS (final concentration 125 mM), 
propidium iodide in PBS (final concentration 125 µg/ml propidium iodide) and scFv 
4D5-8RFP in PBS (final concentration 4.6 µM). 
BA (10 mg/ml) was mixed with cholesterol (1.6 mg/ml), and cholesteryl 
hemisuccinate (CHEM) (2.1 mg/ml) and dissolved in chloroform. A rotary 
evaporator (Stuart®) under vacuum at 35oC was used to remove the solvent. The 
BA mixture was rehydrated with 0.01 M PBS alone or the desired molecule (125 
mM for AF546, 125 µg/ml propidium iodide, and 4.6 µM scFv 4D5-8RFP) in PBS 
or 10 mM NaCl and transferred to ice. The mixture was sonicated using an MS73 
probe sonicator (Bandelin) for 12 mins at 40% amplitude, performing 15s pulses 
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and pausing for 10s (390 pulses in total). Vesicle size was measured using dynamic 
light scattering (DLS) (Section X). A Nanopartica Analyser SZ-100, (Horiba UK Ltd, 
UK) was used for profiling empty, propidium iodide, AF546 and scFv 4D5-8RFP 
encapsulated vesicles (see section 2.2.6). Vesicles were stored in 0.01 M PBS or 
10 mM NaCl at 4oC. 
2.3.6  Vesicle purification 
A 200 ml column of Sepharose CL-2B beads was prewashed with two volumes of 
vesicle buffer (0.01 M PBS or 10 mM NaCl) before addition of 500 µl of vesicle 
preparation; PBS was used for empty vesicles. Fractions were collected as 1 ml 
volumes with vesicle containing fractions located using DLS and confocal 
microscopy (see sections 2.3.7 and 2.3.13, respectively). 
3.3.6 Dynamic Light Scattering 
Dynamic light scattering (DLS) is a technique used to establish the physiochemical 
properties of a particle, such as the hydrodynamic diameter, also referred to as the 
z-average, and the polydispersity index (PDI) (ISO22412, 2017). DLS measures 
the random interactions of particles in suspension, also referred to as Brownian 
motion, when a laser is directed on the sample. This causes light to scatter as the 
particles randomly diffuse through a liquid. The size of the particles reflects the 
speed at which they interact. DLS measures the intensity of these random and 
temporal fluctuations of the light that is scattered from the particles in the sample. 
Samples of either neat or purified vesicles were loaded into semi-micro disposable 
cuvettes diluted 1:10 in deionised water and particle sizes were measured using a 
Nanopartica Analyser SZ-100 (Horiba) with a range of 0.3 nm - 0.8 µm. A minimum 
of three measurements were taken of each sample. The dispersion medium 
viscosity is 0.895 mPa·s for the deionised water and PBS that the samples were 
measured in. 
2.3.8  Electron microscopy 
Diluted vesicle samples in 0.01 M PBS (1:100) were applied onto freshly glow-
discharged (negatively) carbon-coated copper grids (300 mesh). The grids were 
negatively stained with 2% w/v uranyl acetate using the touching drop method 
(Rubinstein, 2007). Images were obtained using transmission electron microscope 
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(JEM-2100, JEOL) as part of the service provided by the Research Complex at 
Harwell, as part of the national MRC platform initiative. 
2.3.9  Vesicle Stability  
The zeta potential of the vesicles was measured monthly over a four-month period. 
Samples of either empty or AF546 encapsulated vesicles, that had yet to be purified 
by size exclusion chromatography, were injected into a capillary cell, alongside 
vesicle preparations diluted 1:10 in deionised water. Zeta potentials were measured 
using a Nanopartica Analyser SZ-100 (Horiba). Three readings were taken for each 
sample.  
2.3.10 Autofluorescence spectra analysis  
Preparations of 100 µl empty vesicles and PBS were examined in triplicate in a 96 
well microplate (Nunc) using a CLARIOstar fluorescence plate reader (BMG 
Labtech) for a full spectrum scan. 
2.3.11  Cell lines 
Cell lines, neuroblastoma SH-SY5Y and LN229 glioblastoma (ATCC), used for 
vesicle uptake studies were chosen as representative of the cells of the brain during 
disease. SH-SY5Y is a model cell for Parkinson’s disease. LN229 is a glioblastoma 
derived cell line. Cells were grown in Dulbecco’s Minimum Essential Medium 
(DMEM) with 5% v/v foetal bovine serum (FBS, previously heat decomplemented 
by 30-minute incubation at 56°C; Biosera Ltd., UK), 1% v/v penicillin and 
streptomycin. Cells were incubated at 37oC for 3-4 days under 5% v/v CO2 until 
70% confluent.  
2.3.12  Routine cell culture  
All cell line work was performed in a laminar flow hood with aseptic technique. Cells 
were maintained in sterile 75 cm2 flasks. Cells were passaged when they appeared 
70% confluent. Spent media was removed and cells were washed with sterile 0.01 
M PBS without Ca2+ for 5 minutes at 37oC. PBS was removed and 0.25% w/v 
trypsin, 1 mM EDTA was added and cells were incubated for 5 minutes at 37oC. 
Following dilution of trypsin with fresh medium containing 5% v/v FBS, cells were 
counted using a haemocytometer, centrifuged at 800 x g using an IEC CL30 
41 
 
centrifuge for 5 minutes, resuspended and re-plated for further growth or 
experimentation at 15,000 cells/cm2 in appropriate medium. 
Chamber slides were seeded with 1x105 SH-SY5Y or LN229 cells/cm2 and cultured 
for 2-3 days. Cells were then incubated for 30 minutes, LN229, with final 
concentration of 3.5 µg/ml AF546 encapsulated vesicle in media prior to removal of 
spent medium, washing with PBS, fixing by immersion in 4% v/v formaldehyde in 
PBS for 10 minutes. SH-SY5Y cells were washed and counterstained for 1-hour 
incubation with 1:1000 dilution of CellMask™ Plasma Membrane stain (Thermo 
Fisher Scientific), to stain the plasma membrane. LN229 cells were washed and 
counterstained with phalloidin-acti-stain-488 (Cytoskeleton Inc) (1:140 dilution), for 
visualisation of the cytoskeleton, for 20 minutes. DAPI (final concentration 50 
ng/ml), to define the nuclei, was used for 10 minutes. Chamber slides were then 
washed and mounted with Mowiol 4-88 (24% w/v glycerol, 9.6% w/v Mowiol, dH2O, 
0.2 M Tris, pH 8.5). 
2.3.13  Confocal microscope 
Confocal microscopy was used to determine the peak fractions of vesicles in 
unknown samples and in uptake studies. Following adjustment of gain and offset, 
cells and vesicles were imaged at 1024 x1024 resolution, using an oil immersion 
x63 objective on a Leica LSM880 laser scanning confocal microscope running Zen 
software. A minimum of 3 images were collected per well. Lasers used were 405 
nm diode laser (for DAPI stain), 488 nm Argon-Krypton (for Phalliodin cytoplasmic 
staining), 561 nm diode (for AF546), and 633 nm HeNe (for the plasma membrane 
stain). 
2.3.14 Encapsulation efficiency of bolaamphiphile vesicles 
The encapsulation concentration is a quantitative indication of the efficiency of 
encapsulation of the delivery system. It is a measure of the amount of molecule 
incorporated in the delivery system which is defined as the percentage of molecule 
in the system (final concentration) relative to the initial concentration of molecule 
(Papadimitrious and Bikiaris, 2009). The encapsulation efficiency of the vesicles 
was calculated using following formula from equation 1: 
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The concentration of encapsulated AF546 was determined by comparison with a 
standard curve consisting of serial dilutions of AF546, range 0.1- 100 µM assayed 
by fluorescence spectrophotometry. Preparations of 100 µl vesicles or standards 
were examined in triplicate in a 96 well microplate (Nunc) using a CLARIOstar 
fluorescence plate reader (excitation filter 540-20 nm, emission filter 590-30 nm) 
(BMG Labtech). Linear regression analysis was performed using MARS Data 
Analysis Software (BMG Labtech). Fluorescence values for encapsulated vesicles 
were compared with linear regression results to determine the final concentration. 
A typical standard curve is presented in figure 2.4. 
 
Figure 2.4 Standard curve of Alexa Fluor 546 concentrations. 0.1-100 µM of 
AF546 were assayed by fluorescent spectrophotometry (excitation 540-20 nm, 
emission 590-30 nm) to determine the concentration of AF546 encapsulated within 
vesicles. R2=0.9994 
2.3.15  Statistical Analysis 
Results are expressed as mean ± standard error of mean (SEM). All statistical 
analysis was performed using SPSS (version 25). Data was analysed using one-
way ANOVA test with post hoc analysis using Tukey’s honest significant difference 
test. Values of p ≤ 0.05 were considered significant. 
  





















































2.4  Results 
To investigate the capabilities of our BA vesicles as a drug delivery system in vitro, 
they were encapsulated with tracer dyes, including PI and AF546. To explore the 
ability to carry therapeutic proteins the BA vesicles were encapsulated with 
antibody fragment scFv 4D-8RFP, recombinantly expressed and purified from E. 
coli. In vitro work for PI and scFv 4D5-8RFP encapsulated vesicles is carried out in 
chapter 3.  
2.4.1  Expression of scFv 4D5-8RFP 
The antibody recognising the HER2 protein incorporating the red fluorescent 
protein, scFv 4D5-8RFP (figure 2.2) was produced in Rosetta gami (DE3) E.coli, 
purified using nickel affinity chromatography and analysed by SDS-PAGE (figure 
2.5). The product obtained was consistent with that seen previously. The full length 
polypeptide species has a molecular weight of 52 kDa which was seen. In addition 
two major cleavage products were seen which is consistent with previous 
observations. Markiv et al (2011) reported frequent cleavage of either one side or 
other of the flexible, variable region as observed (figure 2.5). The purity of the full-
length protein, 77%, was determined using Image J (Baker et al, 2019), by 
comparison with the molecular weight of the full length polypeptide. The cells 
expressing the protein were bright red. It was decided that the protein was 
sufficiently pure to be concentrated and for its encapsulation to be studied. 
 
Figure 2.5. Purification of fluorescent scFv 4D5-8RFP. Recombinant 4D5-8RFP 
expressed in E.coli, was purified by Ni-NTA affinity chromatography resolved by 
12% w/v SDS-PAGE and stained with Coomassie Brilliant Blue R250. Lanes 1-4: 
Ni-NTA column elutions lane 5: molecular weight markers, 116, 66.2, 45.0, 35.0, 
25.0, 18.4 and 14.4 kDa. 
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2.4.2  Dynamic light scattering characterisation of empty, AlexaFluor 
546, Propidium Iodide and scFv 4D5-8RFP encapsulated vesicles  
The vesicles were synthesised with PBS (empty vesicles), AF546, PI or scFv 4D5-
8RFP. The starting BA material obtained from Professor William’s group (Rutgers) 
was combined with cholesterol and cholesteryl hemmisuccinate as described in 
section 2.4 (Grinberg et al, 2005). Their physical properties were characterised by 
DLS (table 2.2). 
Table 2.2. Dynamic light scattering and polydispersity analysis 
measurements of empty vesicles, and vesicles encapsulating either Alexa 
Fluor 546, propidium iodide or antibody fragment scFv 4D5-8RFP (n=3). 







(mean ± SEM) 
183.7 ± 1.3 183.5 ± 3.0 182 ± 2.1 307.3 ± 4.7 
PDI (mean ± SEM) 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 
 
Vesicles encapsulating scFv 4D5-8RFP are nearly 70% larger than empty or those 
encapsulating the tracer dyes, which were of remarkably uniform size. However, 
scFv 4D5-8RFP is a larger molecule at 52 kDa than AF546 (1080 Da) and PI (668 
Da). PI and scFv 4D5-8RFP encapsulated vesicles have been physically 
characterised in this chapter, and further in vitro work has been undertaken in 
Chapter 3. 
2.4.3 Electron microscopy  
In order to verify and further characterise the size and the morphology of our BA 
vesicles, transmission electron microscopy (TEM) was used. Prior to purification by 
size exclusion chromatography, empty vesicles diluted 1:10 demonstrate particle 
















Figure 2.6. Electron microscope imaging of empty bolaamphiphilic vesicles. 
Vesicle size indicated by scale bar, mean size verified by dynamic light scattering 
(DLS) as 180 nm. Image taken on a JEM-2100 microscope at the Research 
Complex at Harwell. 
2.4.4  Size exclusion chromatography for the purification of vesicles 
Following encapsulation, vesicles were separated from non-encapsulated dye by 
size exclusion chromatography on a 200 ml Sepharose CL-2B column. Eluting 
fractions were profiled by DLS to identify the population of vesicles purified away 
from free dye. Free PI was observed visually between fractions 47 to 55. For the 
AF546 encapsulated vesicles, non-encapsulated/unbound dye was observed 
eluting in fractions 24-29. No colouration was observed for the antibody fragment 
vesicles by eye as was visible for the PI and AF546 encapsulated vesicles. Purified 
samples were verified by DLS measurements.  
DLS was used to profile the purified vesicle fractions to determine the location of 
purified vesicles. From the DLS profile, AF546 encapsulated vesicles were found 
in fractions 8-14 (table 2.3). The profiles of F10 and F11 demonstrate low PDI, 
indicating a more monodispersed population, with size distributions similar to that 
of the neat vesicles, prior to purification. Therefore, both F10 and F11 were used in 
further experimental work. This distribution was also observed with the DLS profiles 




Table 2.3. Analysis of Alexa Fluor 546 vesicle fractions purified by CL-2B 
chromatography.  The Z-average and polydispersity index (PDI) readings of 
purified fractions of AF546 encapsulated GLH-20 vesicles (n=3). 
 
2.4.5  Zeta potential of vesicles 
Zeta potential is a measure of the surface potential and can be used to assess 
stability and propensity for aggregation. If the effective charge is low, then the 
repulsion between the individual vesicles will similarly be low. A charge on vesicles 
between +10 mV and -10 mV is considered to be effectively neutral (Clogston and 
Patri, 2011). A surface potential in this range indicates that the vesicles have the 
potential to aggregate with time.  The zeta potential of the various vesicles made 
was therefore analysed to give an indication of their stability (table 2.4). 
Table 2.4. Zeta potential measurements of bolaamphiphilic vesicles. Empty 
vesicles or vesicles encapsulating AF546, PI or antibody fragment were shown to 
have negative zeta potentials and are therefore, anionic (n=3). 
 
All samples indicated that the electric repulsion was great enough that they are 
considered to be stable with the exception of the antibody fragment, scFV 4D5-
8RFP, as the potential falls below the -10 mV to +10 mV range (Clogston and Patri, 
2011). However, the charge was unexpectedly negative, which is inconsistent with 
the structure of GLH-20 which would possess a positive zeta potential. It is 
hypothesised that the original material was not GLH-20 and that an unexpected 
product had resulted during the production. This indicating a novel material. It was 
decided therefore to test the uptake of these vesicles to determine if the material 
still had properties capable of facilitating cellular delivery.  
Fraction number F8 F9 F10 F11 F12 F13 F14 
 
Z-average (nm) 













































(mV) (± SEM) -65.7 ± 1.4 -42.2 ± 0.6 
 
-23.0 ± 1.6 
 
-5.0 ± 1.2 
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2.4.6 Preliminary in vitro work uptake of Alexa Fluor 546 encapsulated 
vesicles 
To investigate the delivery capabilities of the BA vesicles, and whether they are able 
to penetrate biological barriers in vitro, studies were undertaken using a neuronal 
cell line representative of the brain. Newly synthesised AF546 vesicles, 
approximately 1 week since synthesis, were selected for AF546’s photostability and 
strength of signal. Plasma membrane stain, CellMask, was used for staining the 
cell membrane. Uptake of AF546 encapsulated vesicles was assessed by confocal 
microscopy following a two-hour exposure. AF546 vesicle uptake can be seen as 
fluorescent yellow spots within the cells, suggesting that the vesicles are potentially 
still intact (figure 2.7). What is clear is that these negatively charged vesicles 








Figure 2.7. Uptake of Alexa Fluor 546 encapsulated vesicles in SH-SY5Y 
neuroblastoma cell line. Confocal microscopic image of SH-SY5Y cells incubated 
for 2 h with final concentration of 3.5 µg/ml of AF546 encapsulated vesicles at 37 
oC in 5% CO2 in air. Vesicles encapsulating AF546 (yellow) were counterstained 
with 1:1000 dilution of CellMask Deep plasma membrane marker (blue). Scale bar 
= 20 µm. 
2.4.7  Long term stability of vesicles  
The zeta potential of the vesicles is negative demonstrating that the vesicles are 
negatively charged (table 2.4). To evaluate the stability of the purified AF546 
vesicles, zeta potential measurements were taken over a four-month time course 
(table 2.5). Vesicles were stable for 3 months at 4oC. Their potential drops by 











Table 2.5. Zeta potential measurements of Alexa Fluor 546 encapsulated 




This zeta potential indicated the AF546 encapsulated vesicles were stable for 3 
months at 4oC. The decrease is zeta potential is significant (p=0.023) for the final 
reading against the initial reading using a one-way ANOVA whilst still remaining 
significantly above the stability limit defined by Clogston and Patri (2011). 
2.4.8 In vitro work uptake of Alexa Fluor 546 encapsulated vesicles.  
In order to investigate the uptake of purified AF546 vesicles by potential targets 
within the brain we used glioblastoma cell line, LN229, it is an ideal target to assess 
whether vesicles can enter relevant brain cells. Uptake of AF546 encapsulated 
vesicles assessed by confocal microscopy following a thirty-minute exposure, 
revealed vesicle uptake. There was possible vesicle lysis as AF546 can been seen 
in diffuse staining of the cytosol of the cells (figure 2.8) as opposed to the punctate 
staining in SH-SY5Y cells (figure 2.7). A greater fluorescence signal of AF546 is 
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Figure 2.8. Confocal images of Alexa Fluor 546 encapsulated vesicle uptake, 
and non-encapsulated Alexa Fluor 546 (control), in the human glioblastoma 
cell line LN229. Cells were treated for 30 minutes with a final concentration of 3.5 
µg/ml of purified AF546 (red) encapsulated vesicles, at 37°C in 5% v/v CO2 in air, 
prior to counterstaining with 0.1 µM AF488-conjugated phalloidin (green), and 50 
ng/ml DAPI (blue), fixation with 4% w/v formaldehyde and confocal microscopy. 
Staining of AF546 is apparent in the cytoplasm of the LN229 cells only. Scale bar = 
20 µm. 
 
As part of the in vitro work undertaken, and as AF546 is diluted in PBS prior to 
vesicle synthesis, the autofluorescence of the PBS was studied to ensure PBS does 
not autofluoresce, giving false readings. The fluorescence spectrum demonstrates 
that empty vesicles follow the same spectrum as PBS with lower fluorescence 
intensity (figure 2.9).  
 
LN229 





Figure 2.9. Autofluorescence spectra of PBS and empty vesicles using 
CLARIOstar fluorescent plate reader.  
2.4.9 Linear regression analysis to determine the encapsulation 
efficiency and concentration of Alexa Fluor 546 and propidium iodide 
encapsulated vesicles. 
To determine the concentration of AF546 from the purified fractions (figure 2.10) 
and hence, the encapsulation efficiency of the vesicles, fluorescence readings 
(AF546 excitation and emission spectrum is 556 and 573 nm, respectively and the 
filters used include excitation 540-20 nm, emission 590-30 nm) of the encapsulated 
AF546 vesicles was measured and compared against a standard curve derived 
from a dilution of the AF546 employed in these assays (figure 2.4). From the initial 
concentration of AF546 (125 mM) the highest concentration of Alexa Fluor after 
purification was measured at 18.72 ± 1.55 µM by a fluorescence plate reader (figure 
2.10), allowing an encapsulation efficiency to be measured of 0.02% for the peak 
fraction (F11), using the equation presented in section 2.3.14.   
Of the 7 purified fractions of AF546 encapsulated vesicles measured using a 
CLARIOstar fluorescence plate reader (figure 2.10) the total encapsulation efficiency 
of the preparation was calculated at 0.04%, using the same calculation as 
mentioned above. Although more fractions were measured, the plate reader could 
only detect a signal in the fractions recorded. This makes the assumption that there 
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is no quenching of the Alexa Fluor signal by the BA material. An absorption 
spectrum of empty BA vesicles across the range 340-670 nm revealed no apparent 
light absorption, consistent with this. 
 
Figure 2.10. The encapsulation concentration of Alexa Fluor 546 
encapsulated vesicles as calculated from the linear regression (Figure 2.4). 
Preparations of vesicles were examined using a CLARIOstar fluorescence plate 
reader (excitation filter 540-20 nm, emission filter 590-30 nm). From the 
measurements, fraction 11 of the purified vesicle population had the greatest 
concentration of AF546 (n=3).  
2.5 Discussion 
This study set out to manufacture vesicles from GLH-20 material applied by our 
collaborators. The material should have been the BA GLH-20 which has an 
acetylcholine head group giving the resulting BA and its derived vesicles a positive 
charge.  The material produced vesicles of a size consistent with previous reports 
when combined with cholesterol and cholesterol hemi-succinate, however, the 
vesicles produced had a negative zeta potential.  This investigation has revealed 
that this novel bola material was capable of forming vesicles encapsulating a 


















































penetrating neuronal cells in vitro.  These vesicles retained a stable negative zeta 
potential over a period of four months at 4°C, attesting to good stability. 
The original formulation of the GLH-20 vesicles, prepared Dr Sumi Lee and 
Professor Lawrence Williams (Rutgers), was deemed to have a low yield as 
compared to other studies synthesising vernonia oil vesicles (Popov et al, 2010). 
However, this was not problematic as this was a proof of concept study. The 
material was then being tested to establish if we could encapsulate a variety of 
payloads for delivery to neuronal cells and specific types of such cells, for example 
glioblastomas.  Vesicles were produced to see whether it was possible to 
encapsulate a large molecule such as the scFV 4D5-8RFP antibody fragment. 
Vesicles were first encapsulated with tracer dye molecules such as AF546 and PI 
to study their consistency with previous work and their uptake by cells.  
Dyes to encapsulate in vesicles were selected due to their specific properties and 
size. AF546 has a relatively low molecular weight (1080 Da), however it would not 
be expected to cross the BBB.  It has a fluorescent intensity several fold brighter 
than that of Cy dyes, rhodamine or fluorescein with an increased photostability 
(Panchuk-Voloshina et al, 1999; Berlier et al, 2003) and is non-toxic.  PI (0.668 
kDa) is a nuclear stain excluded from living cells. scFv 4D5-8RFP was selected as 
a test molecule that would show if it was possible to deliver next generation drugs 
that can target specific cells whilst carrying chemotherapeutic payloads. The 
antibody (52 kDa) recognises human epidermal growth factor receptor 2 (HER2). 
Whilst HER2 is overexpressed primarily in breast and ovarian cancers, it has also 
been observed to be amplified in other cancers including glioblastomas (Yan et al, 
2015). It was also included as a proof of principle in relation to the possible transport 
of scFv conjugated drug molecules across the BBB. Furthermore, scFv 4D5-8RFP 
expresses the red fluorescent protein, enabling imaging using either confocal or 
epifluorescent microscopy.  
2.5.1 Characterisation of BA vesicles  
There are a number of parameters to characterise for a drug delivery system, the 
two main parameters being size and shape/structure (Mourdikoudis, Pallares, and 
Thanh, 2018). It is necessary to standardise such techniques in order to maintain 
reproducibility and alignment for testing and characterising such systems 
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(Björnmalm, Faria, and Caruso, 2016; Mulverny et al, 2016; Gao and Lowry, 2018; 
Mourdikoudis, Pallares, and Thanh, 2018). Therefore, we have followed the 
techniques for characterisation that other studies have followed in the development 
of BA vesicles (Popov et al, 2010; Dakwar et al, 2012). We have used DLS, TEM 
and size exclusion chromatography in order to characterise our BA vesicles.  
GLH-20 vesicles produced by Dakwar et al (2012), encapsulating bovine serum 
albumin conjugated to fluorescein isothiocyanate (BSA-FITC) were 203.8 ± 4.8 nm 
in comparison to their empty vesicles of 104.7 ± 2.5 nm. BSA is a larger molecule 
(66 kDa) than the scFv we employed (52 kDa). Similarly to the Dakwar study, the 
size of our scFv encapsulated vesicles was considerably larger than our empty 
vesicles. It might appear the larger the molecule the larger the size of the vesicle 
(Gdowski et al, 2015). This is true when comparing the neat, AF546 and PI 
encapsulated vesicles to the antibody fragment. Other factors that may influence 
the size of the vesicles in addition to the molecular weight of the encapsulated 
material include the concentration of the polymer material and surface tension 
(Abyadeh et al, 2017). Further considerations may be due to the interactions 
between the vesicle material and the antibody fragment (Zeng et al, 2011; Press et 
al, 2017). The pH of the solution of cargo to be encapsulated can influence the 
interaction between the carrier formulation and molecule to be encapsulated (Press 
et al, 2017). 
TEM highlights the range of variability in our sample, which is further supported and 
indicated by the PDI value. This is perhaps inevitable as this is a sample of the 
unpurified vesicles. According to Danaei et al (2018) a PDI of 0.3 and below, which 
are the values we recorded, indicates a homogenous population. Perhaps this 
should be revised as there is heterogeneity in our neat sample. Once they have 
been purified by size exclusion chromatography, the vesicles should be eluted 
according to their sizes, as is performed for proteins, the larger molecules eluting 
first and the smallest molecules eluting later (Stetefeld et al, 2016). They will also 
be separated from the media (including unincorporated payload material) in which 
they were synthesised. The fractions of purified vesicles profiled in this study using 
DLS, did not appear to separate based on size. The DLS readings appear to show 
that the vesicle sizes of the peripheral fractions have anomalous readings either 
side of the peak fractions. One hypothesis may be that these results are due to the 
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low concentration of vesicles at that size. If the concentration of the sample is too 
low, the number of scattered light events may be too low to measure accurately 
(Lim et al, 2013). The DLS is sensitive to large particles, as they scatter more light, 
potentially skewing the data (Bhattacharjee, 2016; Stetefeld et al, 2016). It may be 
that the smaller vesicles are unstable and therefore aggregate causing the 
instability, or it may be a result of the low concentration (Lim et al, 2013, Maguire 
et al, 2018). As we are searching for the peak population it may be expected that 
vesicles would appear in each of the fractions in a heterogenous sample. If this is 
the case, the lack of sensitivity is a limitation when using low concentrations of 
sample with the DLS. As the concentration of vesicles that we are working with 
appears small this may skew the results. Nonetheless, on locating the peak 
fractions, the DLS detected measurements similar to the initial readings of the 
unpurified sample. The fluorescent plate reader also verified this, as the peak 
fluorescence signal was detected in the same fraction, supporting the use of DLS 
in this instance. A technique which could overcome this limitation is Nanoparticle 
Tracking Analysis (NTA) (Mehn et al, 2017). NTA is a method based on Brownian 
motion that identifies and track individual particles in solution, allowing the 
measurement of particle size distribution and particle concentration (Filipe et al, 
2010; Mehn et al, 2017).  
2.5.2 Zeta potential and stability 
The zeta potential is a measure of electrostatic repulsion/attraction between 
nanoparticles in solution and therefore, a measure of stability - the greater the 
electrostatic repulsion the less likely the vesicles will aggregate. A nanoparticle with 
a zeta potential value > ± 30 mV is considered highly stable (Patel and Agrawal, 
2011). The zeta potential of the empty vesicles had the greatest negative potential. 
This result was not anticipated as the vesicles were expected to be cationic and 
therefore should have a positive zeta potential. The zeta potential of all the vesicles 
was negative, indicating that the BA material from which the vesicle has been 
synthesised are not only anionic, but novel. No formulation of anionic BA vesicles 
derived from vernonia oil has been reported. The formulation of the vesicles is 
therefore not the formulation we set out to have synthesised and must also be 
further explored (see chapter 4). Our novel BA vesicles were taken up in vitro 
indicating that regardless of the charge they possess, they were still able to cross 
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the cell membrane in SH-SY5Y and LN229 cells. Anionic vesicles have been 
investigated as potential drug delivery systems to treat CNS diseases (Lockman et 
al, 2004). After 1 minute of exposure, anionic nanoparticles, of a similar size to our 
BA vesicles and highly negative zeta potential, were shown to cross the BBB in rats 
at a higher concentration than cationic nanoparticles. Contrary to these author’s 
initial hypothesis the particles were not repelled or excluded by the negative charge 
of the BBB. It would be of interest to investigate if an increase in exposure time, 
increases the uptake of the anionic particles. This would be undertaken in human 
endothelial cells, such as hCMEC/D3, as they are first cells on the BBB that the 
vesicles would have to overcome in vivo.  
Chattopadhyay et al (2008) investigated the uptake and release of anionic solid 
lipid nanoparticles (SLNs) in immortalised human endothelial cells hCMEC/D3. 
These particles, of a similar size to our BA vesicles, encapsulated the tracer dye 
rhodamine 123 (R123), a fluorescent tracer specific for mitochondria. They found 
that uptake of the tracer dye was higher for the encapsulated dye than for the non-
encapsulated dye. They suggested the irregular uptake within the cell population 
observed in their microscopy images was a result of Brownian motion and 
electrostatic interactions (Chattopadhyay et al, 2008). Due to the anionic properties 
of biological barriers it is important to investigate mechanisms by which the anionic 
BA vesicles can penetrate. Different cell lines will help to characterise different 
uptake kinetics (Korang-Yeboah et al, 2015). This should be explored for future 
work, using different cell lines to investigate the level of uptake. Different biological 
barriers have differing apicobasal membrane polarity, which is important to 
consider particularly when comparing to the transendothelial electrical resistance 
(TEER) values for the BBB and peripheral organs (Crone and Christensen, 1981; 
Redzic, 2011). Our BA vesicles present an interesting and potentially novel drug 
delivery system which requires further investigation.  
An important parameter in drug delivery for BA vesicles is vesicle stability (Puri et 
al, 2009). The zeta potential can provide an insight, in vitro, of the stability of the 
vesicles in vivo (Bhattacharjee, 2016). Popov et al (2010), investigated the storage 
of GLH-20 encapsulating carboxyfluorescein at room temperature and 4°C. GLH-
20 vesicles were observed to be no longer stable after 13 days. Our empty and 
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AF546 BA vesicles demonstrated high stability, as a result of the ability to repel 
other particles based on their zeta potential. This zeta potential is dependent upon 
the properties of the material used for the vesicle formulation and the solvent the 
analytes are suspended in (Joseph and Singhvi, 2019). Low zeta potential values, 
as observed with scFv 4D5-8RFP encapsulated vesicles, may be influenced by van 
der Waals interactions/attractions which may lead to aggregation (Clogston and 
Patri, 2011; Joseph and Singhvi, 2019; Savage, Hilt and Dziubla, 2019). On 
measuring the zeta potential, if the isoelectric point is reached the electrostatic 
repulsion between particles/vesicles diminishes and the attraction of forces such 
as van der Waals are more dominant (Pfeiffer et al, 2014). The antibody fragment 
has an isoelectric point of 6.5 and is therefore soluble at physiological pH (7.4) 
(Markiv et al, 2011). It is therefore, suggested that perhaps the interactions between 
the antibody fragment and the vesicles may be influencing the overall isoelectric 
point of the vesicles, which in turn is influencing the low zeta potential, indicating 
carrier-cargo interactions influencing vesicle behaviour. It cannot be discounted 
that the low zeta potential may be a result of the solvent the BA vesicles were 
suspended in, which was deionised water. As deionised water produces carbonic 
acid in the presence of carbon dioxide, this can lower the pH of deionised water, 
thus influencing the zeta potential of the vesicles. However, Jesus et al (2016) 
observed that the zeta potential of their particles, encapsulating different 
concentrations of recombinant hepatitis B surface antigen, was influenced by the 
addition of chitosan rather than the concentration of protein or the solvent the 
analyte was suspended in. 
2.5.3  Encapsulation efficiency 
Encapsulation efficiency is paramount in the development of a drug delivery system 
and is an indication of the potential efficacy (Furtado et al, 2018; Çalış et al, 2019). 
The concentration of encapsulated AF546 is limited in comparison to the initial 
concentration of AF546 added to the original synthesis. One hypothesis may be 
that as AF546 is a negatively charged molecule, the repulsion between the vesicles 
and AF546 may be influencing the encapsulation efficiency. Press et al (2017) 
believe that interactions between the carrier (BA vesicles) and the cargo (molecule 
encapsulated) can influence encapsulation. Although the charge may have an 
influence, this may not be the overarching factor regarding the low incorporation 
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value. It may be worth investigating encapsulating cargoes that have a higher 
concentration (Halayqa and Domańska, 2014; Derman, 2015). The same studies 
should be reprised with an increase in AF546 concentration to investigate if the 
charge of cargo has influenced the encapsulation efficiency as will be seen in no 
change in encapsulation efficiency. Conversely, if the charge is not influencing the 
efficiency then there will be an increase in encapsulation and therefore, fluorescent 
signal as measured using a fluorescent plate reader as used previously.  
As the concentration of the polymer may be a factor influencing encapsulation 
efficiency (Yeo and Parks, 2004; Bozzuto and Molinari, 2015), perhaps increasing 
the concentration of BA material with cholesterol and cholesteryl hemisuccinate 
may increase the overall encapsulation efficiency (Harayqa and Domańska, 2014; 
Derman, 2015, Kim et al, 2020). The relevant dose will be dependent upon a 
number of parameters including the encapsulation efficiency, the therapeutic to be 
encapsulated and the therapeutic dose (Bozzuto and Molinari, 2015). Bozzuto and 
Molinari (2015) indicate that in many cases the toxic effects of the drug are not 
dissimilar to the therapeutic dose. We need to ensure that the vesicles are not only 
able to encapsulate an effective dose in order to elicit the response it is designed 
to induce, but that the vesicles are able to deliver that dose to the target site (Kita 
and Dittrich, 2011).   
Factors that influence the encapsulation efficiency include solubility of the polymer 
in organic solvent, concentration of polymer, solubility of solvent, the rate of removal 
of solvent, the ratio of dispersed phase (the vesicles/delivery system) and 
continuous phase (the liquid in which they are dispersed) (Yeo and Parks, 2004; 
Sun and Chiu, 2005; Bozzuto and Molinari, 2015). Other factors include 
morphology of the vesicles/nanoparticles, such as size and shape (Sun and Chiu, 
2005). The effect of the solvent solubilising the lipid material may not be a factor for 
our vesicles as according to Ong et al (2016) chloroform is the most suitable 
solvent. Liposomes prepared with chloroform were shown to have the highest 
negative zeta potential as well as highest encapsulation efficiency (Ong et al,2016). 
It appears there may be other factors influencing this efficiency, such as the material 
and formulation. The rate of solidification may be a factor that can be investigated 
in the future. One observation was the effect of over sonication on the size of the 
vesicles (Taurozzi et al, 2010). This is referred to as coagulation. The sonicated 
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material is influenced by numerous factors, such as increased collision frequency, 
increased localised pressure and temperature gradients, from the acoustic energy 
that conversely forms aggregates of the primary particles (Aoki et al, 1987; Taurozzi 
et al, 2010). Although only observed once, it was seen to be adversely influencing 
the size of vesicles and it might be of interest to investigate different techniques 
such as such as ethanol injection, a method in which our BA material is dissolved 
in ethanol then injected in an aqueous buffer to form vesicles (Huang et al, 2010; 
Shaker et al, 2017; Kim et al, 2020). Perhaps an alternative method may be to use 
a water bath sonicator as perhaps factors such as the temperature and the intensity 
of the sound waves may be inversely influencing the encapsulation efficiency. 
Hadian et al (2014) investigated the effect of water bath sonication against probe 
sonication and a combination of the two and how that influenced efficiency for 
liposomes encapsulating omega-3 fatty acids. They found that the water bath did 
not improve encapsulation efficiency for liposomes.   
Popov et al (2013) investigated the effect of encapsulation of analgesic peptides in 
different pH conditions to optimise encapsulation. The different peptides, including 
leu-enkephalin and kyotorphin, were encapsulated in 3 different pH conditions (pH 
3.5, 7.4 and 9.5) to investigate how this influences encapsulation efficiency due to 
the isoelectric point of each of the analgesic peptides. Their findings appear to 
support the higher the pH the greater the encapsulation concentration of two 
analgesics- leu-enkephalin and kyotorphin. In the instance of leu-enkephalin the 
increase was nearly 5-fold as the pH increased from 3.5 (2.9%) to 9.5 (16.7%). As 
leu-enkephalin is a neutral molecule pH 7.4 by increasing the pH the molecule 
becomes negatively charged and their vesicles were cationic. This may explain the 
increase in encapsulation efficiency seen as a result of a favourable cargo-carrier 
interaction (Harayqa and Domańska, 2014). Thus, indicating that unfavourable 
steric interactions between AF546 and our vesicles may explain the low 
encapsulation efficiency that we have observed. It will be important to investigate 
this further in the future.  
2.6 Future studies 
The preliminary uptake studies undertaken only demonstrate qualitatively that the 
AF546 vesicles were able to cross the cellular membrane of SH-SY5Y and LN229 
59 
 
cells. Further work is required to quantify the uptake kinetics in vitro and ultimately 
in vivo and content release. Although the vesicles may appear punctate in the SH-
SY5Y cells it needs further work to investigate whether the vesicles are intact. This 
would be performed using tracer dyes that bind to compartments or molecules 
within the cell, such as propidium iodide which binds to nucleic acids. The kinetics 
of cargo uptake and release will need to be investigated in different cell lines. 
Harayqa and Domańska (2014) increased the polymer concentration of their 
poly(DL-lactide-co-glycolide) nanoparticles encapsulating psychotic therapeutics 
which resulted in an increased encapsulation. However, the resulting nanoparticles 
were in the 300 nm range. The addition of poly(vinyl alcohol) (PVA), a 
biodegradable polymer. decreased this size however this lowered the 
encapsulation efficiency. Derman (2015) found that increasing the concentration of 
cargo, caffeic acid phenethyl ester loaded, in PLGA nanoparticles increased the 
encapsulation efficiency. As we are interested in increasing the encapsulation 
efficiency, increasing the polymer concentration should be investigated for future 
studies as well as increasing the concentration of the cargo.  
To measure the encapsulation efficiency and quantify the concentration of scFv 
4D5-8RFP antibody fragments encapsulated within the lumen of our BA vesicles. 
The vesicles will need to be dissolved in suitable solvent or media such as Triton-
X 100 (Popov et al, 2012). The released antibody fragments will need to be 
separated from the vesicle material via centrifugation (Popov et al, 2012). The 
protein will be in the supernatant which can be quantified by either measuring the 
fluorescence using a fluorescent plate reader creating a standard curve as done 
previously (section 2.3.15) to calculate the concentration of antibody fragment 
released from the vesicles (Popov et al, 2010 and 2012), or by creating a protein 
assay from the antibody fragment, producing a standard curve from the stock 
concentration of antibody fragment, from which the concentration can be calculated 
(Gdowski et al, 2015). 
Although the zeta potential for AF546 encapsulated vesicles over a period of 3 
months demonstrates the stability of the vesicles being stored at 4 °C, the decrease 
over the 3-month time frame does show a small but statistically significant 
decrease. However, the zeta potential does not drop below -30 mV which 
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demonstrates, despite the significant drop, the vesicles are still very much stable 
(Clogston and Patri, 2011; Patel and Agrawal, 2011). The vesicles were stored in 
dH2O, which may influence the charge and, by extension, the zeta potential. The 
vesicles, therefore, should also be resuspended and stored in a physiologically 
relevant buffer system, such as PBS during the analysis. 
Further work would include the encapsulation of dye such as pHrodo dye to 
investigate the effect of pH and the encapsulation efficiency. The fluorescence of 
pHrodo increases with lower pH (Ogawa et al, 2010). Popov et al (2013) observed 
an increase in encapsulation efficiency as pH increased. Therefore, to replicate this 
effect we would use a pH sensitive dye such as pHrodo to measure the increase in 
fluorescence on encapsulation efficiency. These vesicles could also be used to 
investigate the porosity of the vesicles, by investigating the effect the external 
environment has on the internal environment of the vesicles. This would be 
important for future interactions to determine the effect of the external environment 
on the encapsulated therapeutic.  
Incorporation of additional lipids such as polyethylene glycol (PEG) with liposomes 
has been used with conflicting results on encapsulation efficiency.  Folate 
PEGylated liposomes increased encapsulation efficiency compared to PEGylated 
liposomes (Cho et al, 2014), whereas Garinot et al (2007) observed no change and 
Muralidharan et al (2014) a reduction. Therefore, it would be of interest for future 
studies to incorporate the folate PEGylation with our vesicles in order to increase 
encapsulation efficiency. PEGylation has been linked to increase efficiency of drug 
delivery through prolonged systemic circulation due to reduced opsonisation (Zeng 
et al, 2011; Press et al, 2017). It appeared to increase the uptake of liposomes 
encapsulating chemotherapeutics (Gabizon et al, 2003). However, an increase in 
the condition palmer-plantar erythrodysesthesia has been linked to the PEGylation 
of PEGylated liposomal doxorubicin (Lorusso et al, 2007). The non-PEGylated 
version of the same liposome, encapsulating the same drug (doxorubicin) 
demonstrated limited to no effects (Leonard et al, 2019). Therefore, we will 
investigate the effect of incorporation of PEGylation of our vesicles by performing 




The original synthesis undertaken was designed to produce GLH-20 cationic 
vesicles. Dakwar et al (2012) had used these vesicles to demonstrate that 
encapsulated FITC conjugated BSA could cross the BBB in vivo.  Initially we had 
wanted to investigate the use of GLH-20 encapsulating an antibody fragment. 
During the profiling and characterisation of the BA vesicles the zeta potential was 
negative indicating that the vesicles were anionic and indeed novel and 
unexpected. The material synthesised was not the original GLH-20 material, 
indicating that a novel product has been synthesised.  The only step which differs 
from the experimental procedure is the initial step of hydrolysis of the esters. This 
may have influenced the synthesis downstream. From our own investigations the 
method used appeared to be non-selective at hydrolysing the esters as well as non-
selectively opening of the epoxide groups. As a result of the material producing 
novel vesicles, further investigation was undertaken to explore what this material 
was and is reported in Chapter 4. Further work was undertaken to determine the 
potential of these vesicles. The BA vesicles are not only novel, they have a negative 
zeta potential, they were shown to cross biological barriers as shown in preliminary 
in vitro uptake studies and have been shown to encapsulate different cargoes. 
Therefore, it is important to further investigate their potential as a drug delivery 
system. It is recommended that future in vitro work include toxicity, viability and 
immunogenicity to investigate their safety and utility. It is also proposed that future 
work includes uptake in other cell lines representative of the body and brain, and 
that the release kinetics is further investigated. Finally, it is recommended in order 
to investigate the potential of these BA vesicles as a drug delivery system in vivo 





3.1  Introduction 
As shown in the previous chapter, BA vesicles are suitable carriers to be used for 
drug delivery and are capable of penetrating biological barriers in vitro. Directly 
delivering drugs across the cerebromicrovascular wall is the most effective means 
of treating diseases of the brain, but due to the physical, functional and 
pharmacological restrictions of the BBB, this route of drug administration to the 
brain is greatly limited (Abbott, 2013; Daneman and Prat, 2015; McArthur et al, 
2016; Pardridge, 2007). Developing a drug delivery system capable of penetrating 
the BBB and carrying a variety of cargoes into the brain parenchyma is thus a very 
appealing goal for treatment of the numerous neurological and psychological 
diseases of the brain, for which glioblastoma serves as a typical example. 
3.1.1 Safety and utility of vesicles  
Prior to clinical testing further, challenges surrounding the drug delivery system 
must be addressed. The main purpose of in vitro testing is to assess the potential 
of the vesicle/formulation causing an adverse effect in vivo (Dobrovolskaia and 
McNeil, 2013). In vitro testing is used as a surrogate indicator to rapidly evaluate of 
the effects in vivo. Performing these studies enables an understanding of potential 
acute responses. These include release, localisation and toxicity/inflammation. 
Therefore, it is important to investigate the safety and utility of the system. 
Prior to undertaking such studies there are several factors that should be 
considered, including selection of a relevant model, selection of an end-point, 
choosing appropriate controls, appropriate range of in vitro assays to test vesicles 
and understand how the results of the assay translates in vivo, to ensure there is 
relevant and translatable in vitro/in vivo correlation (Dobrovolskaia and McNeil, 
2013). The advantages of in vitro studies extend to cost, speed and ethical 
considerations (Kumar et al, 2017). There are several assays that can be used to 
assess safety, including proliferation assays, apoptosis and necrosis assays, 
oxidative stress assays and DNA damage assays (Kumar et al, 2017). Whilst it is 
fundamental to test toxicity, it is of equal importance to address any immunogenic 
responses as inflammation in the CNS can be an indicator of pathology 
(Dobrovolskaia and McNeil, 2013). As there is a paucity of toxicity and viability 
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studies performed for BAs, we will be undertaking numerous assays to profile the 
BA vesicles from the previous chapter (Fariya et al, 2014). 
Moreover, the rate at which the vesicles are taken up and cross biological barriers 
and release their contents in vitro provide evidence regarding their bioavailability in 
vivo (Korang-Yeboah et al, 2015; Jain and Thareja, 2019). There are a number of 
factors which ultimately influence this from the cell line used, the formulation of the 
vesicles, the pH of the environment and the temperature (Siepmann and Göpferich, 
2001; Fu and Kao, 2010; Korang-Yeboah et al, 2015). The release profile is an 
important parameter to include for the utility of a drug delivery system (Korang-
Yeboah et al, 2015).   
As outlined in chapter 1, we believe that BA vesicles represent an efficient drug 
delivery system and have undertaken studies to examine their effectiveness. 
Following the production and physical characterisation of the BA material detailed 
in chapter 2, the safety and utility of these vesicles will be tested in cellular and 
whole animal models.  
3.2  Specific Aims: 
1. To evaluate potential adverse effects caused by the vesicles using brain relevant 
immortalised cell lines 
2. To investigate the ability of different cells of the brain to take up and lyse vesicles 
carrying different cargoes 
3. To test the ability of BA vesicles carrying different cargoes to enter the brain in 
vivo 









3.3  Methods  
3.3.1 Materials- source of reagents 
Table 3.1 The list of all materials and their suppliers used throughout 
chapter 3. 
MATERIALS SUPPLIER ADDRESS 
rat collagen (catalog # 08-
115) 
EMD millipore Darmstadt, Germany 
DMEM (catalog # BE12-
614F), PBS (catalog # 
BE17-516F), Trypsin/EDTA 
(catalog # CC-5012), 
penicillin/streptomycin 
(catalog # 09-757F),  EGM2 
MV (catalog # CC-3202),  
and catalog # CC-4147 for 
the following reagents: 
hydrocortisone (HC), human 
epidermal growth factor 
(hEGF), human fibroblast 
growth factor (hFGF), 
recombinant insulin-like 
growth factor (R3-IGF-1), 
vascular endothelial growth 
factor (VEGF), ascorbic 
acid, and gentamicin  
Lonza Slough, UK 
Fetal bovine serum heat 
inactivated (catalog # FB-
1001H) 
Biosera East Sussex, UK 
Annexin A5-FITC detection 
kit (catalog # 640914) 
BioLegend  California, USA 
calf collagen (catalog # 
9007-34-5), glycerol 
(catalog # G5516), sucrose 
(catalog # S0389) 
Sigma Aldrich Irvine, UK 
Propidium Iodide (catalog # 
BMS500PI), N2 nutrient 
supplement (catalog # 
17502048), Blasticidin S 
(catalog # A1113902), 
CellMask Plasma 
Membrane stain (catalog # 
C10046), actinomycin D 







3.3.2 Cell lines 
Cell lines used for vesicle uptake studies were chosen as representative of the cells 
found in the brain. Human SH-SY5Y neuroblastoma (American Type Culture 
Collection- ATCC), human LN229 glioblastoma (ATCC), human hCMEC/D3 
cerebromicrovascular endothelial cells (VH Bio Ltd.), human HASTR/ci35 
astrocytes (Prof T. Furihata, Kyoto University, Japan) and murine BV2 microglia 
(Prof E. Blasi, University of Modena and Reggio Emilia, Italy). For comparison with 
other body tissue types the human kidney cell line HEK-293T (ATCC) was used. 
SH-SY5Y, LN229, BV2 and HEK-293T cells were grown in Dulbecco’s Minimum 
Essential Medium (DMEM) (Lonza, Basel, Swizterland) with 5% v/v fetal bovine 
serum (FBS, previously heat decomplemented by 30 minute incubation at 56°C; 
Biosera Ltd., UK), 1% v/v penicillin and streptomycin. The human endothelial cell 
line, hCMEC/D3 (VHBio Ltd) was grown in complete EGM-2 medium supplemented 
with gentamicin (50 µg/ml), 2.5% v/v FBS, ascorbic acid solution (1 µg/ml), 
hydrocortisone (0.2 µg/ml) , human epidermal growth factor (hEGF) (5 ng/ml), 
human fibroblast growth factor (hFGF) (10 ng/ml), insulin-like growth factor-1 (R3-
IGF-1) (20 ng/ml) and human vascular endothelial growth factor (hVEGF) (0.5 
ng/ml) (Lonza, Basel, Switzerland).  Endothelial differentiation medium was 
replaced by EGM-2 omitting VEGF prior to experimentation. The HASTR/ci35 
immortalised astrocyte line was grown in DMEM supplemented with N2 nutrient mix 
(Thermo Fisher Scientific UK Ltd.), blasticidin S (4 µg/ml), 10% v/v FBS and 1% v/v 
(4',6-diamidino-2-
phenylindole) (catalog # 
D1306), PrestoBlue (catalog 
# A13261), 
Lipopolysaccharide (LPS) 
(catalog # 00-4976-03), 
TNF-α ELISA kit (catalog # 
BMS607-3), bovine serum 
albumin (catalog # B14) 
CaCl2 (catalog # C1016), 
formaldehyde (catalog # 









penicillin and streptomycin (Lonza). Differentiation media for the astrocytes was as 
above, but omitted blasticidin S. 
All cells were incubated for 3-4 days until 70% confluent at 37°C, or 33°C for 
HASTR/ci35, under 5% v/v CO2. HASTR/ci35 cells, once differentiation medium 
was added, were then grown at 37°C under 5% v/v CO2 until confluent. 
3.3.3  Routine cell culture  
All cell line work was performed in a laminar flow hood with aseptic technique. Cells 
were grown in sterile 75 cm2 flasks; in the case of hCMEC/D3 and HASTR/ci35 
cells these were previously coated with 15 µg/cm2 type I collagen. Cells were 
passaged when they appeared 70% confluent. Spent media was removed and cells 
were washed with sterile 0.01 M PBS without Ca2+ for 5 minutes at 37°C. PBS was 
removed and 0.25% w/v trypsin, 1 mM EDTA was added and cells were incubated 
for 5 minutes at 37°C. Following dilution of trypsin with fresh medium containing 
5% v/v FBS, cells were counted using a haemocytometer, centrifuged at 800 x g 
using an IEC CL30 centrifuge, resuspended and re-plated for further growth or 
experimentation at 15,000 cells/cm2 in appropriate medium. 
Chamber slides were seeded with 1x105 SH-SY5Y, HEK-293T, BV2 or LN229 
cells/cm2 and cultured for 2-3 days. Cells were then incubated for 2-24 hours with 
a sample of the vesicle fraction in media prior to removal, washing, fixing by 
immersion in 4% v/v formaldehyde in PBS for 10 minutes. Cells were washed and 
counterstained with phalloidin-acti-stain-488 (Cytoskeleton Inc; 1:140 dilution), for 
visualisation of the cytoskeleton, for 20 minutes. Cells were stained with 50ng/ml 
4',6-diamidino-2-phenylindole, dihydrochloride (DAPI; Thermo Fisher Scientific) for 
10 minutes to define nuclei. Cells stained with CellMask™ Plasma Membrane stain 
(1:1000 dilution, Thermo Fisher Scientific) were incubated for 1 hour. Cells were 
then washed in PBS and mounted with Mowiol 4-88 (40% w/v glycerol, 9.6% w/v 
Mowiol, 0.2 M Tris, pH8.5).   
3.3.4 Annexin A5-Propidium Iodide Viability Assay 
12 well plates (Nunc) were seeded with 0.5 x 106 cells- human astrocytic 
(HASTR/ci35) or endothelial (hCMEC/D3) cells and cultured for 3-4 days at 37oC 
under 5% v/v CO2 in standard growth medium. Cells were either untreated, treated 
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with 0.1 µg/ml actinomycin D (ThermoFischer Scientific), PBS, or various 
concentrations of empty vesicles (50 µg/ml, 25 µg/ml, 10 µg/ml and 5 µg/ml in PBS) 
and incubated overnight. Cells were washed with PBS-/- and centrifuged at 1000 g 
for 5 min at room temperature. Cells were then resuspended in binding buffer (0.01 
M PBS with 0.1% w/v BSA and 1 mM CaCl2) containing annexin A5-FITC (0.45 µg, 
Biolegend Inc., USA) and propidium iodide (0.9 µg) before being incubated at room 
temperature in the dark for 15 min. After incubation, 400 µl of additional binding 
buffer was added to the cell suspension, and gently mixed. Samples were kept on 
ice in the dark, until analysed by flow cytometry, using the 488 nm blue laser and 
the FITC and PerCP-CyTM5.5 filters. Single stains were used for compensation of 
these fluorochromes. Flow cytometric analysis was performed using a BD 
FACSCanto II (BD Biosciences) and FACS Diva Software. Cells were gated using 
forward scatter (FS) and side scatter (SS) to distinguish from and exclude cellular 
debris. Data were analysed using FlowJo software (Treestar Inc, OR, USA).  A 









Figure 3.1. A typical annexin A5-FITC profile for healthy and apoptotic 
HASTR/ci35 cells. Immortalised astrocytes were either untreated or treated with 
0.1 µg/ml cytotoxic drug, actinomycin D. Untreated cells show a high concentration 
of healthy cells, whilst the treated cells indicate a higher population of early and late 
apoptotic cells. Each of the four quadrants represents the stages of cell health- 
healthy (bottom left), early apoptotic (bottom right), late apoptotic (top right) and 



























3.3.5  PrestoBlue viability assay 
Endothelial cells, hCMEC/D3, were seeded at a density of 1x104 cells/cm2 on to a 
collagen coated 96 well plate (Sterillin) and cultured for 2-3 days. Cells were treated 
with either medium only (negative control), PBS (negative control), 10 µg/ml 
Actinomycin D (positive control) or 50 µg/ml empty vesicles for 24 hours at 37°C, 
5% CO2. PrestoBlue was added at 1:10 dilution to each well and incubated for 10 
minutes at 37°C. Fluorescence was measured using CLARIOstar plate reader 
using filters 545-20/600-40 nm.  
3.3.6  TNF-α ELISA 
Cells of the murine microglial line, BV2, were seeded at a density of 1.5x105 
cells/cm2 onto 48 well plates (Sterillin) and cultured for 2-3 days. Cells were then 
treated with either medium only, 10 µg/ml lipopolysaccharide (LPS) (Jin et al, 2018; 
Barabutis et al, 2019) or 50 µg/ml empty vesicles for 24 hours at 37°C, 5% CO2 in 
triplicate. Sample medium was collected and TNFα content was measured with a 
murine TNF-α solid-phase enzyme linked immunosorbent analysis (ELISA), 
(ThermoFisher). Recombinant mouse TNFα was used to establish a standard curve 
at 1000, 500, 250, 125, 62.5, 31.25, 15.625 and 7.8125 pg/ml (figure 3.2) according 
to the manufacturer’s instructions. End-product absorbance at 450nm was 




Figure 3.2. Standard curve of TNF-α concentrations (1000 – 7.8125 pg/ml) 
assayed by spectrophotometry (OD 450 – 570 nm) to determine the inflammatory 
response caused by 50 µg/ml vesicles to murine microglial cell line, BV2, after 24 
hour exposure.  
3.3.7 Release kinetics of propidium iodide encapsulated vesicles  
LN229 glioma cells were seeded at a density of 1x105 cells/cm2 on 24 well plates 
and treated with purified PI encapsulated vesicles for different times (4, 3, 2, 1 hour 
and 30 minutes). Spent medium was removed, and cells were washed in 0.01 M 
PBS. Once PBS was aspirated cells were trypsinised for 5 minutes. Detached cells 
were collected and centrifuged for 5 minutes at 800 x g using an IEC CL30 
centrifuge. The supernatant was aspirated, and the pellet was resuspended in final 
concentration of 50 ng/ml DAPI for 5 minutes. Cells were once again centrifuged 
as described above. The supernatant was aspirated, and cells were resuspended 
in cold PBS. Samples were kept on ice in the dark, until analysed by flow cytometry 
using the violet (405 nm) and blue (488 nm) lasers and the DAPI and PerCP-
CyTM5.5 filters. Analysis was performed as described in section 3.3.4.  Figure 3.3 
shows the gating strategy in order to determine single cell from the populations of 

































3.3.8  Confocal microscope 
Confocal microscopy was used to determine the peak fractions of vesicles in 
unknown samples and in uptake studies. Following adjustment of gain and offset, 
cells and vesicles were imaged at 1024x1024 resolution, using an oil immersion 
x63 objective on a Leica LSM880 laser scanning confocal microscope running Zen 
software. A minimum of 3 images were collected per well. Lasers used were 405 
nm diode laser (for DAPI stain), 488 nm Argon-Krypton (for PI), 561 nm diode (for 
RFP of the antibody fragment), and 633 nm HeNe (for the plasma membrane stain). 
PI encapsulated vesicles have a maximum excitation wavelength of 493 nm and 
the emission wavelength of 636 nm. For vesicles encapsulating AF546 and scFv 
4D5-8RFP the excitation wavelengths are 556 nm and 584 nm respectively, and 
emission values are 573 nm and 607 nm respectively. Excitation and emission 
wavelengths for DAPI were 358 nm and 461 nm, respectively. CellMask™ plasma 
membrane stain has an excitation wavelength maximum of 649 nm and emission 
wavelength maximum of 699 nm. Cytokeletal stain, phalloidin-acti-stain-488, 




Figure 3.3. Gating strategy for flow cytometry analysis. The cell populations 
with low forward and side scatters and high forward and side scatters were 
established in order to locate single cell events. This is then gated to include the 
population of LN229 cells of interest.  Flow cytometry dot plot on the left shows side 
scatter- area (SSC-A) versus forward scatter-area (FSC-A), referring to the 
population of events that represents the LN229 cells of interest. This population is 
‘gated’ and then further analysed using the forward scatter height (FSC-H) against 
forward scatter area (FSC-A) is used to determine the singlets or single cell events 
to improve accuracy.  
3.3.9 Animal Studies 
All animal experiments were performed in accordance with the UK Animals 
(Scientific Procedures) Act of 1986 and relevant EU legislation. Animal studies 
were undertaken at University College London (UCL) under procedure project 
licence number 70/8784. 
In order to investigate the ability of the GLH-20 encapsulated vesicles to traverse 
the BBB in vivo studies were performed using 7-week old male C57BL/6 mice (4 
mice per test, of which there were 5 tests, n=20). Mice were purchased from 
Charles River. Mice were kept in individual ventilated cages under controlled 
lighting (12h on, and 12h off) with free access to standard mouse chow and drinking 
water. 
125 µl of sample containing 12.5 µg/ml of the BA starting material (non-
encapsulated AF546, encapsulated AF546, encapsulated scFv 4D5-8RFP, non-
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encapsulated scFv 4D5-8RFP and empty vesicle control) were administered 
intravenously, through the tail vein, by Dr Mariya Hristova and colleagues at 
UCL.  Mice were sacrificed (Pentoject, 0.6-0.8ml/kg) 30 minutes after injection and 
perfused with ice-cold, filtered PBS, by Dr Mariya Hristova. Tissues were collected 
(brain, kidneys, heart, liver, lungs, and subcutaneous adipose tissue- inguinal pad) 
by Dr Simon McArthur, and snap frozen. Half of each brain was snap frozen, whilst 
the other half was collected in 4% v/v formaldehyde in 0.01 M PBS for fixation for 
24h at 4°C, prior to cryoprotection in 30% w/v sucrose and freezing on dry ice. 
Frozen brain, lung, heart and kidney tissue was sectioned (20 µm coronal sections 
for brain) using an OTF5000 cryostat (Bright Instruments Ltd., Cambridge, UK). All 
slices, except fixed brains, were counterstained with 0.1 µg/ml DAPI and mounted 
under Mowiol 4-88 on glass microscope slides for epifluorescence microscopic 
imaging. 
3.3.10  Epifluorescence microscope 
Epifluorescence microscopy was used to analyse mouse tissue samples. 
Fluorescence was detected using the Leica CTR5000 fluorescent microscope with 
MetaMorph software. Tissue samples were imaged at 1024x1024 resolution, using 
either dry (x40 objective) or oil immersion (x63 objective). A minimum of 3 images 
were collected per well. 
Filters used were DAPI and RFP to visualise fluorescent dyes DAPI or AF546 and 
scFv 4D5-8RFP, respectively.  
3.3.11  Homogenisation of tissue samples 
Frozen organ samples (brain, liver, heart, lungs, kidney, subcutaneous adipose 
tissue - inguinal fat pad, and tibialis anterior skeletal muscle) with encapsulated 
AF546, free AF546 and empty vesicles were placed individually in Eppendorf tubes 
to thaw and weighed. 0.25% v/w Triton X-100 final was added to each tube and 
homogenised by maceration (SHMI homogeniser, Stuart) at 35000 rpm for 15 secs. 
Samples were centrifuged (SIGMA 1-16K, Sigma) at 16000 x g for 15 minutes at 
4°C and the supernatant was carefully collected. 100 µl of supernatant samples 
and standards (serial dilutions of AF546, range 0.1- 100 µM) were prepared in 
triplicate in a 96 well microplate (Nunc) and analysed using a CLARIOstar 
fluorescence plate reader (excitation filter 540-20 nm, emission filter 590-30 nm) 
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(BMG Labtech). The concentration of encapsulated vesicles against free AF546 in 
the mouse organs was determined by comparison with an AF546 standard curve 
(serial dilutions of AF546, range 0.1- 100 µM). Alexa Fluor concentrations were 
normalised by tissue weight and against background fluorescence from animals 
treated with empty vesicles. 
3.3.12  Statistical Analysis 
All statistical analysis was performed using SPSS (version 25). Quantitative data 
were assessed for normality of distribution using the Kolmogorov-Smirnov test, 
prior to analysis by one-way ANOVA test with Tukey’s HSD post hoc test. A value 
of p< 0.05 was considered significant. 
3.4  Results 
Prior to in vitro investigations, the vesicles must be shown to be non-toxic. 
Therefore, the annexin A5 apoptosis and PrestoBlue viability assays were used on 
cell lines representative of the cells of the BBB and other major organs of the body.   
3.4.1  BA vesicles are non-toxic  
In order to investigate the toxicity of the vesicle material, an annexin V apoptosis 
assay was performed on representative cells of the brain (HASTR/c35i 
immortalised human astrocytes and hCMEC/D3 immortalised human 
cerebromicrovascular endothelial cells). Empty vesicles were added at dilutions of 
50 µg/ml, 25µg/ml, 10 µg/ml and 5µg/ml from the purified peak fractions.  
Treatment of HASTR/ci35 immortalised human astrocytes with empty vesicles 
(concentrations ranging from 5 µg/ml to 50 µg/ml) had no effect on cell viability after 
either 24 hours or 7 days exposure (Figures 3.4 and 3.5).  In contrast, vesicles at 
the highest concentrations (50 µg/ml and 25 µg/ml) caused a significant increase 
in the proportion of hCMEC/D3 human cerebromicrovascular endothelial cells in 




Figure 3.4. Incubation of HASTR/ci35 immortalised human astrocytes with 
bolaamphiphile vesicles for 24 hours does not increase apoptosis. Cells were 
incubated with 10 µg/ml actinomycin D (positive control), medium only (negative 
control), 0.01 M PBS (vehicle control) or empty vesicles diluted 50 µg/ml, 25 µg/ml 
or 10 µg/ml in 0.01 M PBS vehicle for 24 hours. Apoptosis was evaluated using the 
annexin V apoptosis assay (see section 3.3.4). Data are mean +/- sd; n=3; * p<0.05 

















































Figure 3.5. Incubation of HASTR/ci35 immortalised human astrocytes with 
bolaamphiphile vesicles for 7 days does not cause appreciable levels of 
apoptosis. Cells were incubated with empty vesicles diluted 50 µg/ml in 0.01 M 
PBS vehicle, medium only (negative control), 0.01 M PBS (vehicle control) or 10 
µg/ml actinomycin D (positive control) for seven days. Apoptosis was evaluated 
using the annexin V apoptosis assay (see section 3.3.4). Data are mean +/- sd; 














































Figure 3.6. Incubation of hCMEC/D3 immortalised human endothelia with 
bolaamphiphile vesicles for 24 hours appears to cause low levels of 
cytotoxicity. Cells were incubated with 10 µg/ml actinomycin D (positive control), 
medium only (negative control), 0.01 M PBS (vehicle control) or empty vesicles 
diluted 50 µg/ml, 25 µg/ml, 10 µg/ml or 5 µg/ml in 0.01 M PBS vehicle for 24 hours. 
Apoptosis was evaluated using the annexin V apoptosis assay (see section 3.3.4). 




















































3.4.2 Proliferation studies of vesicles  
In order to investigate effects of the BA vesicles on cellular proliferation in vitro the 
PrestoBlue assay was performed (Helm et al, 2017). Treatment of hCMEC/D3 
human cerebromicrovascular endothelial cells with 50 µg/ml empty vesicles had no 
adverse effect on cell viability after 24 hours exposure using the PrestoBlue assay 
(figure 3.7). 
Viability of hCMEC/D3 endothelial cells was not compromised after 24-hour 
incubation with bolaamphiphilic vesicles. However, actinomycin D significantly 
reduced cell viability. 
 
 
Figure 3.7. Incubation of hCMEC/D3 immortalised human endothelia with 
bolaamphiphile vesicles for 24 hours does not affect cell viability. Cells were 
incubated with 10 µg/ml actinomycin D (positive control), medium only (negative 
control), 0.01 M PBS (vehicle control) or empty vesicles diluted 50 µg/ml in 0.01 M 
PBS vehicle for 24 hours. Apoptosis was evaluated using the PrestoBlue assay 
























































3.4.3  BA Vesicles do not cause TNF-α release in BV2 
An ELISA (enzyme-linked immunosorbent assay) for TNF-α was performed after 
24 incubation of murine microglial cells with either 50 µg/ml empty vesicles, medium 
only or 10 µg/ml LPS (figure 3.8). No production of TNF-α was observed in 
response to vesicles, suggesting the BA vesicles are unlikely to cause an 
inflammatory response. 
 
Figure 3.8. Incubation of murine microglial cells, BV2, for 24 hours with empty 
vesicles do not produce an inflammatory response. Cells were incubated with 
10 µg/ml LPS (positive control), medium only (negative control), or empty vesicles 
diluted 50 µg/ml in 0.01 M PBS vehicle for 24 hours. Inflammation was evaluated 
using the TNF α ELISA (see section 3.3.6). Data are mean +/- sd; n=3. p<0.05 vs. 







































3.4.4 Profiling and uptake of propidium iodide encapsulated vesicles 
Propidium iodide (PI) is a nucleic acid stain unable to penetrate viable cells with an 
intact plasma membrane. Therefore, only cells which had taken up and 
subsequently lysed these vesicles should show any nuclear fluorescent signal. 
Moreover, as PI will not cross viable cell membranes, living cells that exhibit 
fluorescence must have accumulated vesicle encapsulated PI. 
The human neuroblastoma cell line, SH-SY5Y, the mouse microglial cell line, BV2, 
and the human kidney cell HEK-293 were used. Whilst SH-SY5Y and BV2 cell 
parents are found in the brain parenchyma and thus represent typical neural 
populations, the HEK-293 cells, derived from human kidney epithelial cells, served 
as a useful control to represent the principle clearance organ, the kidney. Uptake 
and indication of vesicle opening was apparent in both the microglia and kidney 
epithelial cell lines after 24 hours treatment with vesicles, but little fluorescence was 
observed in neuroblastoma cells (figure 3.9). Nuclear binding was not observed for 
HEK-293 or SHSY5Y cells in the control study. However, the BV2 cells nuclear 





Figure 3.9. Signs of vesicle opening in microglia and kidney epithelium-
derived cell lines, but not in neuroblastoma cells after 24h exposure. Confocal 
images of SH-SY5Y neuroblastoma, HEK293 kidney epithelial and BV2 microglial 
cells were treated for 24 hours with purified propidium iodide-containing vesicles 
and non-encapsulated propidium iodide at 37°C in 5% CO2 in air, prior to fixation 
with 4% formaldehyde and counterstaining with 50 ng/ml DAPI. Confocal 
microscope images (x 63 oil objective) were taken of the samples at excitation 358 
nm, emission 461 nm for DAPI, excitation 493nm and emission 636nm for 
propidium iodide. Scale bar = 20 µm  
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3.4.5 Time-dependency of vesicle uptake in LN229 glioblastoma cell 
lines 
Complementing the uptake studies in which PI was encapsulated in the vesicles 
and was shown to bind to DNA in 24 hours (figure 3.9), we investigated the time-
dependency of vesicle uptake and opening using the LN229 glioblastoma cell line. 
Whilst the previous study demonstrates that the vesicles were lysed it does not give 
a specific time point. It is important to investigate the time frame at which the 
vesicles are lysed, and PI is released to understand the kinetics of the vesicles. 
Therefore, flow cytometry was used in order to quantify the release kinetics of PI 
vesicles from LN229 cells over a four-hour period, revealing a time-dependent 
increase in PI staining (figure 3.10) that was statistically significant by 2h post-
exposure. Typical density plots are presented in figure 3.11 
Epifluorescent images indicate that nuclear labelling was clearly evident after 30 
minutes incubation with propidium iodide containing vesicles, and the staining 
increased in intensity concomitant with exposure times (figure 3.12). This increase 
is significant from hour 2 to hour 4. The spread of PI and DAPI staining increases 
over the course of the study. Non-encapsulated PI is also observed binding to 
nucleic acids within 30 minutes. Thus, demonstrating that PI can penetrate the cell 
















Figure 3.10. Flow cytometry analysis of glioblastoma cell line, LN229, 
incubated with propidium iodide encapsulated vesicles over 4-hour time 
frame. Flow cytometry analysis of LN229 cells incubated at 30 minutes, 1, 2, 3 and 
4 hours at 37oC with bolaamphiphile vesicles encapsulating PI. Uptake and release 
increases over time as observed by an increase in propidium iodide signal. Data 





















































































Figure 3.11. Images of flow cytometry analysis of glioblastoma cell line, 
LN229, incubated with propidium iodide encapsulated vesicles over 4-hour 
time frame. Flow cytometry analysis of LN229 cells incubated at 30 minutes, 1, 2, 
3 and 4 hours at 37oC with bolaamphiphile vesicles encapsulating PI and 
counterstained with nuclear stain DAPI. The PI and DAPI signal intensify over time. 
As more PI is taken up and released from the vesicles, binding increases as well 
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Figure 3.12. Time course of uptake and release of propidium iodide 
encapsulated vesicles in glioblastoma cell line, LN229. Confocal microscopic 
image of LN229 cells incubated at 30 minutes, 1, 2 and 4 hours at 37oC with 
bolaamphiphile vesicles encapsulating PI (red), counterstained with DAPI (blue). 
Nuclear labelling, indicative of propidium iodide release, is clearly evident and 
increases as the time course continues. Scale bar = 20 µm.  
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3.4.6  Profiling and uptake of antibody fragment encapsulated vesicles 
Antibody fragment scFV 4D5-8RFP is specific to the HER-2 receptor which is 
overexpressed in cancerous tissue including breast and ovarian (Markiv et al, 
2011). In order to investigate the uptake of antibody fragment encapsulate vesicles 
SH-SY5Y cells were incubated for 2 hours with scFV 4D5-8RFP encapsulated 
vesicles and unencapsulated scFV 4D5-8RFP antibody fragment as our control. 
Cells were counterstained with deep red plasma membrane stain and imaged using 
confocal microscopy. Vesicles are taken up by SH-SY5Y cells and are punctate 
and intact (figure 3.13). 
  
Figure 3.13. Uptake of antibody fragment encapsulated vesicles in SH-SY5Y 
neuroblastoma cell line. Confocal microscopic image of SH-SY5Y cells incubated 
for 2 hours at 37oC with BA vesicles encapsulating AF546 (yellow), counterstained 



















3.4.7  In vivo work 
To establish whether BA vesicles could cross biological barriers, and particularly 
the BBB, in vivo work was undertaken. Mice were injected intravenously with either 
non-encapsulated scFv 4D5-8RFP, encapsulated scFv 4D5-8RFP, empty vesicles, 
non-encapsulated AF546 or encapsulated AF546 (figure 3.14), with analysis of 
major organ vesicle content 30 minutes post-administration. Whilst brain tissue 
background fluorescence appeared to be increased upon treatment with either free 
AF546 or free antibody, punctate fluorescence was only observed in animals 
treated with encapsulated AF546, indicating entry of the vesicles into the brain 
tissue (figure 3.14). Similar results were seen in the kidney (figure 3.15), whereas 
the liver showed substantially enhanced tissue fluorescence upon delivery of 
vesicle encapsulated AF546 (figure 3.15). Encapsulated AF546 vesicles appear to 
have been opened, releasing the cargo, as AF546 is diffuse throughout the mouse 




Figure 3.14. Fluorescent images of mouse brain tissue samples. A) Non-
encapsulated scFv 4D5-8RFP, B) encapsulated scFv 4D5-8RFP, C) empty 
vesicles, D) non-encapsulated AF546 and E) encapsulated AF546. 30 minutes after 
intravenously injected in the tail vein, mice were sacrificed, and organs collected 
and frozen. Samples were sliced using the cryostat to 20 µm thick. Coronal sections 
were counterstained with nuclei stain, DAPI, and mounted onto slides using mowiol 
488. Filters used were DAPI and RFP to visualise fluorescent dyes DAPI or AF546 
and scFv 4D5-8RFP, respectively. Final concentration of AF546 was 18.72 µM, 
n=4, scale bar = 20 µm.   











Figure 3.15. Fluorescent image of mouse liver (A, B, C) and kidney (D, E, F) 
tissue samples. A), and D) Non-encapsulated AF546, B), and E) encapsulated 
AF546 and C), and F) empty vesicles. 30 minutes after intravenously injected in 
the tail vain, mice were sacrificed, and organs collected and frozen. Samples were 
sliced using the cryostat to 20 µm thick. Coronal sections were counterstained with 
nuclei stain, DAPI, and mounted onto slides using mowiol 488. Filters used were 
DAPI and RFP to visualise fluorescent dyes DAPI or AF546, respectively. Final 
concentration of AF546 was 18.72 µM, n=4, scale bar = 20 µm. 
 
Figure 3.16. Fluorescent image of mouse lung. 30 minutes after intravenously 
injected in the tail vain, mice were sacrificed, and organs collected and frozen. 
Samples were sliced using the cryostat to 20 µm thick. Coronal sections were 
counterstained with nuclei stain, DAPI, and mounted onto slides using mowiol 488. 
Filters used were DAPI and RFP to visualise fluorescent dyes DAPI or AF546, 
respectively. Final concentration of AF546 was 18.72 µM, n=4, scale bar = 20 µm. 
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3.4.8 Homogenisation of tissue samples  
To quantitatively assess the distribution of BA vesicles across major organs, AF546 
content was measured in homogenised brain, lungs, kidney, subcutaneous adipose 
tissue- inguinal pad, liver and heart (figure 3.17). Heart and kidney levels of AF546 
were not detectable, but all other tissues showed a positive signal. The highest 
value of encapsulated AF546 vesicles was located in the lungs (5.7 nmol/g) and 
the liver (3.2 nmol/g). The highest value of non-encapsulated AF546 was found in 
the lungs (15.7 nmol/g). For the distribution plot, only the non-encapsulated and 
encapsulated AF546 samples were included, as the RFP antibody fragment signal 
was not detectable.  
 
Figure 3.17. The distribution of encapsulated Alexa Fluor 546 vesicles and 
non-encapsulated Alexa Fluor 546 30 minutes after IV injection in model 
mouse. Organs from samples that were either treated with encapsulated AF546 
vesicles or non-encapsulated AF546, were homogenised and fluorescence 
measured by CLARIOstar fluorescence plate reader (excitation filter 540-20 nm, 










































3.5  Discussion 
In this chapter, we have demonstrated that our novel anionic BA vesicles do not 
affect cell viability, are non-immunogenic and non-toxic in different brain-relevant 
cell lines, are taken up by cell lines whilst carrying different cargoes, and that these 
cargoes are released inside the cell. Moreover, vesicles could be detected in the 
brain within 30 minutes of intravenous administration in mice, demonstrating that 
BA vesicles possess the key features of a drug delivery system for the brain. Thus, 
demonstrating that our novel BA vesicles meet criteria recommended for 
developing a drug delivery system (Furtado et al, 2018). As discovered in the 
previous chapter (chapter 2) the vesicle material we had thought was GLH-20, was 
not, which was unexpected. As a result, analysis will be carried out in Chapter 4 to 
investigate further the material we have been using and how they can be 
synthesised. However, as these novel BA vesicles demonstrated the ability to cross 
biological barriers in vitro, further investigation was needed to see what these 
vesicles were but also their suitability as a drug delivery system.  
3.5.1  Toxicity studies 
The aim of undertaking in vitro studies is to evaluate, in a cost effective and time 
efficient manner, the potential of the vesicle to cause an adverse reaction in vivo, 
as well as to build upon knowledge (Dobrovolskaia and McNeil, 2013; Dusinska et 
al, 2017). Therefore, to determine the safety implications of the BA vesicles before 
further in vitro and in vivo studies could be undertaken, toxicity and inflammatory 
studies were carried out. The cytotoxicity and viability assays studied were the 
Annexin V apoptosis assay and PrestoBlue assay. Inflammatory studies were 
undertaken using the TNF-α ELISA assay. Thus, demonstrating that our novel 
anionic BA vesicles do not adversely influence cell viability and do not produce an 
immunogenic response. The apoptosis studies gave differing results indicating that 
they are not toxic to astrocytes in 24 hours but may produce a low cytotoxic 
response in hCMEC/D3 cells after 24 hours and after 7 days in HASTR/ci35. As 
there is some cytotoxicity observed PEGylation may overcome this.  
Cell viability is a fundamental parameter of drug delivery (Puri et al, 2009). In order 
to ensure our BA vesicles are safe to use for future studies they need to 
demonstrate that they do not adversely influence cell health. Therefore, BA vesicles 
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were screened using the PrestoBlue assay to test cell viability. BA vesicles did not 
reduce cell viability of the hCMEC/D3 cells after 24 hours incubation using the 
PrestoBlue assay demonstrating their safety to be used in further in vitro and in vivo 
studies. Furthermore, due to the paucity of viability data for BA vesicles made from 
vernonia oil, this is the first time PrestoBlue viability assay has been performed to 
determine cell viability, and our results add to our knowledge of the properties of 
this material.  We showed that our BA vesicles did not adversely affect cell viability, 
and as an important parameter of developing a drug delivery system, indicating that 
they are likely to be safe to use in future studies.  
In order to measure the potential of an adverse immunogenic response to BA 
vesicles in vitro, TNF-α ELISA assay was performed. It is important to investigate 
all potential avenues of adverse responses that a drug delivery system may induce 
(Dobrovolskaia and McNeil, 2013) as there is a lack of information regarding the 
safety of BA vesicles (Fariya et al, 2014). Therefore, it is paramount to contribute 
to further evidence regarding BA vesicles for future studies. Proinflammatory 
cytokines, such as TNF-α, are expressed and secreted from activated microglia in 
response to injury and disease of the CNS (Nishioku et al, 2010; Chang et al, 2017). 
As a result, TNF-α is a measure of activated microglia function in the CNS (Nishioku 
et al, 2010; Varatharaj and Galea, 2017). Vesicles do not induce an inflammatory 
response to murine microglia cells, BV2, after 24-hour exposure. It was observed 
the vesicles induced a lower response than the negative control. Thus, indicating 
that the BA vesicles do not immunogenically compromise BV2s, and are unlikely to 
trigger an acute immune response in vivo, although more extensive immune 
profiling will be important to carry out before these vesicles can be taken to clinical 
use. 
To further assess any potential risk, toxicity studies were undertaken to test the 
potential reactions BA vesicles may induce in different cell lines of the 
neurovascular unit, including astrocytes and endothelial cells. Apoptosis studies, 
using the Annexin V apoptosis assay, appear to demonstrate slightly differing 
results. Whilst the BA vesicles were shown to be non-toxic/pro-apoptotic after 24 
hours exposure to astrocytes, this was not the case for hCMEC/D3 endothelia after 
24-hour incubation and astrocytes after 7 days exposure. During the 7 day study 
the medium was changed only once, after 3 days of incubation, and replenished 
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with fresh medium containing the control or BA vesicles. The level of cytotoxicity is 
dose dependent and is observed at the highest concentrations in hCMEC/D3 cells. 
At the lower doses there are no cytotoxic response in the hCMEC/D3 cells. 
However, as the clinical dose is unknown, it would be dependent upon the drug 
encapsulated and the dose required to induce and effect (Kulkarni, Betageri and 
Singh, 1995; Ong et al, 2016). A further hypothesis for the cytotoxicity observed in 
the astrocytes may be that after 7 days the vesicles may become slightly cytotoxic.  
It may be that as the material degrades it becomes toxic, impairing potential 
therapeutic effects of cargo delivery. The metabolism of the vesicle material may 
produce potential toxic by-products, inducing a cytotoxic response (Sukhanova et 
al, 2018), or it is possible that vesicles may damage mitochondria (Nyugen et al, 
2015), or other cellular membranes (Farnoud and Nazemidashtarjandi, 2019). In 
order to investigate the mechanisms of cytotoxicity further studies would be 
undertaken including ATP assay to assess mitochondrial damage, TdT-mediated 
dUTP-biotin nick end labelling (TUNEL) assay to assess damage to DNA (Ansari 
et al, 1993; Kumar et al, 2017) or Amplex red assay can be used to measure ROS 
production (Kumar et al, 2017). If BA vesicles do have appreciable cytotoxicity 
following long-term exposure, modifying them through coating with, for example, 
polyethene glycol (PEG) is an option which may reduce toxicity, as has been shown 
for other vesicle lipids (Peng et al, 2013, Sukhanova et al, 2018).  
The results from the PrestoBlue assay demonstrate that cell viability was not 
compromised. Whereas the results from the apoptosis assay indicate in the higher 
doses that the early apoptotic population of hCMEC/D3 cells were significantly 
reduced in comparison with the negative (medium only) control. Both assays are 
testing different parameters of cell health, the apoptosis assay is measuring the 
level of membrane integrity through phosphatidylserine binding with annexin V 
(Kumar et al, 2017), whilst PrestoBlue determines cell viability through the reducing 
capabilities of the mitochondria and cytoplasm (O’Brien et al, 2000; Hall et al, 2016). 
However, this may also be a variation of the different assays. Unfortunately, there 
is a paucity of toxicity studies of BAs, making it challenging to compare results 
(Fariya et al, 2014). More studies will need to be undertaken in order to observe 
and monitor these potentially low levels of cytotoxicity to see if they are reproduced 
in future studies.  
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It was also noted that the astrocytes from the 7-day, but not the 24-hour, study 
demonstrated low cytotoxic effect to actinomycin D, similar to that observed with 
the endothelial cells. Actinomycin D is a DNA intercalator which leads to the 
inhibition of transcription. However, it is apparent that there is lower apoptosis after 
7 days exposure compared to 24 hours. One possible explanation may be that the 
astrocytes had recovered after the initial exposure to actinomycin D. Brodská et al 
(2016) observed the EC50 of actinomycin D decrease over a 48-hour period in 
leukaemia cell lines CML-T1, OCI-AML3 and HL-60. This may be a similar effect 
observed in this study.  
3.5.2  Uptake kinetics 
PI encapsulated vesicles have been taken up and released their payload in a range 
of different cell lines demonstrating that BA vesicles are a candidate for drug 
delivery. Thus, demonstrating that BA vesicles are released in different cell lines 
and across different species. PI encapsulated vesicles were observed to release 
their cargo in both human cell lines, SH-SY5Y and HEK-293T, as well as murine 
microglia cells, BV2, within 24 hours. Although only qualitative, PI release is 
appreciable in both HEK-293T and BV2 cell lines. Although present, there is 
considerably less uptake and less binding of PI to RNA and DNA in SHSY5Y cells 
than in HEK and BV2 cell lines. BV2 microglia are highly enzymatically active due 
to the presence of their lysosomes (Wu et al, 2013). Microglial lysosomes contain 
lipases, proteases and nucleases enabling them to perform their protective and 
degradative role, engulfing and destroying foreign substances and necrotic cells 
(Liu et al, 2007). HEK cells also express high enzymatic activity due to their role in 
excretion and removal of waste (Robinson and Goochee, 1991). This may account 
for the marked uptake in these two cell lines. The uptake kinetics may also be driven 
by the cell types used as was investigated and observed using pancreatic 
tumorigenic cell lines (Korang-Yeboah et al, 2015). This may be a further 
explanation for the diverse kinetics observed in the different cell types.  
PI is unable to penetrate the cell membrane and bind to its target, RNA and DNA. 
PI should not be seen in any of the controls, as is the case with the HEK and SH-
SY5Ycells. However, there is appreciable DNA binding observed with both controls 
for the BV2 and LN229. It has been observed that phospholipid membrane turnover 
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is a measurement of tumour proliferation which may explain the PI uptake observed 
in glioblastoma cells, LN229 (Podo et al, 1999). Macropinocytosis is the 
internalisation or invagination of plasma membrane and extracellular fluid through 
vesicle formation called macropinosomes (Lim and Gleeson, 2011; Ha et al, 2016; 
Palm, 2019). Macropinocytosis is an endocytic pathway which is over expressed in 
glioblastoma (Ha et al, 2016). Macropinocytosis was shown to invaginate a particle 
of 300 nm in size (Tan et al, 2013). However, this was observed in Chinese hamster 
ovarian cancer (CHO) cells and although not investigated, cell type may be a factor 
that influences parameters such as flexibility of macropinosomes as well as 
expression of macropinocytosis. Thus, indicating that we may see different 
expression in different cell lines which appears the case for cancer and 
macrophages (Ha et al, 2016; Solé-Domènech et al, 2016). While membrane 
turnover may be occurring for LN229 cells, it does not explain the penetration and 
binding for the murine microglial cell line, BV2. In order to survey the extracellular 
environment macrophages highly express the endocytic pathway macropinocytosis 
from harmful materials (Ha et al, 2016; Solé-Domènech et al, 2016). Perhaps 
microglia monitor their extracellular environment through macropinocytosis which 
may explain the uptake of PI, through non-selective macropinocytosis (Yin et al, 
2017).  
3.5.3  Distribution pattern and clearance 
BA vesicles have also demonstrated the ability to cross the BBB in murine model, 
indicating the ability of the vesicles to be used as a drug delivery system to treat 
diseases of the brain. The mechanism by which the vesicles are able to traverse to 
the brain is not yet known. Despite the limited delivery mechanisms to transport 
molecules across the BECs into the brain, there are possible pathways. One 
hypothesis may be that the cells are taken up via pinocytosis, as mentioned above 
(section 3.5.2) (Tan et al, 2013). Interestingly, clathrin-mediated transport was 
observed as the main route of transcytosis for nanoparticles of a similar size and 
zeta potential as our vesicles (Neves et al, 2016). Thus, indicating receptor 
mediated transport as a potential route of transport. 
As the vesicles have crossed the BBB it is important to investigate their potential 
as a drug delivery system in vivo. It is important to explore the biodistribution of the 
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vesicles within the brain tissue to elucidate where the vesicles are located and 
potential pathways to enhance delivery and targeting. As a result, the original study 
should be reprised, and the use of immunohistochemistry performed to determine 
the localisation and distribution of the BA vesicles in vivo. The antibodies used 
would include anti-glial fibrillary acidic protein (GFAP) for astrocytes, for 
endothelium anti-platelet endothelial cell adhesion molecule (PECAM-1 or CD31) 
and a primary antibody specific for microglia is anti-ionised calcium binding adaptor 
molecule 1 (Iba-1) (Singh-Bains et al, 2019). Nonetheless, in the absence of such 
results, it may be hypothesised that the vesicles are taken up by the microglial and 
macrophages, acting as the immune cells of the CNS (Gustafson et al, 2015). If 
this is found to be the case, then this could be a useful target for future treatment 
for neurological diseases. Activated microglial and macrophages are linked to the 
progression of a number of neurodegenerative diseases including AD, PD and 
glioblastomas (Zhang et al, 2016, Sørensen et al, 2018). There is increasing 
evidence that tumour-associated microglia and macrophages (TAMs) have an 
integral role in the microenvironment of the glioblastoma, reportedly constituting 
approximately 30% of the tumour (Li and Graeber, 2012; Sørensen et al, 2018). 
The tumours influence the TAMs to develop a distinct phenotype to support the 
progression of the tumour (Charles et al, 2011; Li and Graeber, 2012; Sørensen et 
al, 2018). Tumours with high TAMs appear to correlate with lower survival rates 
(Elechalawar et al, 2019), suggesting that targeting TAMs may be a viable 
treatment approach.  
The distribution of the vesicles indicates high clearance via the lungs for both the 
encapsulated AF546 vesicles and non-encapsulated AF546. It has been reported 
that rapid clearance of cationic liposomes occurs by the lungs, liver and spleen 
(Thurston et al; 1998). As a result of the high vascularisation of the lungs, this 
distribution of the vesicles is expected. Our vesicles were also transported to the 
liver. Popov et al (2010) observed that 60 minutes after intravenous administration 
of cationic BA vesicles in mice, the liver displayed the highest value of radiolabelled 
vesicles. In a further study investigating the distribution of cationic BA vesicles, the 
kidneys were the organ expressing the highest clearance (Popov et al, 2012). 




3.5.4  Limitations 
As one of the main aims was to encapsulate different cargoes it was important to 
investigate the potential of our vesicles to encapsulate not only tracer dyes but the 
antibody fragment scFv 4D5-8RFP. A limitation of this study is the concentration of 
the antibody fragment included in the original formulation (4.6 µM). Whilst this was 
a proof of concept study, increasing the concentration is a factor to investigate in 
future experiments. Therefore, it may appear that the signal of the antibody 
fragments was directly proportional to the concentration. Overall, the fluorescence 
of the RFP is thought to be several orders of magnitude lower than that of the Alexa 
Fluor (Siegel et al, 2013). Future studies will employ conjugation of AF546 to the 
antibody fragment to increase the fluorescent signal as well as increasing the 
concentration of the antibody fragments added to the material. It will also be 
paramount to reprise the viability and immunogenic assays with the antibody 
fragment encapsulated vesicles.  
Whilst our study followed the recommendation by Monteiro-Riviera, Inman and 
Zhang (2009) as they suggest two or more independent studies to test for 
cytotoxicity, there were discrepancies in our in vitro findings. Further metabolic 
screening should be carried out in order to determine how the BA vesicles behave 
in vitro. Therefore, it is suggested to investigate the bioenergetic function of BA 
vesicles by measuring reactive oxygen species (ROS) production using, for 
example, the Amplex red assay (Kumar et al, 2017). Whilst in vitro testing was 
focused on the main cell types that we wanted to target for delivery to the brain, the 
cytotoxic response may differ in cells in vivo. Ideally in vitro studies would be 
performed on primary cell lines, which are more representative of in vivo conditions 
due to their sensitivity to environmental changes (Dusinska et al, 2017). However, 
due to the high throughput of immortalised cell lines this offers a more standardised 
platform, as well as cost effectiveness (Dusinska et al, 2017; Kumar et al, 2017). 
Such assays do not provide information regarding the mechanism/s of cell death 
(Adan et al, 2016).  
The clinical dose of our BA vesicles is unknown and is very much dependent upon 
the dose of the drug that they encapsulate. Therefore, this is also very much 
dependent upon the encapsulation efficiency, which was very low (see section 
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2.4.9). At higher doses, based on the apoptosis assay results for hCMEC/D3 cells, 
the BA vesicle formulation may be toxic. However, the dose would be dependent 
upon the drug encapsulated within the vesicle as well as the encapsulation 
efficiency. It is also imperative to investigate and test the level of toxicity of BA 
vesicles encapsulated with therapeutic against the same dose of the drug alone.  
In vivo toxicity was not explored. As in vivo testing will be systemic there are a 
number of other factors/parameters influencing the vesicles that may influence the 
effect of the BA vesicles that have not and need to be investigated (Dusinska et al, 
2017). In particular, toxicity studies are recommended through the collection and 
examining of blood composition to investigate changes after exposure to vesicles 
(Marquis et al, 2009; Love et al, 2012; Winter et al, 2015). Changes can be 
compared to negative controls or pre-treatment samples (Marquis et al, 2009). 
Similarly, immunogenicity testing can be carried out, screening for increase in 
release of cytokines and chemokines (Marquis et al, 2009).  
Our BA vesicles have not been formulated for a specific target. Whilst the initial 
studies were to investigate the uptake in biological barriers and then, in vivo, the 
potential as a drug delivery system to cross the BBB. They must be designed to be 
target specific, as this is a fundamental principle of development of a drug delivery 
system (Puri et al, 2009). One potential option is using a PEGylated folic acid 
compound (see section 3.5.5). 
Whilst we know that the vesicles are opened, as observed in the release kinetics 
studies, we do not know the mechanism by which cargo is released. Other studies 
have demonstrated that their vesicles were designed with a release mechanism, 
the vesicles release their cargo in the presence of acetylcholinesterase due to the 
addition of acetylcholine head groups in the BA formulation (Popov et al, 2010; 
Dakwar et al, 2012; Popov et al, 2013). This is a fundamental parameter in the 
release kinetics, as it will determine not only release but target specificity of the 
vesicles. Puri et al (2009) suggest that creating a defect in the structure of the 
vesicles may trigger release of cargo either internally, enzymatic release or 
changes in pH, or externally, such as heat. Our vesicles may be pH sensitive and 
therefore, lysed within the lysosome of cells. However, this will need further 
investigation (section 3.5.5) 
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It is important to investigate how the BA vesicles are transported across cellular 
membranes, specifically the BBB. The mechanism by which the vesicles are 
endocytosed, for example clathrin-mediated endocytosis or caveolae- mediated 
transport, may influence their ability to transcytose (Salatin and Khosroushahi, 
2017; Villaseñor et al, 2019). It is important to understand the mechanisms by which 
the drug delivery system traverses biological barriers to determine the 
pharmacokinetics and pharmacodynamics.  
3.5.5 Future studies 
As the efficacy of a chemotherapeutic is governed by its ability to penetrate the 
BBB rather than its efficacy to treat the tumour, there is a current focus on improving 
delivery, concentration and uptake of combinations of current chemotherapeutics 
(Pardridge, 2001; Ananda et al, 2011; Pinto et al, 2017).  
One aspect which is imperative to investigate is the transport mechanism the 
vesicles use in order to penetrate the BBB. It is hypothesised that the mechanism 
by which the anionic vesicles are able to cross the cellular membrane is due to the 
caveolae mediated transport, by virtue of their lipid composition (Voigt, Christensen 
and Shastri, 2014). Voigt, Christensen and Shastri (2014) hypothesised that the 
interaction between the receptor and ligand was influenced by the hydrophobic and 
electrostatic interactions. They applied this to their highly anionic particles that they 
hypothesised were able to cross the cell membranes based on their high lipid 
content and, therefore, high affinity for lipid membranes, as well as the anionic 
surface charge of the nanoparticles which was believed to counteract the charge 
between the cell membrane and the particles. Therefore, this may explain how our 
anionic vesicles penetrated the mouse BBB.  
As Voigt, Christensen and Shastri (2014) observed uptake of particles of a similar 
size and charge as our vesicles via caveolae mediated transport, this may be the 
mechanism by which our BA vesicles are able to cross the BBB. However, the size 
of caveolae, approximately 70 nm, indicates that this may not be likely (Bastini and 
Parton, 2010). A further confounding challenge may be the lower expression of 
caveolae-mediated transporters on BECs than other peripheral endothelial cells 
(Huang et al, 2018). However, in the BBTB increased expression of caveolae is 
observed (Zhan and Lu, 2012). 
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It has been observed that clathrin mediated transport was the mechanism utilised 
by lipid nanoparticles, produced with cetyl palmitate, to transcytose Caco-2 cells 
(Neves et al, 2016). As these nanoparticles are of a similar size and charge to our 
vesicles, it may be that our vesicles transcytose via the same pathway. As a result, 
all routes of entry should be explored by inhibiting each pathway with different 
concentrations of inhibitors to ensure that the dose is not lethal, but that it is able to 
exert its effect.  
In order to carry out such studies this experiment may benefit from being tested 
using an in vitro BBB such as the static transwell plates or a dynamic flow system 
such as Kirkstall system. The inhibitor methyl-β-cyclodextrin has been 
recommended a suitable inhibitor for caveolae mediated transport (Ivanov, 2008) 
as it is involved in the extraction of cholesterol from the plasma membrane 
(Zidovetzki and Levitan, 2007). Amiloride or cytochalasin D are inhibitors of 
macropinocytosis (Ivanov, 2008).  Amiloride acts as a Na+/H+ inhibitor reducing pH 
of the cytosol (Recouvreux and Commisso, 2017), whereas cytochalasin D inhibits 
polymerisation of actin (Dutta and Donaldson, 2012). Chloropromazine is a specific 
inhibitor of clathrin-mediate endocytosis (Ivanov, 2008) as it prevents the function 
of AP2 proteins, specific to formation of clathrin vesicles, as well as the 
sequestering of clathrin receptors and AP2 in endosomes preventing the recycling 
of clathrin to the membrane surface (Francia et al, 2019).  
In order to investigate the intracellular behaviour of the BA vesicles further studies 
involving lysotracker should be employed (Wu et al, 2013). To further investigate 
the endocytic/transcytotic pathway of the BA vesicles, lysotracker will be 
encapsulated in the lumen of the BA vesicles, during the synthesising process. 
Lysotracker encapsulated vesicles will be incubated with confluent BV2s, the cell 
type representative of the microglia. The BA vesicles would be tracked and imaged 
continuously over a 24-hour time period, as from previous experimental work the 
vesicles appear to have been lysed well within this time frame. 
It is important to investigate all routes of excretion in order to calculate the true 
clearance values. Future in vivo work would include the collection of urine and 
stools as well as blood to measure the fluorescence, alongside the homogenised 
tissue samples to investigate the overall fluorescence of all samples collected to 
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investigate more comprehensively the pathways and level of clearance. In this 
current study these samples were not collected. Therefore, this study should be 
reprised.   
It would be pertinent to test the BA vesicles as a drug delivery system to treat 
diseases of the brain. It is suggested that the study would be reprised 
accompanying an animal model of CNS disease, such as 5xFAD as an AD mouse 
model (Jankowsky et al, 2017) or GL261 murine model (Oh et al, 2014). It is 
important to explore the distribution of the vesicles within the brain tissue to 
elucidate where the vesicles are located and potential pathways to enhance 
delivery and targeting (Sanavio et al, 2018).   
Future work includes investigating the targeting of the vesicles in the brain. One 
potential route of exploration could be the inclusion of PEGylated folic acid during 
the synthesis of BA vesicles as suggested (Chapter 2, section 2.6). PEGylation is 
the addition of polyethylene glycol during the vesicle synthesis step in order to 
increase delivery to specific cells (Suk et al, 2016). PEGylation has been observed 
to reduce rapid clearance due to increased half-life resulting in increased circulation 
time (Zhang et al, 2016; Zhang, Mintzer and Uhrich, 2016). It has also been 
observed to reduce opsonisation but also reduce uptake in activated microglia 
(Papa et al, 2014). However, the lipid nanoparticles used in this study were 
PEGylated and the formulation was conjugated with folic acid. The high expression 
of the folate receptor (FR) in diseased brain suggests it may be used as a target in 
the delivery of therapeutics (Kamaly et al, 2009; Low, Henne and Doorneweerd, 
2007; Pourgholi et al, 2016). Particularly as the folate receptor is not highly 
expressed in normal healthy cells (Low, Henne and Doorneweerd, 2007). As 
hypothesised, the vesicles may be taken up by the microglia. Therefore, in the 
diseased state these cells, referred to as TAMs, would be a potential target as they 
account for approximately 30% of the tumour mass (Søresen et al, 2018; Li and 
Graeber, 2012). The folate receptor is found in many isoforms including β which is 
expressed on TAMs of cancers such as liver, kidney, skin and glioblastoma 
(Elechalawar et al, 2019). This system has been used in a similar way, with a folate 
tagged PEGylated liposome in the imaging of ovarian tumours with a 4-fold 
increase in uptake within two hours (Kamaly et al, 2009). Therefore, the folate 
receptor may be used as a TAM-specific target, enabling delivery of BA vesicles 
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tagged with folate and encapsulating therapeutics to TAMs as part of the tumour 
microenvironment.  
Kulkami and Feng (2013) investigated the effects of size and surface modification 
of nanoparticles and found nanoparticles smaller than 200 nm and coated with D-
α-tocopheryl polyetheylene gycol 1,000 succinate (TPGS) appeared to avoid 
opsonisation. Therefore, surface modification may be a further factor to investigate 
to avoid first pass metabolism and improve targeting. 
The route of administration in our in vivo study investigated intravenous 
administration. However, the route of delivery may influence the biodistribution of 
lipid nanoparticles (Chenthamara et al, 2019). Perhaps other non-invasive routes 
such as inhalation through intranasal administration, which also avoids first pass 
metabolism but is hypothesised to bypass the BBB and directly enter the brain via 
the trigeminal nerve, may influence the efficacy and delivery of the BA vesicles 
(Furtado et al, 2018; Chenthamara et al, 2019).  
3.6 Conclusion  
The BA vesicles used in our study have been shown to be non-toxic at low doses 
and do not influence cell viability. They do not induce an immunogenic response in 
vitro. Our BA vesicles have been observed to be lysed in vitro in different cell lines 
representative of the body as well as the diseased brain. They have also been 
shown to encapsulate cargoes of differing sizes from tracer dyes, such as AF546 
and propidium iodide to larger fluorescently tagged antibody fragment scFv 4D5-
8RFP. AF546 encapsulated vesicles have demonstrated the ability to cross the 
BBB. The BA vesicles used to cross the BBB were originally thought to be cationic 
GLH-20 vesicles. However, the zeta potential demonstrated that our BA vesicles 
are not only anionic but also novel. Therefore, demonstrating that our novel vesicles 
have the potential to be used as a drug delivery system to use to treat disease of 





The initial studies of vesicles made with our preparation of GLH-20 from vernonia 
oil revealed that they possessed a negative zeta potential. Further investigation of 
these novel bolaamphiphilic (BA) vesicles in previous chapters, has shown them to 
be stable and to be taken up in a number of cell lines. They do not induce apoptosis 
or cause inflammation and are able to cross the BBB in vivo after 30 minutes. These 
vesicles are not the GLH-20 as they are anionic as demonstrated by the negative 
zeta potential. This highlights that the vesicles developed here are novel. 
Therefore, analysis will need to be undertaken to investigate what these vesicles 
are so that they can be reproducibly produced in the future as part of a potential 
brain delivery system.   
Produced from the oil of the African sunflower, Vernonia galamensis, GLH-20 
vesicles have shown the potential to cross the BBB. Vernonia oil has a high epoxide 
acid concentration (78%) making it attractive in comparison to other similar fatty 
acid oils, such as soybean and linseed, comprised of linoleic acid (Carlson et al, 
1981; Grinberg et al, 1994). Vernolic acid, the single chain fatty acid of vernonia oil, 
is an attractive alternative to linoleic acid, due to its viscous properties (Grinberg et 
al, 1994).  It is used in industry to provide stability, flexibility and durability in 
particular as a coating for steel plates (Carlson et al, 1981; Grinberg et al, 1994). 
BA compounds, synthesised from vernolic acid, can form a mono-layered 
membrane in the form of a raft, that when disrupted forms vesicles. BAs have been 
used in numerous applications and have been suggested as a drug delivery system 
(Dakwar et al, 2012; Kim et al, 2013; Gupta et al, 2015). Bors and Erdő (2019) 
suggest that cationic liposomes are more suitable drug delivery systems due to 
more effective interactions with biological barriers demonstrating enhanced uptake.  
Anionic vesicles have been shown to cross the BBB in rats in low concentrations 
(Lockman et al, 2004). Highly anionic lipid nanoparticles are suggested to traverse 
the BBB despite the high charge of the nanoparticle, as the polarity of the BBB 
effectively cancels out the charge, thereby enabling the lipophilic interaction 
between the cell membrane and the nanoparticle (Voigt, Christensen and Shastri, 
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2014). These authors believe that the physiochemical modification facilitates the 
transcytosis of the particle through caveolae-mediated transport.  
Grinberg et al (2008) synthesised cationic BA vesicles from vernonia oil. It appears 
that this study has, created a novel vesicle based on the synthesis of GLH-20 
vesicles using vernonia oil (figure 4.1). The original synthesis of our BA vesicles 
followed a similar experimental procedure to Grinberg at al (2008). However, our 
vesicles were found to have a negative zeta potential. In order to understand this 
difference, high resolution mass spectrometry (HRMS) of the original material was 
performed. The analysis was then used to design a method to recreate and 
synthesise the vesicles used in the previous chapters. The newly synthesised 
vesicles were then characterised to ensure that they displayed the same 
physiochemical properties as the BA vesicles in the earlier part of this study.   
Figure 4.1. Schematic representation of vernonia oil. Starting material for the 
synthesis of GLH-20 vesicles shown to penetrate the BBB. 
4.2 Aims: 
1. To determine the material used for the synthesis of the original novel anionic BA 
vesicles from chapter 2 and 3 
2. To develop a robust methodology for producing and purifying BA vesicles 




4.3 Experimental Procedures  
4.3.1 Materials  
Table 4.1 The list of materials and their suppliers used throughout chapter 4. 
4.3.2 General Procedures  
Reactions employing air and/or moisture-sensitive reagents were performed under 
an atmosphere of nitrogen (unless otherwise specified) in flame-dried apparatus. 
Anhydrous reagents were handled under nitrogen using standard techniques.  
MATERIALS SUPPLIER ADDRESS 
Candida Antarctica lipase B 
(CALB) (Novozym 435) (catalog 
# 06-3123) 
Strem Chemicals Newtown, 
Cambridge, UK 
EtOH (catalog # 20821.330DP) VWR Chemicals Leicestershire, UK 
Cholesterol (catalog # C8667), 
cholesteryl hemisuccinate 
(catalog # C6512) 
Sigma Aldrich Irvine, UK 
acetic acid (catalog # 1038490), 
1,10 decanediol (catalog # 
10403515), chloroform (catalog 
# C2432), methanol (catalog # 
10675112), propidium iodide 









PBS (catalog # BE17-516F) Lonza Slough, UK 
Toluene (catalog # 108331), 
diethyl ether (catalog # 309966), 
chloroacetic acid (catalog # 
800412), silica powder (catalog 
# S5130), thionyl chloride 





trimethyltin hydroxide (catalog # 
71167.03), petroleum ether 
(catalog # 42085.K7), ethyl 
acetate (catalog # 22912.K2), 
dichloromethane (catalog # 
L13089 AP), 
tetrabutylammonium fluoride 
(catalog # L13303.09), 
anhydrous MgSO4 (catalog # 
33337.36)  






Room temperature varied between 19-25°C. “Removed at reduced pressure” refers 
to the use of a rotary evaporator with the water bath temperature generally not 
exceeding 40°C.  
4.3.2.1 Nuclear magnetic resonance  
Nuclear magnetic resonance (NMR) was performed through Key Organics. The 





C) and fluorine (
19
F) nuclear magnetic resonance (NMR) 
spectra were recorded on a Bruker Avance 300 spectrometer operating at 300.1 
MHz for 
1
H, 75.5 MHz for 
13
C and 282 MHz for 
19
F, Bruker Avance II 400 operating 
at 400.1 MHz for 
1
H and 100 MHz for 
13
C. Chemical shifts were recorded at δ values 
in parts per million (ppm). Spectra were acquired in CDCl3, DMSO-d6, CD3OD, 





C NMR spectra recorded in CDCl3, DMSO-d6, CD3OD and deuterium 
oxide, the peak due to residual CDCl3 (7.27 ppm for 
1
H, 77.00 ppm for 
13
C), DMSO-
d6 (2.5 ppm for 
1
H, 39.5 ppm for 
13
C), CD3OD (3.31, 4.79 ppm for 
1
H, 49 ppm for 
13
C) or water (4.72 ppm for 
1
H) was used as the internal reference. H NMR data 
are reported as follows: chemical shift (δ), relative integral, multiplicity (defined as: 
s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad singlet), 
coupling constant(s) J (Hz), assignment.  
4.3.2.2 High resolution mass spectrometry 
High resolution mass spectrometry (HRMS) was performed by Dr Emmanuel 
Samuel at UCL. The protocol is outlined. HRMS was recorded on a Waters 
Micromass, LCT to Time of Flight mass spectrometer, coupled to a Waters 2975 
HPLC. Chemical ionisation (CI) was recorded on a Waters Micromass GCT Time 
of Flight mass spectrometer. The parent ion (M, [M+H], [M+Na], [M+Acn+Na] or [M-
H]) is quoted, followed by significant fragments with relative intensities.  
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4.3.2.3 Analytical thin layer chromatography  
Analytical thin layer chromatography (TLC) was conducted on Merck pre-coated 
(25 μm) silical gel 60F254 plates or on aluminium-backed 0.2 mm thick silical gel 60 
F254 plates (Merck) and the plates were visualised by treatment with either 
Seebach’s ‘magic’ stain dip or alkaline potassium permanganate dip, followed by 
heating with a heat gun. The retention factor (Rf) quoted is rounded to the nearest 
0.01. Flash chromatography was conducted using silica gel 60F254 as the stationary 
phase and the solvent indicated.  
4.3.3 Synthesis of dichloroacetate diepoxystearate  
This is a three-step procedure. The first step is the production of 6,7-epoxy stearic 
acid (i, figure 4.2), followed by the production of decane diepoxystearate (ii, figure 
4.2) and finally the dichloroacetate diepoxy stearate (iii, figure 4.2). 
A solution of vernonia oil in MeOH/H2O was treated with NaOH at room temperature 
for 1 h. Due to non-specific opening of the epoxide this method was no longer used.  
A mixture of vernonia oil and trimethyltin hydroxide in 1,2-dichloroethane was 
stirred at 80°C for 24 h (Nicolaou et al, 2005) to afford 6,7-epoxy stearic acid. 6,7-
epoxy stearic acid was refluxed with 1,10 decanediol, Candida antarctica lipase B 
(CALB) (Novozym 435) in toluene for 24 h at 110°C to give decane diepoxystearate. 
Decane diepoxystearate and chloroacetic acid in toluene was heated at 85°C for 
48 h to afford dichloroacetate diepoxystearate (Grinberg et al, 2008; Stern et al, 
2014). 
4.3.3.1 6,7-epoxy stearic acid (Nicolaou et al, 2005) (i, figure 4.2) 
(Yield 88%). Rf 0.4 (pet ether: EtOAc, 60:40); m/z (ES+) 296 [(M+H)+], 100%. The 
data (figure 4.9) were in good agreement with the literature values (Grinberg et al, 
2005). 
4.3.3.2 Decane diepoxystearate (Grinberg et al, 2008) (ii, figure 4.2) 




4.3.3.3 Dichloroacetate diepoxystearate (Grinberg et al, 2008; Stern et al, 
2014). (iii, figure 4.2) 
(Yield 15%). Rf 0.4 (pet ether: Et2O, 70:30); m/z (ES-) 917.6098 [(M-H)-] 
 
 
Figure 4.2. Schematic representation of the synthesis of dichloroacetate 
diepoxystearate. The starting material, vernonia oil, is used to produce step 1 6,7-
epoxy stearic acid (i). The next step is the production of decane diepoxystearate 
(ii) and the final step produces dichloroacetate diepoxystearate (iii).  
4.3.4 Diepoxystearate tetrol  
The production of diepoxystearate was initially produced following the protocol for 
dichloroacetate diepoxystearate (section 4.3.3). This was later improved upon due 
to yield.  
4.3.4.1 First attempt diepoxystearate tetrol  
As following the protocol for dichloroacetate diepoxystearate the first two steps 
were produced (section 4.3.3.1 and 4.3.3.2). Decane diepoxystearate was 
suspended with distilled water was refluxed at 60°C for 9 days (Wang et al,2007). 
However, this reaction did not occur. Therefore, the protocol was improved. 
4.3.4.2 Second attempt diepoxystearate tetrol 
Hydrolysis of the esters has been followed and produced (section 4.3.3.1).  
6,7-epoxy stearic acid was suspended with NaOH, dH2O and MeOH and refluxed 
at 60°C for 24 h to afford 6,7-diol stearic acid (iv, figure 4.3). 6,7-diol steric acid was 
refluxed with 1,10 decanediol, Candida antarctica lipase B (CALB) (Novozym 435) 
in toluene for 24 h at 110°C to give diepoxystearate tetrol (v, figure 4.3). TET01 
vesicles were synthesised from this final formulation.  
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4.3.4.2.1  6,7-diol stearic acid (iv, figure 4.3) 
(Yield 31%). Rf 0.4 (pet ether: Et2O, 80:20); m/z (ES+) 313.45 [(M+H)+]. 
4.3.4.2.2 Diepoxystearate tetrol (Grinberg et al, 2008) (v, figure 4.3) 
(Yield 4.8%). Rf 0.4 (pet ether: Et2O, 70:30); m/z (ES+) 831.6177 [(M+Acn+Na)+] 
Figure 4.3. Schematic representation of the synthesis of diepoxystearate 
tetrol. The starting material, vernonia oil, is used to produce step 1 6,7-epoxy 
stearic acid (i). The next step is the production of 6,7-diol stearic acid (iv). The final 
step results in the production of the compound diepoxystearate tetrol with a low 
yield of 4.8% of the original material. Hence, this technique was optimised to 
improve and increase the overall yield. 
4.3.4.3 Final attempt diepoxystearate tetrol 
Hydrolysis of the esters has been followed and produced (section 4.3.3.1).  
6,7-epoxy stearic acid was suspended with trifluoroacetic acid (TFA), 
tetrahydrofuran (THF) and dH2O and stirred at room temperature for 48 h (Cory et 
al, 1990) to afford gave 6,7-diol stearic acid. 6.7-diol stearic acid was refluxed with 
tert-butyldimethylsilyl chloride (TBSCl), imidazole, 4-dimethylaminopyridine 
(DMAP) and dimethylformamide (DMF) for 24 hours at 80°C. to give 6,7-(tert-
butyldimethylsilyl ether) stearic acid (Corey and Venkateswarlu, 1972). 6,7-(tert-
butyldimethylsilyl ether) stearic acid in anhydrous dichloromethane (DCM) was 
added thionyl chloride at -5°C, and stirred for 1 hr at room temperature. 1,10-
decanediol and stirred at room temperature for 1h to afford diester TBS 
intermediate. Diester TBS intermediate in THF at room temperature was added 
tetrabutylammonium fluoride (TBAF) afforded diepoxystearate tetrol  
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4.3.4.3.1 6,7-diol stearic acid (Cory et al, 1990) 
(Yield 74%). Rf 0.4 (pet ether: Et2O, 60:40); m/z (ES+) 313.45 [(M+H)+]. 
4.3.4.3.2 6,7-di(tert-butyldimethylsilyl ether) stearic acid (Corey and 
Venkateswarlu, 1972). 
(Yield 81%). Rf 0.4 (pet ether: Et2O, 60:40); m/z (ES-) 541.4094 [(M-H)-]. 
4.3.4.3.3 Diester TBS intermediate (D’Angelo and Smith, 2015) 
(Yield 33%). Rf 0.4 (pet ether: Et2O, 70:30); m/z (ES-) 1224.9886 [(M-H)-]. 
4.3.4.3.4 Diepoxystearate tetrol (Corey and Venkateswarlu, 1972). 






Figure 4.4. Schematic representation of the optimised synthesis of 
diepoxystearate tetrol. The starting material, vernonia oil, is used to produce step 
1 6,7-epoxy stearic acid (i). The next step is the production of 6,7-diol stearic acid 
(vi). 6,7-di(tert-butyldimethylsilyl ether) stearic acid (vii) is the following product in 
the next synthesis step. The penultimate step is a two-step process which results 
in the product diester TBS intermediate (viii.a and viii.b). The final step results in 
the production of the compound diepoxystearate tetrol. The overall yield was 
improved to 64%. 
4.3.5 Nanoparticle Tracking Analysis of vesicles 
Nanoparticle Tracking Analysis (NTA) was performed using a NS300 NanoSight 
(Malvern Panalytical, Malvern, UK), configured with a sCMOS camera and a 405 
nm diode laser. Samples were diluted in filter sterile, particle free PBS to ensure 
the number of particles were maintained with a flow rate of 20-40 particles in the 
field of view to maintain a concentration between 1 x 107-1 x 109 particles/ml. 
Camera settings were according to the manufacturer’s instructions (Malvern 
Panalytical), recording 5 x 90 s videos per sample. Data were analysed using the 
NTA software (version 3.4). Triplicates of each experiment were performed.  
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4.4  Results 
The original BA material, from chapters 2 and 3, unexpectedly produced novel 
anionic vesicles. They were also shown to cross the BBB. In order to determine 
what the novel BA vesicles were, so that we can develop a robust methodology for 
future synthesis, high resolution mass spectrometry (HRMS) was performed. 
Based on these results a new synthesis was undertaken to produce a version of 
the initial material from vernonia oil BA vesicles from this newly synthesised BA 
were characterised. 
4.4.1 High resolution mass spectrometry of the original bolaamphiphilic 
material. 
The original production of the vesicles was undertaken in 4 steps (see chapter 2, 
section 2.3.2). This should have resulted in vesicles with a positive zeta potential 
associated with the acetylcholine head group. As a result of the negative charge of 
these vesicles made with this material a sample of the original BA material was 
analysed by high resolution mass spectrometry (HRMS) to determine the molecular 
weight MW [M+H] (figure 4.5). Two predominant peaks were observed in the 
material with molecular weights of 924.7 and 767.7. Neither of these peaks are 













Figure 4.5 High Resolution Mass Spectrometry of the original material. The 
analysis revealed many compounds within the sample. However, the peaks 
demonstrate the relative abundance of the products and the two dominant peaks 
have masses of 924.7 and 767.7. From this analysis further investigations were 
undertaken to elucidate the nature of these species.  
From analysis of the production scheme for GLH-20 the two peaks are 
intermediates of the GLH-20 production. The molecule with molecular weight of 
924.7 is the penultimate product (dichloroacetate diepoxystearate). The other 
molecule (MW 767.7) is an intermediate of the product prior to dichloroacetate 
diepoxystearate (diepoxystearate tetrol). However, this material clearly formed 
vesicles that can penetrate cells. Therefore, we attempted to reprise production of 
this new material from vernonia oil to replicate the material found within the HRMS 
spectra.  
4.4.2 Synthesis of novel material- FASCA01 
The starting material is oil derived from Vernonia galamensis. The protocol used by 
Dr Sumi Lee and Professor Lawrence Williams (Rutgers) was followed for the initial 
steps. Hydrolysis of the esters is the first step followed by a coupling reaction with 
1, 10-decanediol to link two of the derived fatty acids through esterification, to 
increase the hydrophobic chain. The stability of BA vesicles has been shown to be 
dependent upon the length of the hydrophobic chain (Popov et al, 2010). Figure 4.6 
is the proposed procedure to be undertaken in order to synthesis the final product. 
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The analysis indicates the presence of two species (FASCA 01 and TET01). The 
final steps in the production included the opening of the epoxy group (figure 4.6). 
The purpose of this is to add polarity to the BA, consistent with the observed 
negative charge. Therefore, we set out to produce dichloroacetate diepoxystearate 
(FASCA 01) and analyse the properties.  
 
Figure 4.6. Schematic representation of the production of bolaamphiphile 
(FASCA 01). There are three steps involved in the production of BA; step 1; 
hydrolysis of the esters to produce 6,7-epoxy stearic acid, step 2; coupling of the 
1,10 decanediol to link two molecules of stearic acid to produce decane 
diepoxystearate, step 3; opening of the epoxide through the addition of chloroacetic 
acid to produce dichloroacetate diepoxystearate. 
4.4.2.1  Step 1-Hydrolysis of esters 
1 g of vernonia oil (generously supplied by Professor Lawrence Williams), 1 g (5.5 
mmol) of trimethyltin hydroxide and 50 ml of 1,2-dichloroethane was used to 
hydrolyse the esters of the starting material (figure 4.7). After 24 hours of reflux at 
80°C, the material was cooled, and removal of solvent was performed by rotatory 
evaporation under vacuum. Hydrolysis was verified using thin layer 
chromatography (TLC), a chromatographic technique in which samples are 
separated on a stationary phase (a silica coated glass plate) in a mobile phase (the 
solvent to be used) by capillary action. The solvent employed here was petroleum 
ether (pet ether) (60°C – 80°C): ethyl acetate (EtOAc) in the ratio 3:2 and then 
analysed by staining with potassium permanganate (20 mM KMnO4, 100 mM 
K2CO3, 5% w/v NaOH). Silica gel column chromatography was prepared with silica 
powder to purify the sample. Fractions containing the purified sample were 
collected and concentrated by rotatory evaporation under vacuum. The sample was 
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then analysed using high-resolution mass spectrometry (HRMS) and determined 
the molecular weight MW [M+H] 296.2351 (figure 4.8).  
Figure 4.7. Schematic representation of the production of 6,7-epoxy stearic 
acid. Vernonia oil is the starting product which is hydrolysed with trimethyltin 
hydroxide and 1,2-dichloroethane at 80°C for 24 hours to produce 6,7-epoxy stearic 
acid. 6,7-epoxy stearic acid was confirmed by TLC and HRMS.  
Silica gel column chromatography was used to separate and purify the products of 
the first hydrolysis reaction. The elution fractions were collected, and the solvent 
was removed for HRMS analysis (figure 4.8).  
Figure 4.8. The resultant mass spectra from HRMS after the first step-
hydrolysis of esters. The accurate mass measurement of product 1 was 
confirmed as 296.2351, chemical formula C18H32O3.  
The results from HRMS demonstrates that the hydrolysis of the starting material 
gave rise to the product 6,7-epoxy stearic acid. This was supported by the greatest 
peak demonstrating the relative abundance of this molecule in the sample.  
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Figure 4.9. Proton NMR spectra of 6,7-epoxy stearic acid. Our analysis is in 
accordance with the literature.  
NMR analysis of 6,7-epoxy stearic acid also supports the literature (Grinberg et al, 
2005) (figure 4.9). 
4.4.2.1.1  Step 2-Synthesis of decane diepoxystearate  
0.55 g (1.85 mmol) of 6,7-epoxy stearic acid (product of step 1) was refluxed with 
0.162 g (0.93 mmol) 1,10 decanediol, 0.0143 g of Candida antarctica lipase B 
(CALB) (Novozym 435) in 60 ml toluene with azeotropic distillation for 24 hours at 
110°C (figure 4.10). Azeotropic distillation is a technique used to distil solutions that 
share a similar boiling point proving challenging to separate. Two distillation tubes 
are employed, one for dehydration and the other for separation of the solvent 
selected to purify the two samples, by altering the temperature, from the final 
product. Once the material had cooled to room temperature the lipase was filtered 
off. The solvent was removed by rotary evaporation under vacuum. In order to 
precipitate the product 70 ml of methanol was added to the cooled mixture and 
incubated overnight at 4°C. This was filtered and washed with cooled methanol. 
TLC was performed (using a mobile phase of 7:3 pet ether: Et2O for a more 
accurate and less polar separation) and the TLC was stained with KMnO4. The 
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sample was then analysed using high-resolution mass spectrometry (HRMS) and 




Figure 4.10. Schematic representation of the production of decane 
diepoxystearate. 6,7-epoxy stearic acid with 1, 10 decanediol, Candida antarctica 
lipase B and toluene was refluxed for 24 hours at 110°C. Decane diepoxystearate 
production was confirmed by HRMS.  
Figure 4.11. The resultant mass spectra from HRMS after the second step-
coupling reaction. The accurate mass measurement of decane diepoxystearate 
was confirmed as 731.6190, chemical formula C44H78O6.  
Decane diepoxystearate is the intermediate that is required in order to produce the 
products of both predominant peaks from the HRMS analysis (figure 4.5).  
4.4.2.1.2  Synthesis of dichloroacetate diepoxystearate  
0.25 g of decane diepoxystearate (0.342 mmol) and 0.454 g of chloroacetic acid in 
25 ml toluene was heated at 85°C for 48 hours (figure 4.12). The mixture was 
cooled, and a further 150 ml of toluene was added. The reaction mixture was 
washed with 6% (w/v) sodium bicarbonate solution (NaHCO3) and then water. A 
separating flask was used to separate the aqueous from the organic phase. The 
organic phase was collected and dried out over anhydrous magnesium sulphate 
(MgSO4) and filtered. The solvent was removed using a rotary evaporator under 
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vacuum. TLC was performed using a mobile phase of 7:3 pet ether: Et2O and the 
staining with KMnO4. 
Figure 4.12. Schematic representation of the final product dichloroacetate 
diepoxystearate. FACSA 01 (dichloroacetate diepoxystearate) was produced from 
the heating of decane diepoxystearate, chloroacetic acid and toluene for 48 hours 
at 85°C. This was further separated, dried out and filtered before removing the 
solvent from the final product.  
HRMS (figure 4.13) confirmed the addition of chloroacetic acid to decane 
diepoxystearate to produce dichloroacetate diepoxystearate (FACSA 01) as 
determined by the molecular weight MW [M-H]- as 917.6098.  
Figure 4.13. The resultant mass spectra from HRMS of the final product 
FACSA 01 (dichloroacetate diepoxystearate). The HRMS measurement of the 




4.4.3  Synthesis of novel material- TET01 
The initial reaction, hydrolysis of the esters, has been maintained throughout the 
optimisation steps (section 4.4.2.1.). This method produced vesicles though the 
yield of bola material was low and the production time lengthy (figure 4.14).  
Figure 4.14. Schematic representation of the production of novel 
bolaamphiphile TET01. There are three steps involved in the production of BAs; 
step 1; hydrolysis of the esters, step 2; opening of the epoxide ring, step 3; coupling 
of 1,10 decanediol to link molecules of the ester diol. 
4.4.3.1  Step 2- Formation of ester diol (6,7-diol stearic acid). 
0.7435 g (2.5 mmol) 6,7-epoxy stearic acid was suspended with 0.3 g (7.5 mmol) 
NaOH, 10 ml dH2O and 20 ml MeOH in a 50 mL flask, refluxed at 60°C (figure 4.15) 
and monitored by TLC for 24 hours using Seebach’s ‘magic’ stain to identify the 
final product. After completion, the mixture was washed with 6% w/v NaHCO3 
solution and then water, dried over MgSO4, and then filtered to give the crude 
product. Purification by silica gel column chromatography resolved the final 
product. TLC was performed using a mobile phase of 4:1 pet ether: Et2O and the 




Figure 4.15. Schematic representation of the production of 6,7-epoxy stearic 
acid. Opening of the epoxide ring of 6,7-epoxy stearic acid was performed by the 





O for 24 
hours at 60°C 
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The sample was then analysed using high-resolution mass spectrometry (HRMS) 
and determined the molecular weight MW [M+H] 313.45, chemical formula 
C18H33O4 (figure 4.16).     
Figure 4.16. The resultant mass spectra from HRMS after the second step-
opening of the epoxide ring. The accurate mass measurement of product 2, 6,7-
diol stearic acid, was confirmed as 313.45, chemical formula C18H33O4.  
4.4.3.2 Final step- Coupling of 6,7-diol stearic acid molecules to 1,10 
decanediol forming diepoxystearate tetrol. 
0.3197 g (1.018 mmol) of 6,7-diol stearic acid (product of step 2) was refluxed with 
0.09 g (0.517 mmol) 1,10 decanediol, 0.14 g of Candida antarctica lipase B (CALB) 
(Novozym 435) in 60 ml toluene with azeotropic distillation for 24 hours at 110°C 
(figure 4.17) as performed for the synthesis of decane diepoxystearate (section 
4.4.2.1.1). The lipase was filtered off once the material had cooled to room 
temperature. The solvent was removed by rotary evaporation under vacuum. 70 ml 
of methanol was added to the cooled mixture to precipitate the product and 
incubated overnight at 4°C. This was filtered and washed with cooled methanol. 
Purification by silica gel column chromatography resolved the final product, 
diepoxystearate tetrol. TLC was performed using a mobile phase of 7:3 pet ether: 




Figure 4.17. Schematic representation of the production of final product 
diepoxystearate tetrol. Diepoxystearate tetrol was produced from the coupling of 
6,7-diol stearic acid, with 1,10 decanediol in the presence of catalyst Candida 
antarctica lipase B and toluene for 24 hours at 110°C. The product was confirmed 
by TLC and HRMS. This was purified through silica gel column chromatography.  
The sample was then analysed using high-resolution mass spectrometry (HRMS) 
and determined by the molecular weight [M+Acn+Na]+ as 831.6177 (figure 4.18). 
 
Figure 4.18. The resultant mass spectra from HRMS after the final step- 
synthesis of TET01 (diepoxystearate tetrol). The HRMS measurement of 
diepoxystearate was confirmed, peak in black, in positive mode [M+Acn+Na]+ as 
831.6177, chemical formula C46H86O8.  
The yield was too low (4.8%). Therefore, a new technique was devised in order to 
increase yield. Vesicles were produced from this final synthesis and were 
characterised and analysed, as discussed further.  
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4.4.4 Optimisation of synthesis of novel material- TET01 
Attempts were undertaken to improve yield and production time of the TET01 bola 
material. The protection of the hydroxyl groups initially with trimethylsilyl ethers and 
then tert-butyldimethylsilyl ethers was investigated (figure 4.19). The protection of 
the hydroxyl groups is designed to reduce potential non-specific interactions as well 
as increase the yield of the bola material.  
Figure 4.19. Schematic representation of the production of novel TET01 
bolaamphiphile. There are three steps involved in the production of novel BA 
TET01, step 1; hydrolysis of the esters, step 2; opening of the epoxide ring, step 3; 
protecting the hydroxyl groups with tert-butyldimethylsilyl chloride (TBS-Cl), step 4a 
and 4b; 2 step reaction, first the formation of a chloride acid, followed by the 
coupling of 1,10 decanediol to extend the carbon chain, step 5; removal of TBS to 
produce diepoxystearate tetrol 
4.4.4.1 Step 2- Formation of ester diol (6,7-diol stearic acid) 
0.4465 g (1.508 mmol) 6,7-epoxy stearic acid was suspended in 100 µl 
trifluoroacetic acid (TFA), tetrahydrofuran (THF) (3 ml) and dH2O (3 ml), mixed and 
122 
 
monitored by TLC for 48 hours at room temperature (figure 4.20). The eluent 
system used was pet ether: Et2O (3:2), and Seebach’s ‘magic’ stain. The mixture 
was washed with dH2O and Et2O and acidified with the addition of 1 M HCl (10 ml) 
to pH 3.8. The organic phase was dried over MgSO4 and filtered to give the 6,7-diol 
stearic acid. The final yield was measured at 74%. This is an improvement over the 
31% yield of the original synthesis. 
 
Figure 4.20. Schematic representation of the optimised production of 6,7-diol 
stearic acid. Opening of the epoxide ring of 6,7-epoxy stearic acid was performed 
by the addition of trifluoroacetic acid (TFA) as the reactant, tetrahydrofuran (THF) 
as the solvent and water at room temperature. 6,7-diol stearic acid was confirmed 
by TLC and HRMS. The chemical formula of the new product, 6,7-diol stearic acid, 
is C18H33O4 with a molecular weight of 313.45.  
The sample was then analysed using high-resolution mass spectrometry (HRMS) 
and determined the molecular weight MW [M+H] 313.3, chemical formula C18H33O4 





Figure 4.21. The resultant mass spectra from HRMS after the opening of the 
epoxide groups. The accurate mass measurement of product 6,7-diol stearic acid 
was confirmed, highest peak, as 313.3, chemical formula C18H33O4 
4.4.4.2  Step 3- Formation of 6,7-di(tert-butyldimethylsilyl ether) stearic 
acid 
0.0354 g (0.1127 mmol) of 6,7-diol stearic acid was refluxed with 0.1 g (0.6635 
mmol) tert-butyldimethylsilyl chloride (TBSCl) and 0.06 g (0.8814 mmol) imidazole 
in the presence of catalyst 0.025 g (0.2049 mmol) 4-dimethylaminopyridine (DMAP) 
and 50 ml dimethylformamide (DMF) for 24 hours at 80°C (figure 4.22). The 
reaction was monitored by TLC using eluent system pet ether: Et2O (3:2), and 
Seebach’s ‘magic’ stain to identify the final product. After completion, the mixture 
was washed with Et2O and then water. Of the separated phases the organic phase 
was washed three times with Et2O, dried over MgSO4, and then filtered to give the 
crude product. Purification by silica gel column chromatography resolved the final 
product 6,7-di(tert-butyldimethylsilyl ether) stearic acid. Toluene was added prior to 





Figure 4.22. Schematic representation of the production of 6,7-di(tert-
butyldimethylsilyl ether) stearic acid. 6,7-di(tert-butyldimethylsilyl ether) stearic 
acid was produced from the addition of tert-butyldimethylsilyl chloride and imidazole 
in the presence of catalyst 4-Dimethylaminopyridine (DMAP) and 
Dimethylformamide (DMF) 24 hours at 100°C. The product was confirmed by TLC 
and HRMS. This was further separated, dried out and filtered before removing the 
solvent from the final product. 
The sample was then analysed using high-resolution mass spectrometry (HRMS) 
and determined the molecular weight MW [M-H]-541.4094, chemical formula 
C18H33O4 (figure 4.23). 
Figure 4.23. The resultant mass spectra from HRMS after the silyation of the 
epoxide groups. The accurate mass measurement of product 6,7-di(tert-
butyldimethylsilyl ether) stearic acid was confirmed, highest peak, as 545.42, 
chemical formula C24H50O4Si2. 
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4.4.4.3  Step 4- Synthesis of diester TBS intermediate 
0.2635 g of diester TBS intermediate (0.5749 mmol), was refluxed in anhydrous 
dichloromethane (DCM) was added thionyl chloride (0.10 ml) at -5°C. After stirring 
for 1 hour at room temperature, all starting material had dissolved. DCM and 
unreacted thionyl chloride were removed under reduced pressure. The product was 
redissolved in DCM (5 ml) under N2 at 0°C. Next, 0.035 g 1,10-decanediol (0.20 
mmol) was added. The reaction mixture was stirred at room temperature for 1h and 
was then quenched by the slow addition of ice cold NaHCO3 solution and extracted 
with 50 ml EtOAc. The aqueous and organic phases were dried with MgSO4 and 
the solvents removed under reduced pressure (figure 4.24). The resultant residue 
was purified by silica gel column chromatography, eluting with pet ether: Et2O (7:3) 
to give diester TBS intermediate  
Figure 4.24. Schematic representation of the two-step production of diester 
TBS intermediate. Diester TBS intermediate was produced from the coupling of 
6,7-di(tert-butyldimethylsilyl ether)stearic acid, in a two-step process initially with 
dichloromethane and thionyl chloride for 1 hour at room temperature. Then 1,10 
decanediol is added for 1 hour at room temperature. The product was confirmed by 
TLC and HRMS. This was purified through column chromatography.  
The sample was then analysed using high-resolution mass spectrometry (HRMS) 









(figure 4.25).  
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Figure 4.25. The resultant mass spectra from HRMS after the coupling of 6,7-
di(tert-butyldimethylsilyl ether) stearic acid. The accurate mass measurement 








4.4.4.4  Step 5- Synthesis of diepoxystearate tetrol-TET01 
To a stirred solution of 0.10 g diester TBS intermediate (0.08 mmol) in 10 ml THF 
at room temperature 0.12 ml tetrabutylammonium fluoride (TBAF) was added. After 
8 h at room temperature the mixture was then partitioned between aqueous phase 
(10 ml NaHCO3) and organic phase (20 ml DCM). The aqueous and organic phases 
were dried with MgSO4 and the solvents removed under reduced pressure. The 
resultant residue was purified by silica gel column chromatography, eluting with pet 
ether: Et2O (4:1) afforded the final product diepoxystearate tetrol (figure 4.26). The 
overall yield was improved from 4.8% to 64%. 
Figure 4.26. Schematic representation of the production of the final product 
diepoxystearate tetrol. Diepoxystearate tetrol was produced by the removal of 
TBS with TBAF for 8 hours at room temperature. The product was confirmed by 
TLC and HRMS.  
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The sample was then analysed using high-resolution mass spectrometry (HRMS) 
and determined the molecular weight MW [M+H] 766.63227, chemical formula 
C18H33O4 (figure 4.27).  
Figure 4.27. The resultant mass spectra from HRMS of the final product 
diepoxystearate tetrol. The accurate mass measurement of product 
diepoxystearate tetrol was confirmed, in black, as 766.63227, chemical formula 
C46H86O8. 
Each step of the synthesis for the production of diepoxystearate tetrol (TET01) and 
dichloroacetate diepoxystearate (FASCA 01) produced a yield, which was then 
used for the next step (section 4.3.3 and 4.3.4, figure 4.28). For the production of 
dichloroacetate diepoxystearate (FASCA 01) the yield of the first step, the 
production of 6,7-epoxy stearic acid, was 88% (figure 4.28). From this 88% of 6, 7-
epoxy stearic acid, 50% of decane diepoxystearate was produced. This is an overall 
yield of 44% of the original starting material, vernonia oil (50% x 88%= 44%). The 
final synthesis step saw a yield of 15% dichloroacetate diepoxystearate produced, 
which was the equivalent of 6.6% of the starting material. Overall, this synthesis 
generated 66 mg of dichloroacetate diepoxystearate. 
This was similar for the production of diepoxystearate tetrol (TET01). The final step 
of the second attempt synthesis produced 4.8% of diepoxystearate tetrol from the 
previous step 6,7-diol stearic acid. This is an overall yield of 15.2% of the original 
starting material, vernonia oil (figure 4.28). This is the equivalent of 15.2 mg of 
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diepoxystearate tetrol generated using this methodology. Due to the low yield 
production was optimised through the introduction of a novel methodology to 
improve the yield. The final yield of diepoxystearate tetrol was 64% of the previous 
product (diester TBS intermediate), generating 11% of the overall yield, equivalent 




Figure 4.28 Summary schematic of (1) GLH-20, (2) FASCA 01, (3) TET01 (low yield) and (4) TET01 (optimised). The above 
schematic represents the synthesis of the final material used for the synthesis of the FASCA 01 and TET01 vesicles, with the 
initial yields and the improved yield for TET01. The original GLH-20 synthesis generated an overall yield of 1.5%, producing 15 
mg of GLH-20 from 1 g of vernonia oil. The final yield for FASCA  01 is 15%, producing an overall yield of 66 mg from 1 g of 
vernonia oil. The final yield of TET01 produced generating only 15.2 mg (4.8% yield). As a result of the low yield the methodology 
was optimised to improve the yield to 64%, generating 111 mg of final material from 1g of starting material, vernonia oil. The initial 
synthesis of both FASCA 01 (2) and TET01 (3) were used for further characterisation. The limitation of starting material as well as 




4.4.5  Characterisation of FACSA 01 vesicles 
Vesicles were synthesised (Chapter 2, section 2.3.5) with FACSA 01 (figure 4.6) 
material. The cargo to be synthesised with FACSA 01 material was either PBS 
(empty vesicles), AF546, or PI as described in Chapter 2 (section 2.3.5). Once 
synthesised the physical properties of the vesicles were characterised by DLS and 
zeta potential (Chapter 2, section 2.3.7 and 2.3.9, respectively) (table 4.2). The 
physiochemical properties of the resulting FACSA 01 vesicles were analysed by 
both DLS and zeta potential. DLS is a technique based on Brownian motion of 
particles in a suspension in order to provide a profile of the mean Z-average and 
PDI. The zeta potential is a measure of electrostatic repulsion/attraction between 
nanoparticles in solution and therefore, a measure of stability - the greater the 
electrostatic repulsion the less likely the vesicles will aggregate.  
Newly produced vesicles, FASCA 01, were synthesised to encapsulate different 
tracer dyes, as was previously performed with our original BA material to investigate 
reproducibility.  
Table 4.2. Dynamic light scattering, polydispersity index and zeta potential 
analysis of empty, Alexa Fluor 546 or propidium iodide encapsulated FACSA 
01 vesicles (n=3). 
The z-average for PI vesicles (table 4.2) is the appreciably higher than the other z-
average values. Whilst the zeta-potential is considerably lower than either empty 
or AF546 encapsulated FACSA 01 vesicles.  
Stability rapidly decreases at both temperatures for FACSA 01 vesicles. Vesicles 
stored at 37°C are stable for longer than when FACSA 01 vesicles are stored at 
4°C (table 4.3).  
Vesicles Empty AF546 Propidium iodide 
Z-average (d.nm)(mean ± SEM) 163.4 ± 12.2 188.8 ± 16.8 493.9 ± 30.3 
PDI (mean ± SEM) 0.4 ± 0.12 0.4 ± 0.12 0.6 ± 0.3 
Zeta potential (mV) (mean ± 
SEM) -45.7 ± 1.8 -37.5 ± 2.4 -6.0 ± 1.5 
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Table 4.3. Stability of empty FACSA 01 vesicles stored at 4°C and 37°C over 
a five-day time frame (n=3). 
Zeta potential (mV)  
(mean ± SEM) 4°C  37°C  
Day 1 -10.3 ± 2.3 -18.1 ± 1.5 
Day 2 -8.6 ± 3.9 -11.6 ± 3.4 
Day 3 -6.6 ± 0.7 -11.2 ± 0.7 
Day 4 -6.5 ± 0.6 -8.4 ± 2.4 
Day 5 -6.5 ± 0.9 -8 ± 0.1 
4.4.6  Linear regression analysis to determine the encapsulation 
efficiency and concentration of Alexa Fluor 546 encapsulated in FACSA 01 
vesicles. 
To determine the concentration of AF546 encapsulated within purified FASCA 01 
vesicles, fluorescence readings (excitation 540-20 nm, emission 590-30 nm) of the 
vesicles were measured and compared against the standard curve (Chapter 2, 
figure 2.4). Vesicles were purified by size exclusion chromatography. From the 
initial concentration of AF546 (125 mM) the highest concentration encapsulated in 
the FACSA 01 vesicles was 138.21 ± 41.3 µM (figure 4.29). A spectral analysis of 
the vesicles was previously performed (chapter 2, section 2.3.) which demonstrated 
that the material did not absorb light at any wavelength. It is not anticipated that the 
light emitted by the dye was being obscured/interfered with by the bola material. 
The encapsulation efficiency was calculated, using equation 1 from chapter 2 
(section 2.3.14): 








Figure 4.29. The encapsulation concentration of Alexa Fluor 546 
encapsulated FACSA 01 vesicles as calculated from the linear regression 
(Figure 2.4). Preparations of vesicles that had been subjected to separation by 
sepharose CL-2B chromatography were examined using a CLARIOstar 
fluorescence plate reader (excitation filter 540-20 nm, emission filter 590-30 nm). 
From the measurements, fraction 14 of the purified vesicle population had the 
greatest concentration of AF546 (n=3). 
4.4.7  Characterisation of TET01 vesicles 
Vesicles were synthesised with the TET01 formulation (figure 4.14) and 
synthesised with either PBS (empty vesicles), AF546, or PI as described in Chapter 
2 (section 2.3.5). Once synthesised the physical properties of the vesicles were 
characterised by DLS and zeta potential as described in chapter 2 (section 2.3.7) 












































Table 4.4. Dynamic light scattering, polydispersity index and zeta potential 












(Mean ± SEM)  
 
223.7 ± 10.0 
 
165.2 ± 130.0 
 
157.5 ± 5.1 
PDI (Mean ± SEM)  0.3 ± 0.063 0.7 ± 0.230 0.2 ± 0.01 
Zeta potential (mV) 
(Mean ± SEM)  
 
-46.6 ± 0.2 
 
-23.0 ± 2.7 
 
-2.8 ± 2.2 
4.4.7.1 Preliminary Nanoparticle Tracking Analysis of TET01 vesicles 
In order to determine the concentration of particles in the neat empty and PI 
encapsulated each neat formulation Nanoparticle Tracking Analysis (NTA) was 
performed (figure 4.30) and the vesicle size was also measured. From the 
NanoSight analysis the mean size of the vesicles was determined. 179.9 ± 6.1 nm 
was the mean size for the neat empty vesicles, and 161.6 ± 3.2 nm for the neat PI 
vesicles.  
 
Figure 4.30. Concentration of empty TET01 vesicles or TET01 vesicles 





































4.5 Discussion  
From the HRMS analysis of the original BA material, it was found that the material 
was not that of GLH-20, but rather a novel compound. The two predominant peaks 
indicate the presence of two species. Therefore, efforts were made to recreate the 
original BA material which was shown to produce stable vesicles that could cross 
the BBB in vivo. The production of FASCA 01 (dichloroacetate diepoxystearate), 
was characterised and profiled, using DLS and zeta potential. The production for 
TET01 (diepoxystearate tetrol) was lengthy and required modifications in an 
attempt to optimise the yield of the formulation. TET01 was however also 
characterised and profiled. Whilst the two formulations were not combined, this is 
strongly recommended for future studies given that both products form vesicles in 
isolation and that both products are apparent in the HRMS analysis.  
4.5.1 Synthesis of FASCA 01 and TET01 
The basis of the original formulation was taken from the experimental procedures 
used to synthesise the cationic vesicle- GLH-20. Grinberg et al (2008) reported the 
synthesis of BA compound GLH-20 to produce vesicles using the methylester of 
vernolic acid as a starting material.  
The original formulation kindly gifted to us from Professor Lawrence Williams was 
interestingly not the cationic GLH-20 BA initially thought. The experimental 
procedure was followed from Grinberg et al (2008). However, the synthesis 
produced a novel material that had a negative zeta potential when made into 
vesicles inferring that a novel vesicle was being produced. After HRMS analysis, 
the original Rutgers derived material gave rise to two peaks which appeared to 
correspond to intermediate steps of the synthesis. The first was thought to be the 
penultimate step in the production of the GLH-20 vesicles containing the 
chloroacetic head groups (FACSA 01). The other peak was thought to correspond 
to the molecular weight of the coupled bola material with hydrolysed epoxide 
groups. As a result, further investigations were made to synthesise these materials 
and produce vesicles from them to assess their characteristics and their ability to 
act as a drug delivery system in order to treat diseases of the brain. 
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Initial attempts to hydrolyse the esters was undertaken with NaOH, MeOH and 
water. However, non-selective opening of the epoxide was also observed. 
Therefore, the method used was revised. As a result, a more selective methodology 
was employed, whilst avoiding non-specific side reactions. Trimethyltin hydroxide 
and 1,2-dichloroethane was employed for the first step (Nicolaou et al, 2005). This 
technique has been observed to reveal higher yield of carboxylic acids from esters 
(Nicolaou et al, 2005). The introduction of the technique increased the yield of 
vernolic acid (6,7-epoxy stearic acid) from 31% to 88%.  
The second step, the formation of decane diepoxystearate, was then optimised. 
Initial attempts of refluxing 1,10 decanediol in toluene resulted in no formation of 
the product decane diepoxystearate. Therefore, the next attempts were performed 
in the presence of the catalyst 4-(dimethylamino)pyridine (DMAP) (Popov et al, 
2010). DMAP is an effective catalyst for esterification reactions (Kamimura et al, 
2008). However, this was unsuccessful as only a very low yield of decane 
diepoxystearate was observed. Therefore, Novozym 435, a lipase from Candida 
antarctica was employed (Grinberg et al 2008; Stern et al, 2014). This proved 
successful in that the reaction occurred and there was no trace of the coupling 
material, 1, 10 decanediol from TLC analysis, unlike the previous methods used. 
Grinberg et al (2008) reported an increase in yield from 30% to 85% with 10-fold 
increase of lipase. However, they also used a much higher concentration of 6,7-
epoxy stearic acid than we did (92 g to our 0.55 g which is 160-fold greater), which 
may account for the higher yield. Although we did not increase the lipase 10-fold or 
increase the concentration of TET01 bola material the final yield was.50%. 
Nonetheless, this suggests that this step may require further optimisation.  
The final synthesis step in the production of FACSA 01 (dichloroacetate 
diepoxystearate), afforded a final yield of 15%. This is less than the yield reported 
28.5% for dichloroacetate diepoxystearate by Grinberg et al (2008). Vesicles were 
successfully produced from this material Their analysis will be discussed in parallel 
with vesicles made from the other intermediate found in the original synthesis, 
TET01. 
For the initial synthesis of TET01, the same protocol was followed as FASCA 01, 
with the exception of the final step. The initial production of diepoxystearate tetrol 
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was adapted from Wang et al (2007). In this step the reaction is designed to 
selectively open the epoxide without hydrolysing the ester linkage. Due to the 
proton accepting and donating ability of water, acting as a nucleophilic solvent, it 
was expected to speed the reaction rate (Byers and Jamison, 2015). It may have 
been that the water was too weak a nucleophile to hydrate the epoxide in these 
conditions and may have not been selective enough (Vilotijere and Jamison, 2007). 
However, the reaction did not work. As a result, the synthesis was optimised 
attempted by another route. This was attempted as part of an overall revision of the 
pathway. 
To further optimise both the yield and the time taken at each stage of the synthesis, 
with the exception of the first step (hydrolysis of the esters, formation of 6,7-epoxy 
stearic acid), improvements were implemented for the synthesis of diepoxystearate 
tetrol (TET01). As a result, the second step, synthesis of decane diepoxystearate 
(section 4.3.3.2), from the synthesis of FASCA 01, was substituted for the opening 
of the epoxy groups.  
From the original investigations to hydrolyse the esters NaOH was observed to non-
selectively open the epoxides. This was therefore employed as the initial technique 
used for the opening of the epoxide group. However, this was not effective as the 
reaction was slow with a low yield. Trifluoroacetic acid (TFA) has been used for 
opening of epoxy rings (Cory et al, 1990). The concentration of TFA used was 
designed to restrict the potential for non-selective reacting with alkenes as has been 
observed (Peterson et al, 1967). This initial reaction afforded a yield of 31% which 
was increased to 87% after optimisation. 
Once the epoxide groups were opened the final step in the reaction was the 
coupling reaction. The initial attempts were performed with 1,10 decanediol and 
lipase Novozym 435 to afford diepoxystearate tetrol. Once this was completed, 
TET01 vesicles were produced and characterised as will be discussed further. 
The final yield of diepoxystearate tetrol following this procedure was low (4.8%). 
One hypothesis for the low yield may be that the hydroxyl groups were not protected 
(Trader and Carlson, 2012). To prevent this from occurring it is recommended that 
alcohols are protected (Corey and Venkateswarlu, 1972). One such method is the 
derivatisation of the hydroxyl groups via silylation (Greene and Wuts, 1999; Patel 
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et al, 2007). Compounds such as trimethylsilane (TMS) or tert-butyldimethylsilane 
(TBS) may provide the protection required (Su et al, 2017). Initially, silylation was 
performed with TMS and afforded a yield of 80%. However, TMS is more 
susceptible to solvolysis, to attack by nucleophiles, as observed in the non-
selective elimination of TMS during the final synthesis step (the coupling reaction), 
than TBS (Corey and Venkateswarlu, 1972). As observed in the non-selective 
elimination of TMS during the final synthesis step, the coupling reaction. As a result, 
the final product was not formed and so this method was replaced and further 
optimised with the use of TBS. TBS acts to protect the hydroxyl groups, 
transforming them to ethers, which is why it is more suitable that TMS (Corey and 
Venkateswarlu, 1972; Patschinski, Zhang, and Zipse, 2014). DMF used in the 
reaction acts as both the solvent and catalyst, aiding the mild conversion, optimising 
the yield (Patschinski, Zhang, and Zipse, 2014). This afforded a similar yield to TMS 
at 81% but there was no solvolysis as TBS is more suitable for enabling the final 
reaction to complete (Corey and Venkateswarlu, 1972).  
The penultimate step, the coupling reaction, was a two-step reaction. The first step 
was the formation of the acid chloride (D’Angelo and Smith, 2015). Acid chloride is 
highly reactive and is therefore ideal as an intermediate for further reactions. The 
second reaction, the coupling with the 1,10 decanediol to produce diester TBS 
intermediate with a final yield was 33%.  
Due to the high affinity of silicon for fluorine, the final step, the removal of the 
silylated protective groups (TBS), occurred with tetrabutylammonium fluoride, with 
yield of 64% (Corey and Venkateswarlu, 1972). This increase demonstrates that 
the optimisation was successful when compared to the yield of the TET01 
characterised in this study (4.8%). It will be important to characterise this newly 
optimised TET01 material for future work.  
Initially the protocol for the production of the bola material, both FASCA 01 and 
TET01, was comprised of three steps (figure 4.6 and 4.14). However, there were 
numerous limitations such as an exiguous yield and slow reaction time. 
Investigations were made to improve the overall yield of the initial studies. The 
synthesis of the desired BAs was optimised and produced through a final six step 
process. Previous BAs synthesised with vernonia oil also demonstrated the yield 
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decreasing with each production step (Grinberg et al, 2005 and 2008; Popov et al, 
2010) such that the final step gave rise to a 42% yield (Popov et al, 2010). The 
overall yield was increased to 64%. This demonstrates that the optimisation steps 
have been successful at increasing the overall yield. The vesicles must be profiled 
for future studies, individually and in combination with the FASCA 01 formulation.  
4.5.2 Characterisation of FASCA 01 and TET01 
The importance of characterisation is to analyse the physiochemical properties of 
the drug delivery system (Singer et al, 2019). There are several parameters used 
to profile the drug delivery system including the particle size and size distribution, 
using DLS, and shape/morphology (Mourdikoudis, Pallares, and Thanh, 2018, 
Singer et al, 2019). In order to maintain reproducibility, we have used the 
techniques employed in our previous studies (chapter 2) as well reported in other 
studies investigating BA vesicles produced with vernonia oil (Grinberg et al, 2008; 
Popov et al, 2012). The techniques used to characterise our vesicles include DLS, 
zeta potential, size exclusion column chromatography and NTA.  
When comparing the overall size of our original BA vesicles to the newly 
synthesised FASCA 01 and TET01 vesicles the size of TET01 produces the largest 
and FASCA 01 the smallest (163.4 ± 12.2 nm and 223.7 ± 10.0 nm, respectively). 
Considering that essentially FASCA 01 is TET01 with the addition of chloroacetic 
acid it would be expected that they would be a similar size. There may be a number 
of reasons such as the formulation and stability of the vesicles or perhaps the 
synthesis technique. It will be of interest to investigate combining both materials 
together in a vesicle synthesis. This could be explored in future studies. However, 
this is not the case for the PI encapsulated vesicles which behave very differently. 
The size of PI encapsulated FASCA 01 vesicles appears to indicate that there is 
aggregation, especially as the size continued to increase despite attempts to 
sonicate to reduce the size, referred to as sonication induced aggregation (Taurozzi 
et al, 2010). The over sonication is adversely influencing the size and it might be of 
interest to investigate different techniques such as such as ethanol injection. It is a 
method designed to simplify the production of vesicles by dissolving the lipid 
material in ethanol and then injecting it into water, spontaneously forming vesicles 
(Huang et al, 2010; Shaker et al, 2017). Popov et al (2010) employed this method 
139 
 
for their GLH-20 vesicles, as did Kim et al (2020) for their GLH-20 and GLH-19 
combination formulation. However, they also used the bath sonicator to form the 
vesicles. It may be more advantageous to investigate the formation of vesicles 
using a bath sonicator rather than a probe sonicator as it is an indirect method, 
providing lower energy levels than the probe and less likely to form aggregates 
(Taurozzi et al, 2010).  
The NTA measurements of the vesicles appear to demonstrate a discrepancy 
between the two techniques, DLS and NTA, for the size distribution measurements 
for empty TET01 vesicles. NTA is a characterisation technique used for sizing 
particles and providing the concentration of particles within a sample (de Morais 
Ribeiro et al, 2018; Kim et al, 2019). NTA tracks the movement of individual 
particles undergoing Brownian motion and measures their size based on the light 
scattered during the tracking (Filipe et al, 2010; Kim et al, 2019). DLS measures 
the intensity of light scattered by particles under Brownian motion and the speed at 
which they move (Filipe et al, 2010; Bhattacharjee, 2016). Both techniques 
measure the particles based on the diffusion coefficient, measurement of the 
movement of a particle in medium and is dependent upon the frequency and size 
of each movement (Kriczek, 2015). However, DLS reports the size based on the 
intensity of light scattered, whereas NTA reports the size weighted by number (Kim 
et al, 2019). Both techniques have their merits and limitations. Light scattered from 
larger particles can skew the data in some instances when there is polydispersity 
within a sample (Filipe et al, 2010; Bhattacharjee, 2016; Stetefeld et al, 2016). NTA 
can be used to verify the size distribution of DLS as it may be more sensitive in 
measuring accurate size distribution for polydispersed particles (Kim et al, 2019). 
The discrepancy observed in our study has also been observed in others supporting 
the sensitivity of NTA for size distribution (de Morais Ribeiro et al, 2018). However, 
these studies have been reported using standard polystyrene beads rather than 
polydispersed heterogenous populations of particles to assess their strengths and 
limitations (de Morais Ribeiro et al, 2018). The concentration of the vesicles is the 
first time that this has been reported for BA vesicles synthesised from vernonia oil.  
All the vesicles synthesised from TET01 and FACSA 01 formulations were less 
stable that the original BA vesicles. Stability reduces appreciably for FASCA 01 
within 5 days regardless of the temperature at which they are stored. It appears 
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that the stability is modestly enhanced at 37°C than at 4°C however only by 2 days. 
From the HRMS analysis of the original BA material two predominant peaks were 
observed (figure 4.1). It may be suggested that the original BA material is stabilised 
as it is comprised of two species. As a result, the lack of stability observed for 
FASCA 01 and TET 01 may be due to the presence of only a single species within 
this formulation. Popov et al (2013), measured the zeta potential of individual 
formulations and in combination. GLH-20 was measured at +37.2 ± 2.0 mV, GLH-
19 was + 44.1 ± 2.7 mV and in combination (GLH-20 and GLH-19) the zeta potential 
was +45.4 ± 0.6 mV. This appears to support our observations that combination of 
species provides more stability as opposed to the individual formulation. It is 
proposed that both FACSA 01 and TET01 should be included together to 
investigate the effect of two species on stability. 
4.5.3 Encapsulation efficiency  
The concentration of AF546 encapsulated by the original vesicles is low (0.04%). 
(chapter 2, section 2.4.10) in comparison to the FACSA 01 material (0.14%) and 
the initial concentration of AF546 added to the original synthesis (125 mM). A 
possible hypothesis may be that the FACSA 01 material and AF546 are interacting 
and binding more than the original material (Yeo and Park, 2004). Whilst it could be 
considered that the AF546 dye is interacting with the surface of the vesicle as well 
as being encapsulated lumen. However, this may be unlikely as AF546 is negatively 
charged molecule. It is unlikely to interact with the surface of a negatively charged 
compound such as FACSA 01.  
The low encapsulation efficiency of the chromatographically separated peak 
fraction of AF546 original BA vesicles (section 2.4.9) and FASCA 01 vesicles 
demonstrates a need for future optimisation. The same future experiments are 
recommended as mentioned in Chapter 2 (section 2.6) - increasing concentration 
of the BA material (Harayqa and Domańska, 2014), increasing the concentration of 
the cargo (Derman, 2015) and incorporation of folate PEGylated lipid to the vesicle 
material (Cho et al, 2014).  
The cargo encapsulated within may not be the only factor influencing the size of PI 
encapsulated FACSA 01 vesicles. These vesicles are considerably larger than the 
other vesicles with the same formulation. It is an appreciable increase in 
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comparison to the other vesicle sizes and appears to indicate flocculation, and poor 
stability. It appears that the repeated sonication increased the overall aggregation 
(Aoki et al, 1987; Taurozzi et al, 2010). Although, it may be the positive charge of 
the PI is adversely interacting with the FASCA 01 material. Perhaps indicating that 
the PI changes the behaviour of the material as this behaviour was not observed 
with the TET01 material or with other molecules. For future work it may be of 
interest to see if this is observed when both FASCA 01 and TET01 are mixed 
together.  
4.6 Limitations and future work 
In order to optimise further, future work should repeat the coupling reaction in the 
presence of Candida antarctica lipase B as a cataylst, as was performed in the 
initial synthesis (Grinberg et al, 2008). This is the only step from the original protocol 
that has not been optimised 
A further limitation was the low yield of the FASCA 01 bola material. The protocol 
was not optimised during the production of FASCA 01, as we initially wanted to 
make the material, the yield was not the object at this point. However, it became 
apparent during the production of TET01 that optimisation was necessary as 
vernonia oil is a difficult commodity to source and so efficiency was needed to 
improve the yield at each step. Therefore, reprising the same optimisation steps as 
for the synthesis of TET01 is recommended for future production of FASCA 01 
material.  
A further limitation was the overall yield of both FASCA 01 and TET01, as well as 
the time and material constraints, as mentioned in the previous paragraph. This 
restricted more detailed experimentation. Therefore, NTA studies are preliminary 
and, in the future, will be expanded to include the concentration of all vesicles 
synthesised.  
The vesicles do not appear as stable over time as the original BA vesicles. Perhaps 
a combination of both the tetrol (TET01) and chloroacetic (FACSA 01) BA material 
would provide the long-term stability. As the HRMS of the original material appears 
to demonstrate that there are two possible species this may explain the higher long-
term stability observed. Popov et al (2010), investigated the stability as a measure 
of encapsulation. Combinations of at least two different vesicles within a sample 
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were tested over a period of 500 hours (21 days) for encapsulation stability. 
Although certain combinations, such as GLH-20 and GLH-19, were stable, GLH-20 
were no longer stable after 13 days. GLH-19 was more stable when tested alone 
(approximately 50% stability after 21 days). GLH-19 appears to increase the 
stability of both formulations when together (GLH-19 increased GLH-20 vesicles 
stability by 10% for up to 21 days). Again, supporting the observations of combined 
formulations. As our original BA material demonstrated high stability for 4 months 
at 4°C. The stability was still considered high at the end of the third month. As two 
peaks were observed in the HRMS analysis it would be relevant to compare the 
influence of individual species to that of a mix of both formulations on stability. 
Therefore, it is recommended that both formulations are mixed together to 
investigate stability.  
Cationic BA vesicle formulations GLH-19 and GLH-20 have recently been 
combined to improve drug delivery of encapsulated siRNAs to the brain and flank 
tumour (Kim et al, 2020). The individual profiles of each vesicle demonstrate that 
GLH-19 is more stable with higher binding affinity for the siRNAs that were used in 
the study, whereas GLH-20 was shown to have more efficient delivery and release 
kinetics. When both formulations were combined the vesicles indicated that the 
GLH-19/GLH-20 complex combined their individual traits and were shown to deliver 
siRNA in vivo to the brain. As our vesicles are anionic it will be of interest to 
investigate their potential as a drug delivery system using the individual 
formulations and in combination for future studies.  
A further limitation was that there is no EM analysis of the vesicles performed, so 
we cannot confirm whether the vesicles are spherical, as the original material was 
shown to be. As is widely acknowledged, it is necessary to standardise such 
techniques to maintain reproducibility and alignment for testing and 
characterisation of drug delivery systems therefore such an analysis should be 
performed (Björnmalm, Faria, and Caruso, 2016; Mulverny et al, 2016; Gao and 
Lowry, 2018). This will need to be performed to confirm not only the shape but the 
size of the vesicles. EM, confocal microscopy with z-stacking may indicate where 
the vesicles are, for example if the cargo is interacting with the membrane of the 
vesicles or if they are encapsulated. In order to investigate this potential interaction, 
it is suggested that further studies are performed, in particular with vesicles 
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encapsulating the antibody fragment scFv 4D5-8RFP conjugated to AF546, as 
suggested in chapter 3 (section 3.5.4). Therefore, treating antibody fragment 
vesicles with proteinase K to measure the fluorescence using a fluorescent plate 
reader. If the antibody fragments are interacting with the surface rather than 
encapsulated in the lumen of the vesicles, the fluorescence would be expected to 
decrease.  
The encapsulation efficiency must be improved. Initially both formulations should 
be combined to investigate the efficiency. It is also recommended that future studies 
increase either the concentration of the bola material, or the concentration of the 
molecule/drug to be encapsulated (Yeo and Parks, 2004; Harayqa and Domańska, 
2014; Derman, 2015). A further suggestion is to synthesise the vesicles with 
polyethylene glycol (PEG) (Cho et al, 2014). This is not only to investigate the 
potential for the vesicles as candidates as potential drug delivery systems but also 
to compare the effects of these vesicles to that of the original BA material studied 
in chapters 2 and 3.  
To ensure the safety of the FASCA 01 and TET01 formulations, as well as the 
combined formulation, toxicity studies will need to be performed. Further studies 
will include in vitro viability and immunogenicity assays. As we have yet to 
investigate the uptake of the FASCA 01 and TET01 vesicles, such studies will need 
to be undertaken in different cell lines. In order to investigate the opening of the 
vesicles future investigations are recommended to explore release kinetics using 
the encapsulated PI vesicles. It is recommended that the studies investigate the 
uptake and release of the individual as well as the combined formulations. These 
studies will be undertaken in vitro, prior to in vivo work an in vitro BBB should be 
tested using either transwell plates of a flow dynamic system in which bi-tri cultures 
are grown (Helms et al, 2014). Transendothelial electrical resistance (TEER) 
measurements should be taken, using a voltohmmeter, of the in vitro BBB to ensure 
formation of the tight junctions of the brain endothelial cells (Helms et al, 2014). In 
order to evaluate the potential of the vesicles as a drug delivery system they should 
be tested in vivo. 
Further studies would include the encapsulation of therapeutics such as etoposide 
which is able to cross the BBB but is effluxed rapidly by ATP transporters (Löscher 
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and Potschka, 2005). It would be of interest to investigate the encapsulation 
efficiency, after the modifications and optimisation suggested, and study the effects 
in vitro such as stability, uptake and efficacy.   
4.7 Conclusions 
The original BA material supplied by our collaborators which we thought to be GLH-
20, was not. HRMS analysis, has revealed that the material comprised many 
components however, the main products are consistent with two intermediates that 
could be produced during GLH-20 synthesis. A simple synthetic procedure based 
on the GLH-20 synthesis was initially employed to see if they could be produced 
and then optimised to improve yield and reduce production time.  
Vesicles have been characterised for each of the intermediates (FASCA 01 and 
TET01). The material was used to produce vesicles with less negative zeta 
potentials and z-averages to that of the initial BA material used for our in vitro and 
in vivo work (chapter 2 and chapter 3). However, it will be important to explore the 
potential of these vesicles in vitro and in vivo. A further synthesis needs to use both 
BA species mixed together to see if the resulting vesicle material is more stable. 
This should be explored in the future.   
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Chapter 5: General Discussion  
5.1 Introduction 
The incidence of diseases of the brain such as Alzheimer’s disease, Parkinson’s 
disease and glioblastoma are predicted to increase (Prince et al, 2016a; Feigin et 
al, 2017; Dorsey et al, 2018). This increase is due to the increasing population of 
elderly, the incidence of these diseases increasing with age, as well as better 
reporting of such cases globally (Prince et al, 2016b; Feigin et al, 2017). Despite all 
demonstrating different aetiologies, they do share one thing in common - there is 
no cure (Prince et al, 2016a). The treatment for diseases of CNS is only palliative 
and designed to reduce the symptoms rather than treat the underlying issue. One 
of the greatest barriers for treating diseases of the brain is the physical, 
pharmacological and functional barrier of the BBB, the interface between the 
vascular and central nervous systems. Whilst it has an important physiological 
function, protecting the brain from toxins, microbes and other foreign substances 
and maintaining the normal brain environment, it is also an excellent barrier against 
the entry of therapeutic agents to the CNS (Pardridge, 2012; Chaturvedi et al, 
2019). The BBB is exquisitely effective at preventing drug entry, restricting 
approximately 98% of small molecules and the majority of large molecules from the 
brain parenchyma (Habgood et al, 2000; Pardridge, 2003), thus, limiting treatment 
opportunities.  
There have been numerous invasive and non-invasive techniques developed to 
bypass the BBB and deliver drugs. Approaches span from the less invasive, such 
as liposomes, prodrugs, and the use of ‘trojan horse’ endogenous transporters, to 
more invasive techniques such as focused ultrasound and intracerebroventricular 
delivery. There are limitations for each of these methods including non-specific 
delivery, poor uptake in the brain, disruption of the BBB, and rapid clearance of the 
CSF. Clearly, novel drug delivery systems are needed. We hypothesised that BAs 
may offer a possible solution as a drug delivery system. 
BAs are molecules composed of long carbon chains and polar head groups (Han 
et al, 2004), able to form monolayered spherical vesicles and encapsulate a higher 
payload than traditional liposomes (Puri et al, 2009; Fariya et al, 2014). Cationic 
BAs, including GLH-20, synthesised from vernonia oil from the African sunflower, 
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Vernonia galamensis, have been reported to cross the BBB and deliver protein 
sized molecules to the brain (Dakwar et al, 2012; Popov et al, 2012). Therefore, we 
have endeavoured to explore the potential of vesicles synthesised from vernonia 
oil as a potential drug delivery system to treat diseases of the brain.  
5.2 Characterisation of novel, anionic bolaamphiphilic vesicles 
Synthesis of GLH-20 material was performed in collaboration with Dr Sumi Lee and 
Professor Lawrence Williams (Rutgers, USA). As the GLH-20 BA is cationic, due 
to the presence of acetylcholine ester head groups, it was expected that our BA 
vesicles would demonstrate a positive zeta potential. However, this was not the 
case. Rather our BA vesicles were negatively charged demonstrating that they are 
anionic. Presumptively, that they are an unexpected, novel species. We 
investigated the potential of these novel vesicles as a drug delivery system, to 
determine the value of exploring their synthetic chemistry in house.  
Tracer dyes, propidium iodide (PI) and Alexa Fluor 546 (AF546), were initially 
encapsulated in our BA vesicles. These were profiled, along with empty vesicles, 
using dynamic light scattering (DLS), transmission electron microscopy (TEM) (for 
empty vesicles only), zeta potential, and size exclusion chromatography. We also 
investigated the potential of BA vesicles to encapsulate a larger molecule such as 
the small variable antibody fragment scFv 4D5-8RFP. This was selected as it is 
smaller than an antibody, whilst still retaining the antigen binding site, and it has a 
built in marker in the guise of a red fluorescent protein within the architecture of the 
fragment. scFv 4D5-8RFP is specific to protein HER2 which is highly expressed in 
cancers such as breast and ovarian, as well as in some brain cancers. More 
importantly, this was a proof of concept study to investigate whether the vesicles 
could serve as a drug delivery system for therapeutic antibodies targeting brain 
specific antigens. Therapeutic use of antibodies can include as antibody drug 
conjugates. They are used to increase uptake to tumours through specific targeting 
as well as reducing non-target specific interactions of the cytotoxin by targetted 
delivery (Beck et al, 2017; Lu et al, 2020). Many of these are still in clinical trials 
(Corraliza-Gorjón et al, 2017) but if any show promise in targeting brain tumours 
they will require delivery across the BBB. The size of antibody drug conjugates can 
range in size from 300-1000 Da which may influence delivery (Beck et al, 2017). 
The maximum size of molecule that our BA vesicles has not yet been determined. 
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The size of the antibody encapsulated vesicle was larger than the empty vesicles 
or the vesicles encapsulating the tracer dyes. However, this stands to reason as 
the molecule is considerably larger at 52 kDa than the tracer dyes which are smaller 
than 1 kDa. 
Further characteristics of the vesicles were monitored to investigate their drug 
delivery potential. AF546 encapsulated vesicles were profiled for their long-term 
stability as well as their encapsulation efficiency. AF546 encapsulated vesicles 
demonstrated that over a four-month period the stability did reduce by 25%, but the 
zeta potential was still > -30 mV at this time point, indicating that our BA vesicles 
had a high degree of stability when stored at 4°C Popov et al (2010) observed 
stability of their cationic GLH-20 vesicles decreasing after 13 days. This 
demonstrates that our BA vesicles with their high electrostatic repulsion are more 
stable, remaining discrete and therapeutically usable for a minimum of 4 months.  
The encapsulation efficiency for AF546 was measured using a fluorescent plate 
reader analysing all the fractions that had been purified by size exclusion 
chromatography and in which a signal was detectable. Whilst the efficiency is low, 
appreciable amounts of the test AF546 tracer could be detected. These data will 
serve as a baseline for future studies investigating techniques to enhance and 
optimise encapsulation. It is known that efficiency is in part dependent upon the 
dose of the therapeutic to be encapsulated (Bozzuto and Molinari, 2015). 
Our vesicles have demonstrated a similar size and charge to studies investigating 
the potential of anionic nanoparticles as drug delivery systems. These studies have 
demonstrated that anionic particles cross biological barriers in vitro as well as the 
BBB in vivo (Lockman et al, 2004; Chattopadhyay et al, 2008; Voigt, Christensen, 
and Shastri, 2014). This supports our contention that our novel anionic vesicles 
may have potential as a drug delivery system. In order to investigate this further in 
vitro uptake studies were performed. 
5.3 Uptake and kinetic studies 
AF546 encapsulated anionic vesicles prepared in this study were used in the 
preliminary in vitro uptake studies to investigate their capabilities. They were shown 
to be taken up by the neuronal cell line SH-SY5Y within two hours of exposure. 
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Further experiments were undertaken to investigate their ability to be taken up by 
different cell lines.  
Uptake and kinetic studies were performed in the kidney cell line - HEK-293T, 
microglial BV2s, neuroblastoma - SH-SY5Y and glioblastoma - LN229, with our 
novel BA vesicles encapsulating antibody fragment, scFv 4D5-8RFP, or PI. 
Vesicles encapsulating this antibody fragment were shown to be taken up in vitro 
in SH-SY5Y cells. PI binds to nucleic acids and is also unable to cross intact 
membranes, thus making this a useful tool to measure the uptake and release of 
our vesicles, as PI should be excluded from healthy cells. Initial studies with PI 
encapsulated vesicles showed them to be opened after 24 hours incubation in HEK-
293, BV2s, and SH-SY5Y cells to differing degrees, with the lowest nuclear staining 
observed in the SH-SY5Y cells. Whilst this shows uptake it does not provide an 
accurate time frame as to when the vesicles are taken up and lysed. To further 
investigate the uptake kinetics, the study was reprised in glioblastoma, LN229 cells. 
As PI is excluded from healthy cells the premise is that only encapsulated PI will 
be able to enter the cell, and only once the vesicle has been lysed will we see 
fluorescence as PI binds to nucleic acids. We were able to measure not only uptake 
but lysis of the PI encapsulated vesicles through the increase of fluorescence signal 
as the PI bound. Cells were incubated at different time intervals and uptake was 
measured using flow cytometry. Uptake was observed within 30 minutes and 
increased over the four-hour time frame measured. This demonstrated that not only 
were the vesicles being taken up, but they were lysed, releasing their payload. 
Although we know the vesicles are releasing their cargo, we do not know the 
mechanism by which this occurs. This may be cell type specific, as has been 
suggested previously (Korang-Yeboah et al, 2015), but will be an important topic 
for future studies to address. One avenue to explore will be with vesicles containing 
a tracer dye such as lysotracker. These will allow tracking of the vesicles 
microscopically to investigate in which cellular compartment they are taken up and 
when they are lysed.  
5.4 Safety of the vesicles 
To test the safety and utility of our BA vesicles as a drug delivery system, we 
undertook a range of viability and immunogenicity studies in vitro, including the 
annexin A5 apoptosis assay, PrestoBlue cell viability assay, and measurement of 
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secreted TNF-α by ELISA. This study used cell lines representative of the BBB and 
of those that the vesicles may encounter within the brain, namely immortalised 
human endothelial cells hCMEC/D3, murine microglia BV2s and immortalised 
human astrocytes HASTR/ci35. The vesicles were found to induce a small degree 
of cytotoxicity in hCMEC/D3 after 24 hours and HASTR/ci35 after 7 days exposure 
when given at a high dose (50 µg/ml). Importantly however, this dose is significantly 
greater than might be expected to be used in vivo, where administration of 3.5 µg 
per mouse was shown to be sufficient to enable tracer delivery to the brain. This 
suggests that toxic effects of the vesicles are unlikely to prove a major limiting 
factor. There is a lack of toxicity studies regarding vesicles produced from vernonia 
oil and of BA nanoparticles in general, further demonstrating the need for such 
studies to be carried out and reported (Fariya et al, 2014). Nonetheless, strategies 
to improve vesicle targeting and reduce exposure, such as PEGylation, may prove 
valuable for future study (Peng et al, 2013, Sukhanova et al, 2018).  
5.5 In vivo studies 
BA vesicles encapsulating antibody fragment, scFv 4D5-8RFP, or tracer molecules 
were shown to be taken up in vitro, but the critical test for any potential drug delivery 
system is whether uptake also occurs in vivo. Accordingly, we administered BA 
vesicles intravenously to 7-week old male C57BL/6 mice, treating groups with either 
encapsulated AF546 vesicles, non-encapsulated AF546, encapsulated antibody 
fragment, non-encapsulated antibody fragment or empty vesicles. Importantly, 
encapsulated AF546 vesicles were taken up and could be detected within the brain 
after 30 minutes circulation time. This demonstrated that our novel anionic vesicles 
are able to cross the BBB. Lockman et al (2004) have previously observed that 
anionic nanoparticles can cross the BBB more effectively than cationic 
nanoparticles. Cationic vesicles, GLH-20 produced from vernonia oil, were shown 
to cross the BBB in 30 mins, however this study observed high clearance of these 
vesicles in the kidneys (Popov et al, 2012). Our vesicles were effectively cleared in 
the lungs and liver, as has been shown in studies of similar particle clearance 
mechanisms (Thurston et al; 1998; Popov et al, 2010; Zhang et al, 2015). Together, 
these data demonstrate that our novel vesicles have the potential to be used as a 
drug delivery system.  
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5.6 Synthesis of novel bolaamphiphilic material.   
Having shown the potential of BAs as a drug delivery system, we wanted to more 
fully characterise the chemical properties of these vesicles, and to establish an 
effective chemical synthetic pathway. High resolution mass spectrometry (HMRS) 
analysis indicated the presence of two species, both intermediates of the original 
GLH-20 formulation, the penultimate product (FASCA 01) and a further 
intermediate (TET01). Therefore, attempts to reconstruct this material were 
undertaken. This was a time-consuming process as the protocol needed 
optimisation at almost every step to increase the yield. The initial protocol was a 
three-step procedure with the first step being hydrolysis of the esters, followed by 
a coupling reaction to extend the carbon chain and finally the opening of the 
epoxide group with the addition of chloroacetic acid (FASCA 01) or without (TET 
01). The first step was the hydrolysis of the esters, using the original starting 
material, vernonia oil. Initially the procedure followed the methodology reported by 
Grinberg et al (2005 and 2008) and Stern et al (2014) in order to produce the 
intermediates (FASCA 01 and TET01) seen in the HRMS analysis. Both 
intermediates were produced and the overall yield for TET01 was increased from 
4.8% to 64%. Although the process requires future yield optimisation for FASCA 
01, both formulations were synthesised into vesicles encapsulating tracer dyes. 
Profiling of these vesicles with DLS, zeta potential, size exclusion chromatography 
and nanoparticle tracking analysis confirmed that whilst they produced vesicles the 
characteristics differed to that of the original material in that they had poorer 
stability. It is recommended that the two formulations be combined as both 
compounds were present in the original HRMS analysis. Whilst we have 
demonstrated that these vesicles can been recreated, further optimisation and 
testing is required.  
5.7 Future work 
Whilst future studies will include calculating. the encapsulation efficiency of scFv 
4D5-8RFP vesicles it is important to point out that the encapsulation efficiency is 
relative to the drug and dose encapsulated within the vesicle. The most important 
factor is ensuring that they have an effective, deliverable payload, that the 
encapsulation does not compromise biological activity and that the molecule can 
reach its target site (Bozzuto and Molinari, 2015). Nonetheless, due to the 
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encapsulation efficiency being low for vesicles in our studies, it remains important 
to investigate improving this efficiency. A number of variables can be trialled, 
increasing the concentration of bola material, increasing the concentration of 
drug/molecules to be encapsulated and PEGylation. Future work will include 
encapsulating different tracer dyes to further investigate how the external 
environment influences the internal environment of the vesicle, as well as 
lysotracker to investigate how the vesicles are lysed, and investigate the uptake 
mechanism in the presence of various inhibitors. Production of the vesicles will be 
further optimised, particularly by investigating mixing both formulations together 
(FASCA 01 and TET01) to increase stability. The recent study on combined GLH-
19 and GLH-20 vesicles being successfully used to deliver siRNA to mouse brains 
attests to the potential of this approach (Kim et al, 2020). Uptake studies, viability 
and immunogenic assays will be performed in vitro in different cell lines. Ideally, in 
vivo studies will be performed using the newly synthesised vesicles that consist of 
these anionic molecules (FASCA 01 and TET01).  
5.8 Conclusion 
Novel anionic vesicles have been synthesised encapsulating a range of different 
cargoes. They have been shown to be taken up and released in vitro. They have 
also crossed the BBB in vivo, 30 minutes after intravenous injection. We have 
developed a novel methodology for the synthesis of these novel vesicles. These 
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